TW206208B - - Google Patents
Download PDFInfo
- Publication number
- TW206208B TW206208B TW080106438A TW80106438A TW206208B TW 206208 B TW206208 B TW 206208B TW 080106438 A TW080106438 A TW 080106438A TW 80106438 A TW80106438 A TW 80106438A TW 206208 B TW206208 B TW 206208B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- page
- ministry
- cns
- alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 claims abstract description 107
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 48
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 35
- 125000003277 amino group Chemical group 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 12
- 125000001424 substituent group Chemical group 0.000 claims abstract description 12
- 125000005843 halogen group Chemical group 0.000 claims abstract description 11
- 125000003118 aryl group Chemical group 0.000 claims abstract description 8
- 229940124530 sulfonamide Drugs 0.000 claims abstract description 8
- 150000003456 sulfonamides Chemical class 0.000 claims abstract description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 200
- -1 2-pyranyl group Chemical group 0.000 claims description 105
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 44
- 239000007789 gas Substances 0.000 claims description 44
- 238000002360 preparation method Methods 0.000 claims description 34
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 27
- 150000001412 amines Chemical class 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 150000002367 halogens Chemical group 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 7
- 230000001028 anti-proliverative effect Effects 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 229910052786 argon Inorganic materials 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 2
- 239000012948 isocyanate Substances 0.000 claims description 2
- XGEPEZXKPDYNEA-UHFFFAOYSA-N n-(2-anilinopyridin-3-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=CC=C1 XGEPEZXKPDYNEA-UHFFFAOYSA-N 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229910052704 radon Inorganic materials 0.000 claims description 2
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 150000001348 alkyl chlorides Chemical class 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- PHSWVZJTWAQRBH-UHFFFAOYSA-N n-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 PHSWVZJTWAQRBH-UHFFFAOYSA-N 0.000 claims 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 229910052705 radium Inorganic materials 0.000 claims 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical group [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 256
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 182
- 239000000126 substance Substances 0.000 description 130
- 238000002844 melting Methods 0.000 description 110
- 230000008018 melting Effects 0.000 description 110
- 238000000921 elemental analysis Methods 0.000 description 90
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 description 90
- 238000005481 NMR spectroscopy Methods 0.000 description 89
- 238000011049 filling Methods 0.000 description 76
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000002904 solvent Substances 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 29
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000004949 mass spectrometry Methods 0.000 description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- 101150041968 CDC13 gene Proteins 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 238000010531 catalytic reduction reaction Methods 0.000 description 10
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000002079 cooperative effect Effects 0.000 description 9
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 150000008064 anhydrides Chemical class 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000009434 installation Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 150000003460 sulfonic acids Chemical class 0.000 description 3
- RUPDGJAVWKTTJW-UHFFFAOYSA-N 2,3-dinitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1[N+]([O-])=O RUPDGJAVWKTTJW-UHFFFAOYSA-N 0.000 description 2
- MKQNYQGIPARLKO-UHFFFAOYSA-N 2-methoxybenzenesulfonamide Chemical compound COC1=CC=CC=C1S(N)(=O)=O MKQNYQGIPARLKO-UHFFFAOYSA-N 0.000 description 2
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- MSFQEZBRFPAFEX-UHFFFAOYSA-N 4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1 MSFQEZBRFPAFEX-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Natural products CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229910052772 Samarium Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 150000003851 azoles Chemical group 0.000 description 2
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229930003836 cresol Natural products 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000004702 methyl esters Chemical group 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- CLRZCLCPWOVCEN-UHFFFAOYSA-N 1-hydroxyindazole Chemical class C1=CC=C2N(O)N=CC2=C1 CLRZCLCPWOVCEN-UHFFFAOYSA-N 0.000 description 1
- SPSQEKCXVRMSBW-UHFFFAOYSA-N 1-phenylethanesulfonamide Chemical compound NS(=O)(=O)C(C)C1=CC=CC=C1 SPSQEKCXVRMSBW-UHFFFAOYSA-N 0.000 description 1
- MYKQKWIPLZEVOW-UHFFFAOYSA-N 11h-benzo[a]carbazole Chemical class C1=CC2=CC=CC=C2C2=C1C1=CC=CC=C1N2 MYKQKWIPLZEVOW-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- VXZBYIWNGKSFOJ-UHFFFAOYSA-N 2-[4-[5-(2,3-dihydro-1H-inden-2-ylamino)pyrazin-2-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC=1N=CC(=NC=1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 VXZBYIWNGKSFOJ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 description 1
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- KBFOTEODMXCTAN-UHFFFAOYSA-N 2-methyl-2h-phenazin-1-one Chemical compound C1=CC=C2N=C(C(C(C)C=C3)=O)C3=NC2=C1 KBFOTEODMXCTAN-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- HOBMRIJBKDOONZ-UHFFFAOYSA-N 2-nitrobenzaldehyde hydrochloride Chemical compound Cl.[N+](=O)([O-])C1=C(C=O)C=CC=C1 HOBMRIJBKDOONZ-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical class CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- IIGNZLVHOZEOPV-UHFFFAOYSA-N 3-Methoxybenzyl alcohol Chemical compound COC1=CC=CC(CO)=C1 IIGNZLVHOZEOPV-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- BSFLBUQNINRPOU-UHFFFAOYSA-N 3-[(3-nitropyridin-2-yl)amino]phenol Chemical compound OC1=CC=CC(NC=2C(=CC=CN=2)[N+]([O-])=O)=C1 BSFLBUQNINRPOU-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- PCCSYAWZVABITQ-UHFFFAOYSA-N 3-nitro-n-phenylpyridin-2-amine Chemical compound [O-][N+](=O)C1=CC=CN=C1NC1=CC=CC=C1 PCCSYAWZVABITQ-UHFFFAOYSA-N 0.000 description 1
- VDKIMNUBAYDJEU-UHFFFAOYSA-N 4-[(3-aminopyridin-2-yl)amino]phenol Chemical compound NC1=CC=CN=C1NC1=CC=C(O)C=C1 VDKIMNUBAYDJEU-UHFFFAOYSA-N 0.000 description 1
- CDNIYBIKHDLGMT-UHFFFAOYSA-N 4-[(7-hydroxy-6H-pyrrolo[2,3-g][1,3]benzothiazol-8-yl)methylideneamino]-N-pyridin-2-ylbenzenesulfonamide Chemical compound C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=CC3=C(NC4=C3C5=C(C=C4)N=CS5)O CDNIYBIKHDLGMT-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- FDDDEECHVMSUSB-IDEBNGHGSA-N 4-aminobenzenesulfonamide Chemical class N[13C]1=[13CH][13CH]=[13C](S(N)(=O)=O)[13CH]=[13CH]1 FDDDEECHVMSUSB-IDEBNGHGSA-N 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- BAZFUNXYBJUUPW-UHFFFAOYSA-N 4-hydroxy-n-[2-(4-hydroxyanilino)pyridin-3-yl]benzenesulfonamide Chemical compound C1=CC(O)=CC=C1NC1=NC=CC=C1NS(=O)(=O)C1=CC=C(O)C=C1 BAZFUNXYBJUUPW-UHFFFAOYSA-N 0.000 description 1
- XOBAIYPLCUTNFV-UHFFFAOYSA-N 4-n,2-dimethylbenzene-1,4-diamine Chemical compound CNC1=CC=C(N)C(C)=C1 XOBAIYPLCUTNFV-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000605422 Asparagus asparagoides Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- OFZCDISYZAVSTD-UHFFFAOYSA-N C(C)#N.C(=O)=N Chemical compound C(C)#N.C(=O)=N OFZCDISYZAVSTD-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 240000004528 Catalpa ovata Species 0.000 description 1
- 235000010005 Catalpa ovata Nutrition 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 240000007582 Corylus avellana Species 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- SKISFHRYSVMDOB-UHFFFAOYSA-N I.I(=O)(=O)O Chemical compound I.I(=O)(=O)O SKISFHRYSVMDOB-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- JXDYKVIHCLTXOP-UHFFFAOYSA-N Pseudoisatin Natural products C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- QIOZLISABUUKJY-UHFFFAOYSA-N Thiobenzamide Chemical compound NC(=S)C1=CC=CC=C1 QIOZLISABUUKJY-UHFFFAOYSA-N 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- VYZYXBDJIUIYLW-UHFFFAOYSA-N [N].CS(N)(=O)=O Chemical compound [N].CS(N)(=O)=O VYZYXBDJIUIYLW-UHFFFAOYSA-N 0.000 description 1
- ZVDDJPSHRNMSKV-UHFFFAOYSA-N acetaldehyde;hydrochloride Chemical compound Cl.CC=O ZVDDJPSHRNMSKV-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- GCPWJFKTWGFEHH-UHFFFAOYSA-N acetoacetamide Chemical compound CC(=O)CC(N)=O GCPWJFKTWGFEHH-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- ZHNUHDYFZUAESO-OUBTZVSYSA-N aminoformaldehyde Chemical compound N[13CH]=O ZHNUHDYFZUAESO-OUBTZVSYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- KAJZGRFYZKWYDX-UHFFFAOYSA-N benzalamide Chemical compound NC(=O)CC(C)=CC1=CC=CC=C1 KAJZGRFYZKWYDX-UHFFFAOYSA-N 0.000 description 1
- 229950008586 benzalamide Drugs 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- OFWBDYUSWOSTGT-UHFFFAOYSA-N benzenesulfonic acid;toluene Chemical compound CC1=CC=CC=C1.OS(=O)(=O)C1=CC=CC=C1 OFWBDYUSWOSTGT-UHFFFAOYSA-N 0.000 description 1
- WDTPASXEQRTMBN-UHFFFAOYSA-N benzoic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.OC(=O)C1=CC=CC=C1 WDTPASXEQRTMBN-UHFFFAOYSA-N 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001743 benzylic group Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- ZQULWKDLLXZZSP-UHFFFAOYSA-N calcium cyanide Chemical compound [Ca+2].N#[C-].N#[C-] ZQULWKDLLXZZSP-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical group CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002905 metal composite material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CZXGXYBOQYQXQD-UHFFFAOYSA-N methyl benzenesulfonate Chemical compound COS(=O)(=O)C1=CC=CC=C1 CZXGXYBOQYQXQD-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- NSOBZEQTVMSDKT-UHFFFAOYSA-N n-(2-aminophenyl)-4-nitrobenzenesulfonamide Chemical compound NC1=CC=CC=C1NS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 NSOBZEQTVMSDKT-UHFFFAOYSA-N 0.000 description 1
- UDUMJSZCKPUNDT-UHFFFAOYSA-N n-(2-anilino-6-chloropyridin-3-yl)-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=C(Cl)N=C1NC1=CC=CC=C1 UDUMJSZCKPUNDT-UHFFFAOYSA-N 0.000 description 1
- RAZIOXAIVCEQJB-UHFFFAOYSA-N n-(2-anilinopyridin-3-yl)-4-ethylbenzenesulfonamide Chemical compound C1=CC(CC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=CC=C1 RAZIOXAIVCEQJB-UHFFFAOYSA-N 0.000 description 1
- IOSVVTUVQFFNOJ-UHFFFAOYSA-N n-(2-anilinopyridin-3-yl)-4-nitrobenzenesulfonamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=CC=C1 IOSVVTUVQFFNOJ-UHFFFAOYSA-N 0.000 description 1
- YRAMWAWWZWNEDO-UHFFFAOYSA-N n-(2-anilinopyridin-3-yl)benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC1=CC=CN=C1NC1=CC=CC=C1 YRAMWAWWZWNEDO-UHFFFAOYSA-N 0.000 description 1
- XCBRCJFKUBKPEG-UHFFFAOYSA-N n-[2-[(4-aminophenyl)sulfonylamino]phenyl]-4-fluorobenzamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=C1NC(=O)C1=CC=C(F)C=C1 XCBRCJFKUBKPEG-UHFFFAOYSA-N 0.000 description 1
- CRZDJDZSYGTZSC-UHFFFAOYSA-N n-[2-[(4-methoxyphenyl)sulfonylamino]phenyl]-3-methylpyridine-4-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CC=C1NC(=O)C1=CC=NC=C1C CRZDJDZSYGTZSC-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- JVUYWILPYBCNNG-UHFFFAOYSA-N potassium;oxido(oxo)borane Chemical compound [K+].[O-]B=O JVUYWILPYBCNNG-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003217 pyrazoles Chemical group 0.000 description 1
- FGVVTMRZYROCTH-UHFFFAOYSA-N pyridine-2-thiol N-oxide Chemical compound [O-][N+]1=CC=CC=C1S FGVVTMRZYROCTH-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 229960002026 pyrithione Drugs 0.000 description 1
- 150000003257 radon Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical class [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000010904 stalk Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glass Compositions (AREA)
- Chemical And Physical Treatments For Wood And The Like (AREA)
- Pyridine Compounds (AREA)
Description
206208 Λ 6 Β6 經濟部屮央標準X;A工消费合作社印製 五、發明説明(1 ) . 〔工業運用之領域〕 本發明傜關於新穎磺醯胺衍生物,其製法,及包含此 活性成份之醫藥組成。 至今所使用之癌症的化學治療劑含各種物質,例如烷 化劑(如環碟酷肢),抗代謝物,(如methotrexate,氟反 眩淀),抗生素,(如 adriamycin,mitomycin及 bleomycin) 及源自植物者,如vincristine及etoposide,及金屬複合 物,如西絲 Ifi(Cisplatin)。 己發表4 -胺苯磺醯胺衍生物(見日本專利公報號碼3093 / 1 9 6 8 ), 2 -磺醯胺/授喏啉(見日本專利公開號碼4 2 6 / 1987)及 m-RNA衍生物(見 J.Med.Chem·,18, 1110(1975)) 為具有磺IS胺基之活性抗增生化合物。 其中大多數對人類腫瘤僅有低的效用,特別是含低生 長率之固體腫瘤,如肺癌或直腸癌,且其亦表現出睦重 的不良作用》於此情況下,則需要發展一種低毒性且有 極佳之抗腫瘤活性之藥。 本發明目的為提供具有極佳之抗腫瘤活性及低毒性之 新穎磺醯胺衍生物。本發明另一個目的為提供製備此化 合物之方法,及含其為活性成份之醫藥组成物。 〔發明總結〕 當密集地研究以發現具有如上述低番性之抗腫瘤化合 物之後,本發明者已發現一種如下述之新潁磺醯胺衍生 物,其具有極佳之抗腫瘤活性及低痗性。基於此發现而 完成本發明。 -3 - (請先閱讀背面之注意事項再填寫本頁) 裝. 訂 太认化 κ 丨ίΐ Ψ S 屮4阳找(210乂297公贷) 206208 Λ 6 Β 6 五、發明説明(2 ) 因此,本發明傜關於式〔I]所示磺醯衍生物或其藥 理容許鹽:
(I ) R1 Β 式中: R1為氫原子,鹵素,低烷基,低烷氣基,羥基,硝 基,苯氣基,氣基,乙醯基或可被保護之胺基,R2及 R3為相同或不同,各表為氳,鹵素,低烷基或低烷氣 基,R4及R7為相同或不同,各表為氫或低烷基, Rs及Κ6可為相同或不同,各表為氫,鹵素,低烷氣 基或可被取代之胺基, Α為=Ν-或= CH -之基, R 10 (請先閱讀背面之注意事項再塡寫本頁) 裝· 訂- 為 N -或C— 之基,其中R 10為氫原子或低烷基,
Q 經濟部屮央棵準工消费合作社印製 E為-C - R 11之基,其中Q為氣或硫,且R u為铤原子,伯 烷基,胺基,其可取代以低烷基,低烷氣基,2 -怵吩超 2-呋喃基或 所示之基,
夂认A R冷iA ΙΠ屮因Η定说迆(CNSW4姒格(210x297公货) 206208 Λ 6 1} 6 五、發明説明(3) (D為=N-或=CH -之基 且RU及R13可為相同或不同,且各為氫,鹵原子,硝基 ,可被保護之羥基或低烷基);或芳族6員環基,其可 取代以1-3個相同或不同之取代基G,且此環可含#1或 2値氮原子(G為鹵原子,低烷基,低烷氣基,可被保護 之羥基,可被酯化或醯胺化之羧基,低烷硫基或苯氧基。 但下列組合除外: (1) R1為氫原子,低烷基,硝基或可被保護之胺基, R2及R3各為氫原子,A及B各為= CH-,及E為可取代以 1-3値相同或互不相同之取代基G之苯基之组合,及 (2) !?1 , R2及R3為相同或互不相同,且各為氫原子 ,低烷基,硝基或鹵原子,且A及B各為= CH -之组合, 0 II 及E為-C-R 11之基,其中R 11為低烷基,可取代以低烷
(請先閲讀背而之注意事項再填寫本頁) 裝. 訂 線-
經濟部中央梂準局Η工消势合作社印M 其中R12及R13之定菝如上的組合。 下列將對本發明作更詳盡之説明。 於上式〔I〕中 R1 ,R2 ,R3 ,R4 ,R7 ,R10 ,Rii,RU, R 13之定義及於E之定菝中可被取代之取代基G的低烷基 含直鐽或分枝之(^- 6烷基,如甲基,乙甚,正-丙基 ,異丙基,正丁蕋,異丁基,第二丁基,第三丁基,正 本紙5fc尺度逍用中國國家標準(CNS)甲4規格(210X297公;!I:) 206208 Λ 6 Β 6 經濟部屮央#準而Μ工消费合作社印製 五、發明説明(4) 戊基,異戊基,新戊基,第三戊基,1-甲基丁基,2-甲 基丁基,1,2-二甲基丙基,正己基,異己基,1-甲基戊 基,2 -甲基戊基,3 -甲基戊基,1,1-二甲基丁基,1,2-二甲基丁基,2, 2-二甲基丁基,1,3-二甲基丁基,2,3-二甲基丁基,3, 3-二甲基丁基,1-乙基丁基,2-乙基丁 基,1,1, 2-三甲基丙基,1,2, 2-三甲基丙基,1-乙基-1 -甲基丙基及1-乙基-2-甲基丙基。其中,以甲基,乙基 ,丙基及異丙基較佳,又以甲基及乙基最佳。 於R1 ,R2 ,R3 ,RS ,RS ,ϋ11之定義中及Ε之定義中可 被取代之取代基G的低烷氣基為源自上述低烷基,如甲 氣基,乙氣基,正丙氣基,異丙氣基,正丁氣基,異丁 氣基及第三丁氣基。其中,以甲氣基及乙氣基最佳。其 鹵原子含氟,氛及溴原子。 於R5及R6定義中之已取代胺基含取代以低烷基之胺 基(如甲胺基,乙胺基及二甲胺基)及取代以苯基之胺基 〇 於Ε之定義中,可被取代之取代基G中可為已保護之 羥基含羥基,甲氣甲氣基,四氫吡喃氣基,苄氣基,磷 酸酯,硫酸酯,磺酸酯(如對-甲氣苯磺酸或甲烷磺酸 之酯),胺基酸酯(如甘胺酸,丙胺酸,白胺酸,酪胺酸 .天門;酸,麩胺酸,離胺酸,精胺酸,脯胺酸,肌 胺酸,/?-丙胺酸或胺基丁酸),配種體(如甘及涵糖 醛酸),可取代以低烷基之胺基甲醛氣基(如胺甲醛氣基 -6 - (請先閲讀背面之注意事項再填寫本頁) 裝· 線- 本紙5fc尺度边用中國國家標毕(CNS)肀4規格(210x297公龙) 206208 Λ 6 Β 6 經濟部屮央橾準而貝工消费合作社印製 五、發明説明(5 ) ,甲胺甲醯氧基及二甲胺甲醛氧基),低醯氣基(其含1-5 個磺原子,如甲醯氣基,乙醯氧基及待戊醛氧基)及苄 醯氣基。 若需要,此苄醯氣基之芳族環可取代以低烷基,如甲 基,乙基,正丙基或異丙基,低烷氣基,如甲氣基,乙 氧基,正丙氧基或異丙氣基,鹵素,如氟,氯或溴,或 可取代以低烷基之胺基。 於R1定義中可被保護之胺基含未取代胺基,低醯胺 基(含1至4値碩原子,如甲醯胺基,乙g胺基及丙醒胺 基)及苄氧羰胺基。 於E之定義中可被取代之取代基G的定義中,可被酯化 或醯胺化之羧基含羧基,低烷氣幾基洽2 - 5値硪原子,如 甲氣羰基,乙氣羰基及異丙氣羰基),未取代胺羰基, 及取代以Ci- 4烷基之胺羧基(如甲胺羰基,乙胺羰基 及二甲胺羰基)。 式〔I〕所示之磺醯胺衍生物可與酸或鹼形成鹽。本 發明亦包含化合物〔I〕之鹽。其與酸之鹽含無機酸鹽 ,如HC1, HBr及硫酸鹽,及有機酸鹽,如乙酸鹽,乳酸 鹽,琥珀酸鹽,反丁烯二酸鹽,順丁烯二酸鹽,檸様酸 鹽,苯甲酸鹽甲烷磺酸盥及對-甲苯磺酸鹽。其與鹼之 鹽的例子含無機鹽,如納,鉀及鈣鹽,及與有機龄之鹽 ,如三乙胺,粮胺酸及離胺酸。 若存在此化合物之水合物及光學異構物時,則其亦包 (請先閲讀背面之注意事項再填窝本頁) 裝· 線. 本紙尺度边用中國國家樣毕(CNS)甲4規格(210X297公货) 206208 Λ 6 Β 6 五、發明説明(6 ) 含於本發明。本發明化合物表現出強力抗增生之活性, H J π 後合 Π 用化物 作之合 : 謝性化法 代活.明製 行生發之 進增本型 當抗 典 現 其 呈 ),為 合 列 结 下 之 。 内 得 體,。製 活目而 或發⑨ ,^5許 匕含由 彳包ώ 氣.、經 式 物 生 衍 應 反 其 或 酸 磺 之 式 學 化
(請先閲讀背面之注意事哺再場寫本頁) 裝· 及 基 1ΗΛ R 硝 且 , ,基 上氧 如烷 , 義低基 定之胺 之基之 3 羥護 ί以保 2 護已II式 R 保或 ^—^學 中-基式化 式基醯與ί 應 反 物 合 化 示 所 烷 低 或 子 原 鹵 氩 為 乙 基 氰 基 氣 苯 線- 經濟部中央樣準而A工消赀合作社印製
I R 冏或 相或 為護 可保 6a 已 R έ或 及 5a R 基 且氣 •烷 上低 如 , 莪子 定原 之鹵 nHU 或 氫 A,為 ’表 7 R 各 4 R 同 中不 式或 及 本紙張尺度逍用中國困家榣準(CNS)甲4規格(210x297公;«:) ^08208 Λ 6 13 6 經濟部中央標準处3工消1-\··合作杜印製 五、發明説明(7) 己取代之胺基。 磺酸(II)之反應衍生物為一般所 化物,磺醯基酐及N -磺醛眯唑。其 較佳。此反應是以其化學當量來進 之溶劑並無限制,但以可溶解原料 之溶劑較佳。溶劑可為吡啶,四氫 乙醚,二氯甲烷,二甲基甲醯胺及 混合液。當於磺醛基鹵化物之反應 此反應最好於存在適當酸結合劑之 用鹼性溶劑,如吡啶,較佳。當使 入如鹾性磺酸鹽之鹼性物質或有機 使用之溶劑並不限於上述。此反應 且若需要,可於冷卻或加熱之下進 至2 0小時。反應時間一般視原料種 當所得磺醯胺衍生物(I)之胺基, 護時,其可依需要,以一般常用之 如酸處龄處理或催化還原,以 或羧基之化合物(I )。 (2 )將式(I V )所示之化合物 〔化學式16〕 使用者 中,以 行。雖 及不輕 呋喃, 其二者 中會釋 下進行 用中性 三级胺 一般於 ,如磺 磺醯基 然反應 易與原 二呜烷 或二者 放出酸 。因此 溶劑時 。然而 室溫下 醯基齒 鹵化物 所使用 料反應 ,苯, 以上之 時,則 ,以使 ,則加 於此所 進行, 行。反應時間為1 0分 類及反應溫度而定。 羥基或羧基為已保 方法來除去保護基, 得含游離羥基,胺基
R8· (IV) (請先閱讀背面之注意事項再填寫本頁) 裝· 訂- 線· 本紙5艮尺度边用中國Η家標毕(CNS)T 4規格(210x297公址) 206208 Λ 6 13 6 經濟部屮央梂準局β工消#合作社印製 五、發明説明(8 ) 式中i立,R2 ,R3 ,R4 ,R! ,Rf ,R7 ,A及B之定義如上 ,而Ea表為芳族6員環基(其環中可含有1或2個氮原子) ,且其已取代以1-3個相同或互不相同之取代基Ga, Ga 為鹵原子,低烷基,低烷氣基,羥基,可酯化或醯胺化 之羧基,低烷硫基或苯氣基,但璟中至少1艇Ga為羥基, 與式(V )所示化合物反應: X-Y (V) 式中X為可與羥基中氣原子结合之.基,且Y為可移去 之基,或與對羥基有反應性之無機或有機酸酐反應。 X-Y包含芳族及脂族磺酸之反應.衍生物,芳族及脂族 羧酸,可被保護之胺基酸,可被保護之磷酸,可被保護 之碕酸,可取代以低烷基之胺甲酸及可披保護之糖。其 例子含對-甲氣苯磺醯氣,甲烷磺醯氮,鄰-氮苄醛氯, 乙醛氯,N-(第三丁氣羰胺乙醛基)眯唑,氣g化磷,氣 磺酸,Ν,Ν-二甲胺甲醯氮及l,2,3,4-四-鄰-乙醯基-D-葡萄糖醛酸甲酯β酸酐之例子含無機酸酐,如五氣化二 磷及三氣化硫,及有機酸酐,如cr-胺基酸之Ν -羧基酐 (N C A )及靛红酸酐。 雖然反應所用之溶劑並無持別限制,其中以可溶解原 料且不輕易與原料反應之溶劑為目的溶劑。溶劑之例子 含吡啶,四氫呋喃,二吒烷,苯,乙醚,二氛甲烷,二 甲基甲醯胺及其二者或二者以上之混合液。酋使用掖體 -1 0 - (請先閲讀背而之注意事項再填寫本頁) 裝- 訂' 線. 本紙張尺度逍用中國困家標準(CNS)甲4規格(210x297公;Ϊ) 800208 Λ 6 J3 6 五、發明説明(9) 原料,如氧氣化磷,則反應可於不使用任何溶劑之下進 行。 (3)將式(VI)所示化合物: 〔化學式1 7〕
(VI) 上 如 義 定 之 E 及 BA, 7r* a 6 R a 5 R / 3 R / 2 R a R1 中 式
物R4 合 化 之 ”如? 式 式 中在)ί學 下 式存(4化 與 於 C
為之 表aH (請先閲讀背面之注意事項再填寫本頁) 式 物 合 ^ ^ Τ ^ -低鹼 Η 子 原 鹵 為 表 L 且 0 ,應 基反 裝· 線· 經濟部屮央楳準局Μ工消#合作社印製 式
β R 上 如 菝 定 之 Β 及 A V A 6 R V R5aR4,R3, 2 R / a R1 中 式 應 反 物 合 化 本紙尺度逍用中國困家標毕(CNS)平4規格(210X297公釐) 206208 Λ 6 Β6 經濟部屮央梂準局Μ工消赀合作社印3i 五、發明説明(1G) R 11 - Z (VIII) 式中R11之定義如上,Z表為羧基或其反應衍生物,或 • \ 當R 11為低烷胺基,則將其與異気酸低烷酯反應。 此處所用之羧酸反應衍生物可為醛鹵,酸酐,活性醯 胺化合物及活性酯。 此處可用之醯鹵為醯氯及醯溴。此處可用之酸酐可為 混合單烷碩酸酐,含脂族羧酸(如乙酸,特戊酸,戊酸 ,異戊酸及三氣乙酸)之混合酸酐,混合芳族羧酸(如苯 甲酸)及對稱酸酐。此處可用之活性醯胺化合物如酸與 眯唑,吡唑,第四位置已取代之眯唑,二甲吡唑,三唑 ,四唑及苯駢喀唑之醯胺。活性酯為選自甲酯,甲氣甲 酯,氡甲酯,炔丙酯,4 -硝苯酯,2, 4 -二硝苯酯,三氣 苯酯,五氩苯酯,甲烷磺苯酯,苯吖苯酯及1-羥基-1H-2-吡啶_,N -羥琥珀醒亞胺,N -羥酞亞胺或1-羥苯駢三 唑之酯。 羧酸(VIII)可於存在縮合劑,如Ν, Ν' -二環己基碳化 二亞胺(DCC)或Ν -環己基- Ν’ -嗎福啉乙基磺化二亞胺, 與胺(VII)反應。 笛R 11為取代以低烷基之胺基時,則胺(VII)可與異氮 酸低烷酯。當R 11為胺基時,則胺(VII)可與氮酸之龄金 屬鹽反應。 此反應可於存在鹼之下,如有機三级胺(如三乙胺, Ν,Ν -二甲苯胺或吡啶),鹺性碘酸鹽或鹺性硕酸氫鹽, (請先閲讀背面之注意事項再填寫本頁) 裝· 線· 本紙尺度逍用中as家楳华(CNS)f 4規格(210X297公龙) 206208 Λ 6 13 6 五、發明説明C11) 且若需要,於酸之下進行。使用化學當量之反應物來進 行反應。雖然反應所使用之溶劑並無特別限制,但以可 溶解原料且不輕易與原料反應之溶劑為欲得。溶劑可為 吡啶,四氫呋喃,二II等烷,.苯,乙醚,二氯甲烷,二甲 基甲醯胺,及其二種或二種以上之混合液。當所使用之 試劑難以溶於有機溶劑中,如氡酸鹽,則反應可於水合 情況下進行。於此所用之溶劑並不限於上述。反應溫度 並無持別限制,只要反應能進行。但一般是 於室溫下進行,然而若需要,則可於冷卻或加熱下進行 。反應時間一般為5分至2 0小時。反應時間視原料種類 及反應溫度而定。當産物含有被保護之羥基或胺基時, 則可依普通之除去保護基之方法,如酸處理,鹼處理或 催化還原,以得到含游離羥基或胺基之化合物(I)。當 産物含有硝基時,則此基可用一般還原硝基之方法,如 於存在Pd-C催化劑之下進行催化還原反應,或使用鋅粉 及HC1,將此基轉為胺基。 下列將説明製造本發明所使用起始化合物(IX)或其鹽 之製法 〔化學式1 9〕 (請先閲讀背面之注意事項再填窝本頁) 裝· -線 經濟部屮央楳準局β工消t合作社印製
-13- 本紙張尺度边用中國國家標準(CNS)>f 4規格(210X297公货) S06S08 Λ 6 Β 6 五、發明説明(12) 式中R5a, R6a, R7, A, Β及Ε之定義如上。 製法1 〔化學式2 0〕
(IX) (請先閲讀背而之注意事項再璜寫本頁) 經濟部屮央櫺準局β工消f合作社印製 式中L表為齒原子,且Ri ,Rf ,R7 ,Α,Β及Ε之定義如 上。 式(XII)之化合物可依各種已發表之製法來合成,如 J.Med.Chem. ,Vol.21 p.965,J.0rg.Chem. ,Vol.28, p . 3 1 14 , J . Chen . , Soc . Perk in 1.1974, 1611, 1974, 1970及 1979, 135,Helv.Chim.Acta,Vol.61, p.2452或其類似製 法。亦即,其可M將式(X)之化合物與式(XI)之化合物 ,於存在或不存在有機溶劑,如二甲基甲醯胺,乙酵或 二啤烷,於室溫或加熱之下進行反應。 當霈要除去所形成之鹵化氫時,可加入有機齡,如三 -1 4 - 本紙5fc尺度边用中國國家標準(CNS)〒4規格(210X297公放) 206208 Λ 6 Ιϊ 6 五、發明説明(I3) 乙胺或吡啶,或鹼性碩酸鹽以作為酸結合劑,或者將此 反應於每當量之化合物(X)中使用至少2當量之化合物(XI) 來進行。當産物(XII)於其芳族環中具有高活性之鹵原 子時,其可再與烷氧化物或胺反應以轉為其它化合物。 式(IX)之化合物可藉將上述化合物(XII),依一般還原 硝基之方法還原而得。於較佳之還原過程中,催化還原 作用是於存在Pd-C催化劑之下,或使用鋅粉及乙酸以進 行還原作用。催化還原作用一般於有機溶劑,如甲醇, 四氫呋喃或二甲基甲醯胺,於大氣壓或加壓之下進行。 製法 2 〔化學式2 1〕
(請先閲讀背而之注意事項再塡寫本頁) 裝· 訂 線_ 經濟部中央榀準而员工消贽合作社印製 式中R5a, R1, A, B,E及L之定義如上。 式(IX)所示化合物可依如於J.0rg.Chem.,Vol.24.P. 1314所述方法,J.Heterocycl.Chem.Vol.20,p. 1339所 述方法,或其類似之方法而合成。亦即,其可藉將式( X I I I )之化合物與式U I )之化合物,於存在酸催化劑之 下,如II C 1 ,或Η 2 S 0 4 ,溶劑中,如水,乙醇或二伸乙 基雙甘酵中反應而得。為了增加反應速率,則可將反應 -1 5 - 本紙尺边用中國國家標半(CNS)甲4規格(210x297公址) 206208 Λ6 0 6 五、發明説明(I4) 液加熱。 裂法 3 〔化學式2 2 ]
(XIV) (IX) 式中R5a, R6a , R 7 , A , B , E及L之定義如上。 式(IX)所示之化合物可依如於J.Chem.Soc.(c)(1970) ,P. 1355中所述方法或其類似之方法而合成。亦即,其 可藉將式(XIV)所示化合物與式(XV)所示化合物,於存 在或無有機溶劑,如二甲基甲醛胺或二枵烷,及室溫或 加熱之下反應而得。 製法 4 〔化學式2 3〕 (請先閲讀背面之注意事項再填寫本頁) 經濟部屮央#準局β工消费合作社印製
式中Rf,Rg,R7 ,Α,Β及Ea之定親如上,且Eb表為上 述E,其中至少1個G為已保護之羥基。 -16- 各紙張尺度通用中a Η家標毕(CNS)甲4規格(210X297公徒) 806308__ 五、發明説明(15) 式(XVII)所示化合物可藉將式(XVI)所示化合物與下 與筷物 或應合 ,反化 上此與 如。會 義得不 定而以 之應劑 Η反溶 及 X 醉應 中酸反 其機 。 ,有定 物或而 合酸類 化機種 之無之 示之酐 所性及 \)/ \—/ V 活 V /IV ___ Υ 有 Υ X 基 X :羥視 式對件 二 或 喃 呋 氫Η, Τ1 a 四 N ,如 胺 , 醯鹼 甲入 基加 甲可 二 , 如率 fcF- , 速 fct .hul*·' 佳應 為反 劑加 溶增 性了 惰為 之 0 應烷 反鸣 鉀 酸 碩 原 以 氫 ^ ?»·> 為保 R7其 當將 0 9 熱前 加之 条應 應反 反野 將或 或V) /fv· » Y 中X-糸與 應於 反可 至時 胺有 乙 則 三 , 或子 佳 V 一 為U依 基式 , \1|/ Ο I /—\ 保去VI24 一除(X式 基基物 5 學 胺護合法化 般保化製 - 得 後ίρ製二冑 MJi法 物 0 b 0 ί卞7Γ7ΓΜ 如W還 其 將 得 製 (請先閱讀背面之注意事項再填寫本頁) 裝. ,•31-
+
C R -線- 經濟部+央橾準局员工消费合作社印製
β R 本紙5fc尺度通用中國S家楳华(CHS) <fM規格(210X297公没) 206208 Λ 6 13 6
經濟部屮央#準局貝工消货合作社印M 五、發明説明(1匀 式中 R1,, R2, R3, R4, R5a, Rsa, Α,Β 及 L 之定義如上。 式(VII)所示化合物可藉將式(XIX)化合物與式(XX)之 化合物反應而製得。此反應條件是視化合物而定。一般 而言,每當量之磺醯鹵化物UIX),以使用2-4當量之化 合物UX)為佳。反應溶劑以四氫呋喃,二枵烷,吡啶, 二甲基甲醯胺等為佳。此反應亦可於水合情況下進行。 此反應一般是於室溫下進行,但若需要,亦可於冷卻或 加熱之下進行。 當使用本發明化合物作為醫藥時,則其可由口或非經 腸胃之投予。其劑量並無限制。但可視病人之病擻,年 龄,性別,體重及敏威性;投予方法;時間及投予間隔 :製劑性劑,處方及種類;及活性組成之種類而定。 視投予方式而變之劑量範圍一般為成人每天lQ-SOOOing ,以5(]-40〇011^較佳,而以10 0-300 01^更佳。此化合物 之劑量為毎天分1 - 3次投予。 於製備口投予之固體製劑中,若需要,可將結合劑, 崩散劑,澗滑劑,著色劑,矯味劑等加至活性組成中,再 將其製為錠劑,己被覆之錠劑,粒劑,徹細粒劑,粉未 或膠囊。 賦形劑之例子含乳糖。玉米澱粉,白掂,涵萄糖,山 梨糖醇,结晶谢維素及二瓴化矽。結合劑之例子含聚乙 烯醇,聚乙烯醚,乙甚餓雒素,甲基纖維素,阿拉伯膠 ,黃蓍膠,明膠,蟲膠,羥丙基缈維素,羥丙基甲基缃 -1 8 - (請先閲讀背面之注意事項再填寫本頁) 裝· 訂 線· 本紙張尺度边用中國國家標半(CNS)甲4規格(210x297公址) 206208 Λ 6 13 6 經濟部屮央橾準局β工消赀合作社印製 五、發明説明.(17) 維素,擇樺酸鈣 > 糊精及果膠。潤滑劑之例子含硬脂酸鎂 ,滑石聚乙二醇,矽膠及植物油。所用箸色劑為允許加 至醫藥者。矯味劑之例子含可可粉,薄荷腦,芳香粉末 ,薄荷油,冰片及肉桂粉。此錠劑及粒劑可適當地被覆 以糖,明膠等。 於製備注射液中,可依一般方法將PH調節劑,缓衝劑 ,懸浮劑,溶解劑,穩定劑,等滲劑,保存劑等加至活 性組成中以形成靜脈,皮下或肌肉注射液。若需要,則 可將其冷凍乾燥。 懸浮劑之例子含甲基纖維素,Polysorbate 80,羥乙 基缕維素,阿拉伯膠,黃瞢膠,羧甲基纖維素鈉及聚氣 乙烯花揪醣單月桂酸鹽。 溶解劑之例子含聚氣伸乙基-硬Μ麻油,Polysorbate 80,菸鹼醯胺,聚氣乙烯花揪糖單月桂酸鹽,及蓖麻油 脂酸之乙酯。 穩定劑之例子含亞硫酸納,偏亞硫酸納及乙醚,保存 劑之例有對羥苯甲酸甲酯,對羥苯甲酸乙酯,花揪酸, 酚,甲酚及氮甲酚。 〔本發明之效用〕 由下列藥理實驗可説明本發明化合物之效用。 筲驗例 1 對〇細胞(人#咽細胞)之活體外抗增生試驗: 将1 · 2 5 X 1 0 3 ( 〇 . 1 m〗)之κ B細胞懸浮於置於9 6井平底撖 -1 9 (請先閱讀背面之注意事項再填寫本頁) 裝- 訂_ -線- 本紙張尺度边用中國國家標毕(CNS)T4規格(2〗0X297公釐) 206208 Λ 6 Β 6 經濟部屮央榀準而员工消贽合作社印製 五、發明説明(I8) 量平板中的RPMI 1 6 4 0培養基中(日水製藥公司),且此 培養液中含有20 %牛胎血清,盤尼西林(100單/ml) ,鏈微素(100# g/ral),氫硫乙醇(5X10- 5 Μ)及丙酮 酸納(1 m Μ ),於含5 % C 0 2及3 7 °C之下培養1天。 將本發明化合物溶於二甲亞硯中,可得2 0 m g / m 1溶液 ,將其以0.1%牛胎血清/ RPMI 1640培養液稀釋至100 #g/nl。此濃度為最高者,並將其以含0.5 %二甲亞魄 而清 之0 · 1 %牛胎AR Ρ Μ I 1 6 4 0培養液進行二倍糸列稀釋。將此 液〇、1 πι 1加至上述培養平板每個井中之Κ Β細胞,並於含5 % C02及37°C下培養3天。 培養之後,將0.05ml之MTT〔3.-(4, 5 -二甲基喀唑- 2-基)-2,5 -二苯四唑溴〕溶液(3.3rag/nil)加至每個井中, 並再培養1小時。將每値井中之上清液吸除,並將所形 成之甲僭溶於0 . 1 π 1二申亞硪。使用徹平板讀取器測定 540ηπι之吸光度,以作為可存活數目之指數。依下式可 算出抑制作用之百分率,且可測出試驗化合物具有5 0 % 抑制作用(I C 5〇)之濃度。 抑制百分率(% ) = (C-T)/CX 100 T:含試驗化合物之井的吸光度 C:不含試驗化合物之井的吸光度 所測出之I C 50值列於下表1。 -20- 本紙張尺度逍用中國困家樣準(CNS)甲4規格(2丨(1父29’/公龙) (請先閲讀背而之注意事項再填寫本頁) 裝· 訂 206208 3 66 ΛΒ 五、發明説明(19) 經濟部屮央捣準杓员工消f合作杜印製 [0083] [Table 1] Compound (Ex. No.) IC5〇 (pg/ml) Compound (Ex. No.) ics〇 . (μς/ιηΐ) 1 1.5 54 0.54 ' 2 1.7 57 0.17 3 Q .21 58 1.2 4 1.9 59 0 ‘18 5 0.73 61 0.83 6 0.42 62 0.53 7 1.0 63 0.20 8 0.89 64 0.55 9 0.34 65 0.20 10 0.21 ' 67 1.4 11 0.33 68 0.17 13 2,6 70 0.033 16 1.5 71 0.11 17 0.94 72 0.012 18 0.7 3 76 0.13 21 1.1 82 0.026 27 1.4 85 0.010 34 0.11 88 0.010 35 0.45 91 0,07 9 36 0.72 94 0.064 37 1.3 95 0,045 40 2.1 97 0.15 42 0-59 98 0.079 43 0.26 101 0.10 4 7 2.6 104 0.099 52 0.54 106 0.30 -21- (請先閱讀背面之注意事項再塡寫本頁) 裝· 訂_ 206208 Λ 6 Β 6 五、發明説明(20) 實驗例 2 對結腸38(小白鼠結腸之癌症)之活體内抗增生試驗 將75rag之结腸38由皮下移植至7週齡雌鼠BDFi中。將 本發明化合物懸浮於0.5%甲基纖維素,於次日開始每 天以口投予一次此懸浮液之預測量並持續8天。對照組 則口投予〇 . 5 %甲基纖維素。對照組包含1 0隻鼠,投藥 组則含6隻鼠。 移植2 1天後,移出腫瘤並稱重。依下式可測得投藥組 對對照組之腫瘤生長抑制率: 生長抑率(% )(.C-T)/Cx 100 T:投予試驗化合物之群的腫瘤平均體重 C:對照组的腫瘤平均體重 實驗結果列於下表2。 〔表2〕 (請先閲讀背而之注意事項再塡寫本頁) 裝- 經濟部屮央榀準局β工消#合作社印製 化合物 劑 量 (mg/kg/day 生長抑 制 率 處理後之存活率 (第2 1天) 1 10 0 8 0 1 0 0 2 1 0 0 6 9 1 0 0 3 10 0 9 8 10 0 4 10 0 9 9 10 0 6 1 0 0 9 8 10 0 7 5 0 6 1 10 0 7 0 5 0 6 3 10 0 _______-22- 本紙尺度边用中國S家標準(CNS)甲4規格(210x297公tf) 206208 Λ 6 13 6 五、發明説明(21) 實驗例3 :毒性試驗 將例3, 4或6之化合物於甲基繼雒素之0.5%懸浮液投 予至一群含5隻7週齡之雌小白鼠BDF,且於投予7天後 ,觀察其存活力。甚至投予lS51mg/kg化合物,仍無鼠 死亡。 由上述實驗例子中可得知本發明化合物具有相當優異 之抗增生效應。此外,本發明化合物有高安全性,因而 可作為惡性腫瘤之治療劑,如作為抗增生劑。 〔例子〕 由下列製備例子可闡明製備本發明化合物之起始化合 物的製法,且由下列例子可閫明本發明'·之與型化合物,但 本發明並不僅限於此。 製備例 1 2-苯胺基-3-硝吡啶: 〔化學式2 5〕
(請先閲請背而之注意事項再塡寫本頁) 裝· 訂' 線. 經濟部屮央標準局只工消费合作社印製 將 ll_21g(70mniol)2-氮-3-硝吡啶及 19.5Gg(210mraol) 苯胺於1 0 0°C下加熱Μ拌1小時。將反應液冷卻至室溫 並溶於乙酸乙酷。將溶液以掙探酸水及水洗。於M g S 0 a 下乾燥後,減壓蒸除溶劑,並由乙酸乙酯/正己烷再結 -2 3 - 本紙5fc尺度边用中囷國家楳毕(CNS) «Ρ 4規格(210X297公龙) 206208 Λ 6 Β 6 五、發明説明(22) 晶可得1 3 . 7 g目的化合物。 熔點:7 3 - 7 4 °C FAB 質譜 π/ z : 2 16 (〔 M + H〕+ ) ^-NMR (CDC13) δ (ppm): 6 • 84 (1H, dd, J=8.4, 4.4Hz), 7.18-7.22 (1H, m), 7, 37-7.43 (2H, m) , 7 .62-7.68 (2H, m) , 8 .49 (1H, dd f j—4·4/ 2.0Hz), 8 .53 (1H, dd, J=8.4, 2.0Hz), 10,12 (1H, br-s) Cii Η 9 N 3 0 2 .之元素分 析: C H N 計 算 值 6 1.39 4 .22 19.5 3 實 測 值 6 1.49 4 • 34 19.2 3 備 例 2 3 - 胺 基- 2 -苯 胺吡啶: (請先閱T*?背面之注意事項再填寫本頁) 裝_ 經濟部屮央楳準局Μ工消#合作社印製 〔化學式2 6〕 nk2〇^.nh 將製備例1所得化合物6 · 8 g ( 3 1 · 6 m m ο 1 )溶於4 0 m 1四氫 呋喃及6 π 1甲醇中。加人P d - C至溶液中以於大氣K及室 溫下進行氫化作用。濾除P d - C ,減IK蒸除溶劑,並由乙 酸乙酯/正己烷再結晶可得5. 5g目的化合物。 熔點:1 4 3 - 1 4 4 °C -2 4 -
本紙尺度遑用中國國家樣毕(CNS)甲4規格(210x297公址) 線< 206208 Λ6 ___13_6_ 五、發明説明(23) FAB 質譜 m/ z : 1 86 ( [Μ+ΗΓ) ^-NMR (DMSO-d6) δ (ppm): 4.95-5.10 (2H, br), 6.61 (1H, dd, J=7.2, 4.8Hz), 6.80-6.86 (1H, m), 6.90 (1H, dd, J=7.2, 1.6Hz), 7.18-7.24 (2H, m), 7.49 (1H, dd, J=4.8, 1.6Hz), 7.60-7.65 (2H, m), 7.69 (1H, s) C 11 Hu N 3 之元素分析:
C Η N (請先閲誚背面之注意事項再塡寫本頁)
經濟部屮央標準局员工消费合作社印製 將 8.17g(50mmol)2-氮-3-硝吡啶及 16.70g(150mniol) 對-胺酚加至50ml二甲基甲醯胺中,並於100 °C下ig拌40 分。減壓蒸除溶劑,並依製備例1之方法處理之,由乙 醇再结晶可得9.4g目的化合物。 熔點:1 4 3 - 1 4 4 °C FAB 質箝 ra/z: 231(M+ ) -2 5 - 計 算 值 71.33 5.99 2 2.69 實 測 值 71.49 6.04 2 2.59 製 備 例 3 4 - C (3-硝 基-2 -吡啶基)胺基〕 酚 C 化 學 式27〕 本紙張尺度边用中國因家榣毕(CNS)甲4規格(210x297公龙) 206208 Λ 6 13 6 五、發明説明(24) ^-NMR (CDC13) δ (ppm): 5.23 (1H, s), 6.79 (1H, dd, J=4.8, 8.4Hz), 6.84 (2H, d, J=8.8Hz), 7.41 (2H, d, J=8.8Hz), 8.44 (1H, dd, J=1.6, 4.8Hz), 8.52 (1H, dd, J=1.6, 8.4Hz), 9.94 (1H, br-s) C u H 9 N 3 0 3之元素分析: ' C Η N 計算值 57.14 3.92 18.18 實測值 57.15 3.97 18.14 製備例 4 4 -〔( 3 -胺基-2 -吡啶基)胺基〕酚 〔化學式2 8〕
(請先閲讀背面之注意事項再填寫本頁) -裝- 訂- 線·
經濟部屮央橾準局β工消贽合作杜印M 仿製備例2之方法,將製備例3所得産物;3.25g(4Qmmol) 進行催化還原,並將其由甲酵再结晶可得7 · 8 g目的化合 物。 馆點:2 0 5 - 2 0 7。〇 FAB 質譖 ra/z: 202(〔M+H〕 + ) -26- 本紙5fc尺度通用中國Η家#毕(CNS)甲4規格(210X297公龙) 206208 Λ 6 13 6 五、發明説明(25) ^-NMR (DMSO-d6) δ (ppm): 4.94 (2Η, br-s), 6.50 (1H, dd, J=4.8, 7.6Hz), 6.66 (2H, d, J=8.8Hz), 6.82 (1H, dd, J=1.6, 7.6Hz), 7.38 (1H, s), 7.39 (2H,'d, J=8.8Hz), 7.40 (1H, dd, J=1.6, 4.8Hz), 8.85 (1H, s) C u H u N 3 0之元素分析: C Η N 計算值 65.66 5.51 20.88 實測值 65.85 5.51 20.84 製備例 5 3-〔(3-硝基-2-吡啶基)胺基〕.酚 〔化學式2 9〕
(請先閲讀背而之注意事項再填寫本頁) 經濟部中央櫺準而只工消#合作社印製 熔點:1 4 8 - 1 4 9 °C (由乙醇再結晶) F A B 質譜 ra/z: 232 ( [Μ+Η] Ί ^-NMR (CDC13) δ (ppm): 5.31 (1H, br-s), 6.65 (1H, dd, J=8.0, 2.4Hz), 6.85 (1H, dd, J=8.4, 4.8Hz), 7.08 (1H, dd, J=8.0, 2.4Hz), 7.24 (1H, t, J=8.0Hz), 7.37 (1H, t, J=2.4Hz), 8.49 (1H, dd, J=4.8, 1.6Hz), 8.54 (1H, dd, J=8.4, 1.6Hz), 10.11 (1H, br-s) -27- 本紙張尺度逍用中困Η家標毕(CNS)規格(2〗0χ297公:¢) 206208 Λ 6 Β 6 五、發明説明 (26) C 11 Η 9 Ν 3 〇 3 之元 素 分 析: C Η Ν 計算值 5 7 .1 4 3 .9 2 18.17 實測值 5 7 • 33 4 .0 3 18.18 製備例 6 3-〔(3-硝 基_ 2-吡 啶 基 )胺基〕 酚: 〔化學式3 0
熔點:於1 9 8 °C可觀察到缓慢之分解(由乙醇再結晶) FAB 質譜 in/ z : 2 0 2 ( [M+H]+) ^-NMR (DMSO-de) δ (ppm): 5.04 (2Η, s), 6.24—6.28 (1H, m), 6.60 (1H, dd, J=7.6, 4.8Hz), 6.89 (1H, dd, J=7.6, 1.6Hz), 6.97-6.99 (2H, m), 7.23 (1H, br-s), 7.50 (1H, dd, J=4.8, 1.6Hz), 7.57 (1H, s), 9.10 (1H, s) C ii Hu N a 0之元素分析: (請先閱讀背面之注意事項再填寫本頁) 裝· 線· 經濟部屮央橾準历只工消费合作社印製 C Η Ν 計 算 佰 6 5.66 5.51 20.88 實 m 佰 6 5.92 5.58 20.86 備 例 7 -28 本紙5fc尺度边用中國國家標毕(CNS)T4規格(210x297公龙) 206208 Λ 6 13 6 五、發明説明(27) 2-〔(4 -甲氣基甲氣苯基)胺基〕-3-硝吡啶 〔化學式3 1〕CH30CH30-h^-NH^^N 將 8.4g(54.8mmol)4-甲氣基甲氣苯胺及 7.5g(49mE〇l) 2-氯-3-硝吡啶溶於35ml二甲基甲醯胺。加入7.6g(55mmol) 無水碩酸鉀。將所得溶液於1 0 Q °C下加熱攪拌4小時。待 冷卻至室溫後濾除不溶物。減壓蒸除溶劑並將殘渣溶於 乙酸乙酯。將溶液以檸檬酸水及水洗。於MgS04下乾燥 後,減壓蒸除溶劑。並由乙醇再结晶可9. 68g目的化合 物。 焰點:8 0 - 8 1 °C F A B 質譜 in / z : 2 7 5 ( Μ + ) ^-NMR (CDC13) δ (ppm): 3.50 (3Η, s), 5.19 (2H, s) , 6.7 9 (1H, dd, J=4.4, 8.4Hz), 7.08 (2H, d, J=8.8Hz), 7.50(2H, d, J=8.8Hz), 8.45 (1H, dd, J=1.6, 4·4Ηζ), 8.51 (1H, (請先閱讀背面之注意事項再填寫本頁) 裝- 訂 線- 經濟部中央梂準局貝工消費合作杜印製 dd/ J=1.6, 8.4Hz) t 9.99 <1Η, br-s) C 13 Η χ3 Ν 3 0 4 之元素 分析: C Η Ν 計算值 56 • 73 4.76 15 ,27 實測值 57 • 06 4.83 15 . ,02 -29- 本紙張尺度逍用中困國家楳毕(CNS)甲4規格(210X297公龙) 206208 Λ 6 13 6 五、發明説明(28) 製備例 8 _ 2-〔N-苄氣羰基-N-(4-甲氣基甲基氣苯基)胺基]-3 硝吡啶 〔化學式3 2 ]
CHaOCH
C00CH 經濟部+央梂芈局A工消贽合作杜印製 將製備例7所製得化合物4 . 0 g ( 1 4 . 5 m m ο 1 )溶於7 G m 1二 甲基甲醯胺。加人720fflg(18minol)fiaH(60%)。於室溫攪 拌下滴加入3.2ml(22.4nimol)氣甲.酸苄酯。於室溫下攪 拌過一夜後,減壓蒸除溶劑。加入乙酸乙酯及水,並分 離乙酸乙酯層。將所分離之層以水洗,乾燥(於MgS04 ) ,濃縮,並由矽膠柱層析純可得4.5g油狀之目的化合物 〇 ^-NMR (CDC13) 6 (ppm): 3.47 (3H, s), 5.17 (4H, s+s), 7.06 (2H, d, J=8.8Hz), 7.22-7.26 (2H, m), 7.29—7.33 (4H, m), 7.37 (2H, d, J=8.8Hz), 8.29 (1H, d, J=8.0Hz), 8.56 (1H, d, J=4.4Hz) 製備例 9 4-〔N -苄氣羰基- N- (3 -硝基- 啶甚)胺基〕酚: 〔化學式3 3〕 3 0- 本紙5fc尺度边用中國困家標毕((^)肀4規格(210X297公让) (請先閲讀背而之注意事項再填寫本頁)
206208 Λ 6 Β6 五、發明説明(29)
經濟部中央標準局员工消t合作社印製 將製備例8所製得化合物500mg(1.22mniol)溶於6nl四 氫呋喃及lml水中。加入2ml濃HC1。當於室溫下攪拌過· 一夜後,減壓蒸除溶劑。加入乙酸乙酯及飽和碩酸氫鈉 水至殘渣,並分離出所形成之乙酸乙酯層。將此分離之 層以水洗,乾燥(於MgS04 )並濃縮可得445rag目的化合 物。 ^-NMR (DMSO-d6) δ (ppm): 5.11 (2H, s), 6.77 (2H, d, J=8.8Hz), 7.18-7.24 (4H, m), 7.31-7.34 (3H, m), 7.58 <1H, dd, J=4.8, 8.0Hz), 8.51 (1H, dd, J=l.6, 8.0Hz), 8.66 (1H, dd, J=l.6, 4.8Hz), 9.64 (1H, s> 製備例 1 0 第三丁氧羰胺乙酸4-〔(3 -胺基-2-吡啶基)胺基〕苯酯 〔化學式3 4〕(CHa) 3coconhch2coo-^^- nh^n^ 將於製備例9所製得化合物4 4 0 in g ( 1 · 2 n m ο 1 ) , 2 5 0 HI g ( -3 1 - (請先閲讀背而之注意事項再填寫本頁) 裝. 訂 本紙張尺度遑用中明國家楳毕(CNS) T4規格(210X297公釐) 206208 A 6 13 6 五、發明説明(30) 1·43πιιηο1)Ν-(第三丁氣羰基)甘油及 25mg(0.2mmol)4 -二 甲胺吡碇溶於lOral吡啶中。加入290mg(1.41mmol)l,3-二環己基碩化二亞胺。於室溫下攪拌過一夜後,減壓蒸 除溶劑。加入乙酸乙酯至殘渣中,濾除不溶物,並減 壓蒸除溶劑。將殘渣以矽膠柱層析純化,並將所得化合 物於存在P d - C催化劑之下,以普通方法進行催化還原。 濾除催化劑後濃縮,並以矽膠柱層析純化可得2 3 6 m g目 的化合物。 ^-NMR <DMSO-d6) δ (ppm): .. 1.41 (9H, s), 3.93 (2H, d, J=6.0Hz), 5.05 (2H, br-s), 6.62 (1H, dd, J=4.8, 7.2Hz), 6.90 (1H, dd, J=1.6, 7.2Hz), 6.96 (2H, d, J=9.2Hz), 7.37 (1H, br-t, J=6.4Hz), 7.49 (1H, dd, J=1.6, 4.8Hz), 7.64 (2H, d, J=9.2Hz>, 7.79 (1H, s) 製備例1 1 4-〔〔 3-(4 -甲氧苯磺醛胺基)-2 -吡啶基〕胺基〕苯 基-2, 3 ,4, 6 -四-鄰-乙醯基-办-D-吡喃葡糖 〔化學式3 5〕 (請先閲讀背而之注意事項再塡寫本頁) 裝- 訂 線< 經濟部中央標準局貝工消費合作社印製
OAc 3 2 本紙張尺度逍用中國困家標準(CNS)甲4規格(210X297公*) 206208 Λ 6 13 6 經濟部中央標準局貝工消费合作社印製 五、發明説明(31) 將於例6所製得化合物3.753g(lQ.l{lmmol)及3.959g (10.14nimol)e -D -蕕萄糖五乙酸鹽懸浮於200ml 1,2 -二 氦乙烷。於氮氣及冰之冷卻攪拌下滴加入含四氯化錫之 二氛甲烷1 · 0 Μ 3 0 Π 1。於冰冷卻下攢拌2小時後再於室 溫下攪拌4天,再將反應液加入含I6g碩酸氫鈉之冰水中 。減壓蒸除有機溶劑。加入乙酸乙酯至殘渣,並將所形 成之不溶物濾除。分離乙酸乙酯層,水洗,乾燥,濃縮 並由矽膠柱層析純化可得2 . 4 7 g目的化合物。 XH-NMR (CDClj) 5 (ppm): 2.04 (3Hf s), 2.05 (3H, s) , 2.08 (3H, s) , 2.10 (3H, s), 3.80-3.86 (1H, m), 3.84 (3H, s) , 4.17 (1H, dd, J=12.4, 2.4Hz), 4.30 (1H, dd, J=12.4, 5.6Hz), 4.99 (1H, d, J=7.6Hz), 5.16 (1H, t, J=9.6Hz), 5.23-5.32 (2H, m), 6.37 (1H, br-s), 6.54 (1H, dd, J=4.8, 7.6Hz), 6.84 (1H, dd, J=1.6, 7.6Hz), 6.92 (2H, d, J=8.8Hz), 6.94 (2H, d, J=8.8Hz), 7.32 (1H, br-s), 7.38 (2H, d, J=8.8Hz), 7.69 (2H# d, J=8.8Hz), 8.07(1H, dd, J=1.6# 4.8Hz). 製備例1 2 N-(2-胺苯基)-4-甲氣苯磺醯胺: 〔化學式3 6〕 -33- 本·紙張尺年逍用中國國家標毕(CNS)甲4規格(210x297公*) (請先閲讀背面之注意事項再塡寫本頁) 裝· ,?τ- -線- 206208 Λ 6 13 6 五、發明説明(32) C1U0 將 33.1g(0.3mmol)l,2 -伸苯二胺溶於 200ml 二鸣烷。 於攪拌下加人含20.87g(0.1mmol)4 -甲氣笨磺基氣之二 垮烷llOmU將反應液於室溫下攛拌過一夜。加入12.1g (0·ΐ2πιο1)三乙胺。濃縮後加入檸樣酸溶液及乙酸乙酯 ,分離有機層,濃縮,並由矽膠柱層析純化可得27. lg 目的化合物。 熔點:1 4 1 - 1 4 2 °C C由I醇再結晶) FAB 質譜 m/z: 2 7 9 ([Μ+ΗΓ) ^-NMR (DMSO-d6) 6 (ppm): 3.81 (3H, s), 4.91 (2H, br-s), 6.37 (1H, td, J=1.6, 7.2, 8.0Hz), 6.60 <1H, dd, J=1.6, 8.OHz), 6.66 (1H, dd, J=1.6, 8.0Hz), 6.86 (1H, td, J=1.6, 7.2, 8.0Hz), 7.03 (2H, d, J=8.8Hz), 7.61 (2H, d, J=8.8Hz), 9.07 (1H, br-s) (請先閲讀背面之注意事項再填窝本頁) 裝- 訂 線- 經濟部中央標準局貝工消t合作社印製 c 13 H !4 N 2 〇 3 s之元素分析: C H 計算值 56.10 5.07 實測值 55.98 5.03 製備例1 3 N- (2-胺苯基)-4-硝苯磺醯胺 "3 4- N 10.0710.00 各紙張尺度逍用中B B家楳準(CNS)甲4規格(210X297公«:) 206208 Λ 6 13 6 五、發明説明(33) 〔化學式3 7〕
S〇aNHH.N X) 仿製備例1 2之方法可製得目的化合物。 熔點:1 9 0 - 1 9 1 °C (由苯再結晶) FAB 質譜 m/ z : '2 9 4 ^-NMR (DMSO-d6) 5 (ppm): 4.90 (2Η, br-s), 6.42 (1H, dt, J=1.6, 8.0Hz), 6.61 (1H, dd, J=1.6, 8.0Hz), 6.71 (1H, dd, J=1.6, 8.0Hz), 6.91 (1H, dt, J=l.6, 8.0Hz), 7.91 <2H, d, J=8.8Hz), 8.36 (2H, d, J=8.8Hz) Cl2 HllN*〇4S之元素分析: * C Η N 計算值 49.14 3.78 14.33 實測值 49.38 3.82 14.13 製備例 1 4 N-(2-胺基-3-甲苯基)-4-甲氣苯磺醯胺: 化學式3 8〕 (請先閲讀背面之注意事項再塡寫本頁) 裝·
iT 線- 經濟部中央標準局员工消費合作社印製 C1U0 JQr s〇3nh 3 5- 本紙張尺度遑用中國國家橾毕(CNS) τ 4規格(210父297公龙)
206208 Λ 6 13 6 五、發明説明(34) 彷製備例1 2之方法可製得目的化合物。 熔點:177-178 °C (由乙醇再結晶) FAB 質譜 m/ z : 2 9 3 ([Μ+ΗΓ) ^-NMR (DMSO-d6) 5 (ppm): 2.03 (3H, s), 3.81 (3H, s) , 4.75 (2H, br-s), 6.30 (1H, t, J=7.6Hz), 6.44 (1H, dd, J=1.2, 7.6Hz), 6.79 <1H, dd, J=1.2, 7.6Hz), 7.04 (2H, d, J=8.8Hz), 7.61 (2H, d, J=8.8Hz) c 14 H 16 N 2 0 3 S之元素分析: C Η N 計算值 57·52 5.52 9.58 實測值 57.76 5.51 9.57 例 Ν-(2 -苯胺基-3-吡啶基)-對-甲苯磺醯胺: 化學式3 9〕
(請先閲讀背而之注意事項再填寫本頁) 裝· 訂 線- 經濟部中央標準局貝工消费合作社印製 將製備例2所製得化合物3 · 7 g ( 2 Q m ίο ο 1)溶於3 0 m 1吡啶 。於室溫攪拌下分批加人含3.81g(20mmol)對-甲苯磺 基氯之四氫呋喃3Q®U攪拌過一夜後,減壓蒸除溶劑並 將殘渣溶於乙酸乙酯中。將溶液以水洗並於MgS04下乾 燥。減壓蒸除溶劑並由乙醇再結晶可5.2g目的化合物。 -3 6 - 木紙張尺度逡用中Η國家標毕(CNS)甲4規格(210x297公狀) 206208 Λ 6 13 6 五、發明説明(35) 熔點:164-165 °C FAB 質譜 πι/ζ: 3 4 0 ([Μ+ΗΓ] > ^H-NMR (DMSO—d6) δ (ppm): 2.23 (3H, s), 6.73 (1H, dd, J= 4.8, 7.6 Hz), 6.86-6.92 (1H, m) , 7.18-7.24 (2H, m) , 7.24 (2H, d, J=8.0Hz), 7.27 (1H, dd, J=7.6, 1.6Hz), 7,36-7.42 (2H, m), 7.54 (2H, d, J=8.〇Hz), 7.86 (1H, s), 7.99 (1H, dd, J=4.8, 1.6Hz), 9.62 (1H, s) CibHi?N3 〇2 S之元素分析: C Η N 計算值 63.7(] 5.05 實測值 63.77 5.11 12.38 12.28 (請先閲讀背而之注意事項再填寫本頁) 裝. 例 N- (2 -苯胺基- 3-¾啶基)-4 -乙苯磺醛胺 化學式4 0 ] CH3CH2
1~ 訂::線· 經濟部中央標準局员工消費合作社印製 將製備例 2所製得化合物3.11g(16.8mmol)與3.43g (16·8πιιηο1)對-乙苯磺醯基氣反應,並將産物處理以例 1之方法可得5 . 0 g目的化合物。 熔點:1 3 8 - 1 3 9 °C (由乙醇再結晶) -3 7 - 本紙张尺度遑用中國B家標毕(CNS)甲4規格(210 X 297公釐) 306308 Λ 6 13 6 五、發明説明06) F A Β 質譜 m/ z : 3 5 4 ( ( [Μ+Η]。 1H—NMR (DMSO—d6) δ (ppm): 1.02 (3H, t), 2.50 (2H, q) , 6.72 (1H, dd, J=5.2, 8.0Hz), 6.83-6.89 (1H, m), 7.14-7.20 (2H, m), 7.24 (2H, d, J=8.4Hz), 7.29 (1H, dd, J=8.0, 1.8Hz), 7.32-7.37 (2H, m), 7.54 (2H, d, J=8.4 Hz), 7.80 (1H, s), 7.97 (1H, dd, J=5.2, 1.8Hz), 9.60 (1H, s) 計算值 實測值 2 S之元素 分析: C Η Ν 6 4.57 5.42 11.89 6 4.89 5.33 12.00 (請先閲讀背而之注意事項再填寫本頁) 裝· 例 N-(2 -苯胺基-3-吡啶基)-4 -甲氣苯磺醯胺 化學式4 1〕 CH,0
S03NH
Or
NH
線. 經濟部中央標準局貝工消f合作社印製 將製備例2所製得化合物1.39g(7.5ainiol)】.55g(7.5fliniol 對一甲氣苯磺醯氣反應,並將産物處理以例i之方法可 得2 . 6 g目的化合物。 熔點:172-173 °C (由乙醇再結晶) FAB 質譜 ai/ z : 3 5 6 ([M+H]+) 冬紙張尺度遑用中a B家楳毕(CNS)肀4規格(210X297公«:) 206208 Λ 6 Β6 五、發明説明(37) ^H-NMR (DMS〇-d6) δ (ppm): 3.68 (3H, s), 6.71 (1H, dd,丨 J=7.6, 5 6.84-6.90 UH, m), 6.92 (2H, d, J=9. 7.15-7.22 (2H, m), 7.25 (1H, dd, J= 7.36-7.42 (2H, m), 7.57 (2H, d, J=9. (1H, s), 7.97 (1H, dd, J=5 - 0 ,1.2Rz) S) C 16 H 1V N : 3 0 3 S之元素 分析 ; C H N 計算值 6 0.83 4.82 1 1.82 實測值 6 1.02 4.69 1 1.86 4 4-甲氧基 -N - [ 2 - [(4 -甲氣 苯基 )胺基〕 (請先閲讀背面之注意事項再填寫本頁) 裝· 經濟部中央標準局员工消費合作社印製 3 - %啶基〕 苯磺醯胺 〔化學式4_2〕' SOaNH^^ 依例1之方法可得目的化合物。 熔點:145-147 °C (由乙醇再結晶) FAB 質譜 m/ z : 3 8 6 ([M+H]*) ^-NMR (CDC13) δ (ppm): 3-79 (3H, s), 3.85 (3H, s), 6.16 (1H, br-s), 6.52
3 9 私紙張尺度遑用中B國家«準(CNS)甲4規格(210X297公«) ,11_ 線· 206_— 五、發明説明(38) Λ 6 13 6 (1Η, dd, J=4.8, 7.6Hz), 6.85 (3H, d, J=8.8Hz), 6.93 (2H, d, J=8-8Hz), 7.12 (1H, br-s), 7.32 (2H, d, J=8.8Hz), 7.69 (2H, d, J=8.8Hz), 8.07 (1H, dd, J=1.6,4.8Hz) 1S N 3 0 4 S之元素分析: C Η N 值 59.21 4.97 10.90 值 59.26 5.05 10.75 計算 實測 例 5 4 -甲氣基-N -〔 基〕苯磺醯胺 〔化學式4 3〕 (4 -甲氣甲氣苯基)胺基] -吼啶 (請先閲讀背面之注意事項再填寫本頁) 裝- 乂 CH3〇 - —S0aNH^\
"V- Cll3〇CHaQ
訂 -線· 經濟部中央標準局貝工消費合作社印製 依例1之方法可 得目的化合物。 溶點:1 1 8 - 1 1 9 °C (由乙醇再結晶) FAB 質譜 m/ z : 4 1 6 ( ([Μ+ΗΠ ) 'H-NMR (CDC13) δ (ppm): 3.48 (3H, s), 3.83 (3H, s), 5.13 (2H, s), 6.45 (1H, br-s), 6.52 (1H, dd, J=4.4r 7.6 Hz), 6.87 (1H, dd, J=1.6, 7.6Hz), 6.92 (2H, d, J=8.8Hz), 6.97 (2H, d, J=8.8Hz), 7.16 (1H, br-s), 7.31 (2H, d, J=8.8Hz), 7.69 (2H, d, J=8.8Hz), 8.07(1H, d). -40- 本紙張尺本逍用中H國家楳準(CNS)甲4規格(210X297公:*) 206208 Λ 6 J3 6 五、發明説明(39) C 20 Η 21 Ν 3 0 Ξ S之元素分析: C Η 例 計算值 5 7.82 5.09 10.11 實測值 β 5 7.93 5.02 9.84 0 Ν - [ 2- 〔(4 -羥苯基 )胺基〕-3 -吡啶基〕 -4 -甲氧苯磺 醯胺: 〔化學式4 4〕 CH,0
K0
S02NH-^\Vnh^V (請先閲讀背而之注意事項再填寫本頁) 裝· 經濟部中央標毕局员工消费合作社印製 將製備例4所得化合物l.Glg(5mmol)與1.05g(5mmol) 對-甲氣苯磺醯氯反應,並將産物依例1之方法處理可 得1 . 4 3 g目的化合物。 熔點:1 7 8 - 1 7 9 °C (由乙醇再結晶) FAB 質譜 in/z: 372 ( [M+H]*) XH-NHR (DMSO-d6) δ (ppm): 3.75 (3H, s), 6.60 (1H, dd, J=4.8, 7.6Hz), 6.63 (2H, d, J=8.8Hz), 6.98 (2H, d, J=8.8Hz), 7.14 (2H, d, J=8.8Hz), 7.18 (1H, dd, J=1.6, 7.6Hz), 7.58 <1H, br-s), 7.60 (2H, d, J=8.8Hz), 7.88 (1H, dd, J=1.6, 4.8Hz), 8.97 (1H, s), 9.44 <1H, s) c IS H 17 N 3 0 4 s之元素分析: -41- 各紙張尺度遑用中β B家樣毕(CNS) 規格U10X297公龙) 206208 Λ 6 13 6 五、 發明説明 (40) C Η Ν 計 算 值 58.21 4 .6 1 1 Κ 3 1 實 測 值 58.40 4 .67 11.38 將 巨 的化 合物2 . G g溶於 5 0 m 1 四 氫呋喃中。加入0 . 5 m 1 濃HC 1 , 並將溶液濃縮乾燥。將殘渣由甲醇再結晶可得 1 . Sg 目 的化 合物之鹽酸鹽 熔點 : 於2 2 5 °C會逐漸地分解 C ie Η 17 N 3 0 4 S · HC 1之元 素分析 ; C Η N 計 算 值 53.01 4 .4 5 10.30 實 測 值 52.97 4 .33 10.19 例 7 4 - 甲 氣基 -N- [ 2- Γ (4- 吡啶基 )胺基〕-3 -吡啶基〕- 苯磺醯胺: 〔化學式4 5〕
(請先閲讀背面之注意事項再填寫本頁) 裝- 經濟部中央標準局負工消费合作社印製 依例1之方法可製得目的化合物。 熔點:1 7 2 - 1 7 3 °C (由乙酸乙酯再結晶) FAB 質譜 m/z: 357 ( [Μ+ΗΓ} 'H-NMR (DMSO-d6) 6 (ppm): 3.67 (3H, s), 6.86-6.91 (3H, m), 7.37 (1H, dd, J=1.6, 7.6Hz), 7. 48 (2H, d, J=5.6Hz), 7.54 (2H, d, J=9.2Hz), 8.04 (1H, dd, J=l.6, 4.8Hz), 8.26 (2H, d, J=5.6Hz), 8.59 (1H, br-s) -4 2 - 本紙張尺度蟓用中國國家«準(CNS)甲4規格(210X297公龙) 20G208 Λ6 13 6 五、發明説明 (41) C 17 H 1 16 N 4 〇 3 S之元 素分析: C Η Ν 計算 值 5 7.29 4.53 15.72 實測 值 5 7.37 4.56 15.66 例 8 4 -甲 氧基- N- [ 2-[ (4 -甲苯基 )胺基〕 磺醯胺: 〔化學式4 6〕
CHaO-^ y—SQaNH-^ChT-^nh^V (請先閲讀背而之注意事項再塡寫本頁) 裝- 經濟部中央標準局負工消費合作社印製 依例1之方法可製得目的化合物。 熔點:188-189 °C (由乙醇再結晶) FAB 質譜 m/z: 37G ( [M+H]+) XH-NMR (DMS〇-d6) δ (ppm): 2.21 (3H, s), 3.69 (3H, s), 6.66 (1H, dd, J=6.4, 2.4Hz), 6.92 <2H, d, J=7.2Hz), 6.99 (2H, d, J=7.6Hz), 7.21 (1H, dd, J=6.4, 1.6Hz), 7.27 (2H, d, J=7.2Hz), 7.56 (2H, d, J=7.6Hz), 7.75 (1H, s) 7.93 (1H, dd, J=2.4, 1.6Hz), 9-48 (1H, br-s) C 19 H 19 Ng 〇3 S之兀素分析: C Η N 計算值 61.77 5.18 11.38 實測值 61.82 5.21 11.30 -4 3 - 訂- 本紙張尺度遑用中《國家«毕(CNS)甲4規格(210X297公!《:) 206208 Λ 6 13 6 五、發明説明(42 ) 例 9 N-〔 2-〔(2 -氟苯基)胺基〕-3 -吡啶基〕-4 -甲氣苯磺 醯胺: 〔化學式4 7〕 ch3〇
依例1之方法可製得目的化合物。 熔點:1 4 8 - 1 5 0 °C (由乙醇再結晶) FAB 質譜 m/ z : 3 7 4 ([Μ+ΗΓ) lH-NMR (DMSO-d6) δ (ppm): 3.72 (3H, s), 6.76 (1H, dd, J=7.6, 4·8Ηζ), 6.90-6.98 (3H, m), 7.05 (1H, td, J=8.0, 0.8Hz), 7.13-7.20 (2H, m), 7.57 (2H, d, J=8.8Hz), 7.82 (1H, d, J=2.8Hz), 7.95 (1H, t, J=8.0Hz), 8.01 (1H, dd, J=4.8, 1.6Hz), 9.76 (1H, s) (請先閱讀背而之注意事項再填寫本頁) 裝· 訂_ 經濟部中央標準局β工消費合作社印製 C is fi :ie FN Ξ 3 〇 3 S之元素分析: C Η 計算 值 5 7.90 4.32 11.25 實測 值 5 7.93 4.57 10.98 例 10 N-[ 2-[ (3 -氟苯基 )胺基〕-3- -咐旋基 4 -甲氣苯磺 -44 本紙張尺度逍用中《明家標毕(CNS)甲4規格(210X297公*) 206208 Λ 6 13 6 五、發明説明(43) 醯胺: 〔化學式4 8 ]
依例1之 熔點:180-181 °C (由乙醇再結晶) FAB 質譜 m/z: 374 ([Μ+ΗΓ) ^-NMR (DMSO-d6) δ (ppm): 3.69 (3Η, s), 6.67 (1H, td, J=8.4, 2.0Hz), 6.81 (1H, dd, J=7.6, 4.8Hz), 6.92 (2H, d, J=8.8Hz), 7.09 (1H, dd, J=8.4, 2.0Hz), 7.22 (1H, dt, J=8.4, 6.8Hz) , 7.31 (1H, dd, J=7.6, 1.6Hz), 7.49 (1H, dt, J=2.0, 12.4Hz), 7.56 (2H, d, J=8.8Hz), 8.05 (1H, dd, J=4.8, 1.6Hz), 8.12 (1H, s), 9.52 (1H, br-s) (請先閲讀背而之注意事項再塡寫本頁) 裝· 訂' 經濟部中央標準局貝工消费合作社印製 3 S之元素分析 C Η Ν 計算值 57.90 4.32 11.25 實測值 57.89 4.42 11.16 11 -4 5 - 私紙張尺度遑用中國國家«华(CHS)甲4規格(210X297公:¢) 206208 66 ΛΒ 五、發明説明(44) N-〔2-〔(4 -氟苯基)胺基〕-3 -吡啶基〕-4 -甲氣苯磺 醯胺: [化學式4 9〕 ch3〇
依例1之方法可製得目的化合物。 熔點:1 9 6 - 1 9 7 °C (由乙醇再結晶) F AB 質譜 m/ z : 3 7 4 ( [Μ+ΗΓ) iH-NMR (DMSO-d6) δ (ppm): 3.71 (3H, s), 6.72 (1H, dd, J=4.8, 7.6Hz), 6.95 (2H, d, J=8.8Hz), 7.04 (2H, t, J=8.8Hz), 7.25 (1H, dd, &=1.6, 7·6Ηζ), 7.42 (2H, m), 7.58 (2H, d, J=8.8Hz), 7.95 (1H, br-s), 7.98 (1H, dd, J=1.6, 4.8Hz), 9.48 (1H, br-s) C os H ie N 3 0 a S之元素分析: (請先閲讀背面之注意事項再填寫本頁) 裝- 線- 經濟部中央標準局貝工消費合作社印製 C Η Ν 計算值 5 7.90 4.32 11.25 實測值 57.83 4.32 11.21 例 12 N-(2 -苯胺基-3-吡啶基)苯磺醯胺 〔化學式5 0〕 -4 6 - 紙张尺度遑用中國國家樣準(CNS) T4規格(210X297公*) 206208 Λ 6 13 6 五、發明説明(45) 依例1之方法可製得目的化合物。 熔點:1 4 8 - 1 5 0 °C (由甲醇再結晶) FAB 質譜 m/z: 326 ( [Μ+ΗΓ) XH-NMR (DMSO-d6)' δ (ppm): 6.73 (1H, dd, J=7.6, 4.8Hz), 6.87-6.93 (1H, m), 7.18-7.24 (2H, m), 7.25 (1H, dd, J=7.6, 1.6Hz), 7.41-7.47 (2H, m), 7.47-7.51 (2H, m), 7.51-7.57 (1H, m) 7.67-7.72 (2H, m), 7.90 <1H, s), 7.99 (1H, dd, J=4.8, 1.6Hz), 9.73 (1H, s)
C 17 H 15 計算值 實測值 3 〇 2 S之元素分析: C Η N 62.75 4.65 12.91 63.03 4.74 12.67 (請先閲讀背而之注意事項再填寫本頁) 例 13 經濟部中央標準局员工消#合作社印製 4 -甲氣基-N-〔 2-〔(3 -甲氣苯基)胺基〕-3 -吡啶基 苯磺醯胺: 〔化學式5 1〕
4 7 - 本紙张尺度邋用中》a家樣JMCNS)甲4規格(21〇5<297公货) 206208 Λ 6 13 6
五、發明説明(46) 依例1之方法可製得目的化合物。 熔點:1 6 1 - 1 6 2 °C (由乙醇再結晶) FAB 質譜 m/ z : 3 8 6 ([Μ+Η]Ί ^-NMRdDMSO-de) 6 (ppm): 3.67, 3.70 (3Hx2>, 6.47 (1H, dd, J=8.0, 2.0Hz), 6.73 (1H, dd, J=8.0, 4.8Hz), 6.93 (2H, d, J=8.8Hz), 6.97 (1H, dd, J=8.0, 2.0Hz), 7.10 (1H, t, J=8.0Hz), 7.13 (1H, t, J=2.0Hz), 7.29 (1H, dd, J=8.0, 1.6Hz), 7.59 (2H, d, J=8.8Hz), 7.89 (1H, s)t 8.01 (1H, dd, J=4«8/ 1.6Hz)/ 9.55 (1H, s). CisH19N3 04 S之元素分析: C Η N 計算值 5 9.21 4.97 10.90 實測值 5 9.14 4.96 10.74 例 14 4-羥基-N-〔 2-〔(4-羥苯基)胺基〕-3-吡啶基〕苯磺 醯胺: 〔化學式5 2〕 (請先閲讀背面之注意事項再填寫本頁) 裝- 線· 經濟部中央標準局员工消费合作社印製 s〇2nh、^
依例4製得之化合物溶於D M F ,並加入5傾當量之甲 烷硫醇鈉。將所得溶液加熱至1 G 0 °C可得目的化合物。 -4 8 - 本紙張又度遑用中B 8家樣準(CHS)甲4規格(210X297公址) 206208 Λ 6 Β6 經濟部中央標準局貝工消費合作社印製 五、發明説明(47) 熔點:2 5 2 - 2 5 7 °C (分解)(由乙醇/水再結晶) FAB 質譜 m/z: 358 iH-NMR (DMSO-d6) δ (ppm): 6.60 (1Η, dd, J=7.6, 4.8Hz), 6.65 (2H, d, J=8.8Hz), 6.81 (2H, d, J=8.8Hz), 7.14 (1H, dd, J=7.6, 1.6Hz), 7.19 (2H, d, J=8.8Hz), 7.52 (2H, d, J=8.8Hz), 7.61 (1H, s), 7.87 (1H, dd, J=4.8, 1.6Hz), 9.01 (1H, s), 9.39 (1H, s) , 10.42 (1H, s) 例 15 N-〔 2-〔(3,4 -二甲氣苯基)胺基〕-3 -吡啶基]-4 -甲 氧苯磺醯胺: 〔化學式5 3〕 CH3〇O^a2NHTi CHaO-fJh-NH^N^ CH,0 尸 依例1之方法可製得目的化合物。 熔點:126-127 °C (由乙醇再結晶) FAB 質譜 m/ z : 4 1 5 (M+ ) W-NMR (DMSO-d6) δ <ppm): 3.72, 3·73 (3Hx3>, 6.66 (1Η, dd, J=8.0, 3.6Hz), 6.81 (1H, d, J=8.8Hz), 6.96-6.98 (3H, m), 7.02 (1H, s), 7.21 (1H, dd, J=8.0, 1.2Hz), 7.60 (2H, d, J=8.0Hz), 7.73 <1H, s), 7.95 (1H, dd, J=3.6, 1·2Ηζ), 9.45 (1H, br-s) -49- (請先閲讀背面之注意事項再填寫本頁) 裝· .可_ 線- 本紙張尺度逍用中两國家標準(CNS)甲4規格(210X297公*) 206208 Λ 6 13 6 五、發明説明(48)C20H21N3 〇5 S之元素分析: C Η 計 算 值 5 7. 8 2 5.10 10.1 2 實 測 值 5 7 . 7 3 5.10 10.0 7 例 1 6 4 - 甲 氣 基-N-〔 2-[ (ί !-甲氣 苯基)胺 基〕-3 -吡啶基 苯 礎 m 胺 : 化 學 式 5 4] ch3〇
(請先閲讀背而之注意事項再填寫本頁) 經濟部中央標準局負工消費合作社印製 依例1之方法可製得目的化合物。 熔點:1 5 9 - 1 6 0 °C (由乙醇再結晶)FAB 質譜 m/ z : 3 8 6 ( [M+H]+) ^-NMR (DMSO-d6) δ (ppm): 3.78 (3Η, S), 3.89 (3Η, s), 6.69 (1Η, dd, J=7.6, 4.8Hz), 6.87-6.90 (2H, m) , 6.96-7.01 (2H, m), 7.05 (2H, d, J=8.8Hz), 7.66 (2H, d, J=8.8Hz),8.08 (1H, dd, J=4.8, 1.6Hz), 8.10 (1H, s), 8.40 (1H, dd, J=6.4, 2.8Hz), 9.78 (1H, s)C19H19N3 o4 s之元素分析: -5 0 - 私紙張尺度逸用中B B家«準(CNS) T 4規格(210父297公址) 206208 Λ 6 13 6 五、發明説明(49) C Η · Ν 計算值 59.21 4.97 10.90 實測值 59.16 5.01 10.96 例 17 4 -甲氣基- Ν-〔 2-〔(3 -甲苯基)胺基〕-3 -吡啶基〕苯 磺醯胺: 〔化學式5 5 ]
CHaQ
(請先閲讀背而之注意事項再填寫本頁) 經濟部中央標準局貝工消费合作社印製 依例1之方法可製得目的化合物。 熔點:1 4 7 - 1 4 8 °C (由乙醇再結晶) FAB 質譜 m/ z : 3 7 0 ( [Μ+ΗΠ ^-NMRiDMSO-dj) δ (ppm): 2.26 (3H, s), 3.71 (3H, s), 6.71-6.73 (2H, m) 6.95 (2H, d, J=7.6Hz), 7.09 (1H, t, J=7.6Hz), 7.16 (1H, s), 7.25-7.27 (2H, m) , 7.59 (2H, d, J=7.6Hz), 7.90 (1H, s), 8.00 (1H. dd, J=2.8, 1.6Hz), 9.53 (1H, br-s) C H 1S N 3 0 3 S之元素分析-· -51 私紙張尺度逍用中B B家樣毕(CNS)甲4規格(210X297公釐) 裝- 訂- -線- 206208 Λ 6 13 6 五、發明説明(50) C Η Ν 計 算 值 61.77 5.18 11.38 實 測 值 6 1.79 5.18 11.46 例 18 4 -甲氣基- Ν-〔2-〔(2 -甲苯基)胺基〕-3-Ptfc啶基〕苯 磺醯胺: 〔化學式5 6〕
(請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局貝工消费合作社印製 依例1之方法可製得目的化合物。 熔點:1 4 7 - 1 4 8 °C (由乙醇再結晶) FAB 質譜 m/z·· 370 ([M+H]+> iH-NMR (DMSO-de) δ (ppm): 2.06 (3H, s), 3.77 (3H, s) , 6.65 (1H, dd, J=7.6, 4.8Hz), 6.92 (1H, t, J=7.6Hz), 7.03 (2H, d, J=8.8Hz), 7.09 (1H, t, J=7.6Hz), 7.11-7.15 (2H, m) , 7.53 (1H, s), 7.55 (1H, d, J=7.6Hz), 7.63 (2H, d, J=8.8Hz), 7.91 (1H, dd, J=4.8, 1.6Hz), 9.67 (lH,s) C 19 H 1S N 3 0 3 S之元素分析: 訂- 線- 本紙張尺度遑用中BB家樣準(CNS)甲4規格(210x297公;it) 206208 Λ 6 13 6 五、發明説明(51) C 計算值 61.77 實測值 61.80 例19 Η 5.18 5.17 Ν 11.38 11.40 Ν - ( 2 -苯胺基-3 -吡啶基)-4-經苯磺醯胺 化學式5 7〕
(請先閲讀背而之注意事項再填寫本頁) 經濟部中央標準局貝工消費合作社印製 將例3化合物依例1 4之方法處理則可得目的化合物£ 溶點:2 2 6 - 2 2 8 °C (由甲醇再結晶) FAB 質譜 m/ z : 3 4 2 (〔 M + H〕+ ) 'H-NMR (DMS〇-d6) δ (ppm): 6.71 (1H, dd, J=7.6, 4.8Hz), 6.79 (2H, d, J=8.8Hz), 6.88-6.94 (1H, m), 7.21 (1H, dd, J=7.6, 1.6Hz), 7.21-7.27 (2H, m), 7.46-7.51 (2H, m), 7.52 (2H, d, J=8.8Hz), 7.92 (1H, s), 7.97 (1H, dd, J=4.8, 1.6Hz), 9.50 (1H, s), 10.40 (1H, s) 例 20 N-(2 -苯胺基-3-吡啶基)-4 -硝苯磺醯胺: 〔化學式5 8〕 本紙張凡度逡用中國國家標準(CNS)甲4規格(2K1X297公龙) 206208 Λ 6 Β 6 五、發明説明(52 )
依例1之方法可製得目的化合物。熔點:1 9 1 - 1 9 2 °C (由乙醇再結晶) FAB 質譜 in/ z : 37 1 ([M+H]+) XH-NMR (DMSO-d6) δ (ppm): 6.80-6.83 (2Η, m), 7.12 (2H, t, J=8.4Hz), 7.25 (2H, d, J=8.4Hz), 7.40 (1H, dd, J=1.6, 7.6Hz), 7.83 (3H, d, J=8.8Hz), 8.07 (1H, br-s), 8.19 (2H, d, J=8.8Hz>, 9.91 (1H, br-s)Cr7H14N4 〇4 S之元素分析: C Η N 計算值 55.13 3.18 15.13 實測值 55.17 3.97 14.77例 2 1 4 -胺基- N- (2 -苯胺基-3-吡啶基)苯磺醯胺:〔化學式5 9〕 (請先閲讀背而之注意事項再填寫本頁) 裝- 訂- 線· 經濟部中央標準局貝工消t合作社印製
將例2 0之化合物,於存在p - C催化劑之下,依常法進 行催化還原而得目的化合物。 熔點:2 2 8 - 2 3 0 °C (由乙醇再結晶) FAB 質譜 ib/z: 341 ([M+H]+) -54- 表紙張尺來ϋ用中a Η家樣準(CNS)甲4規格(210X297公釐) 206208 Λ 6 13 6 五、發明説明(53) 1H-NMR (DMSO—d6) δ (ppm): 5.99 (2H, br-s), 6.50 (2H, d, J=8.8Hz), 6.70 (1H, dd, J=4.4, 7.6Hz), 6.91 (1H, td , J=0.8, 7.2Hz), 7.18 (1H, dd, J=1.6, 7.6 Hz), 7.24 (2H, t, J=7.6Hz), 7·33 (2H, d, J=8.8Hz), 7.έ3 (2H, dt, J=l.2, 7.6Hz), 7.95 (2H, br-s), 9.31 (1H, s) C 17 H 16 N 4 〇 2 S之元素分析: C Η N 59.98 4.74 16.46 60.08 4.67 16.23 計算值 實測值 例 2 2 N-(2 -苯胺基-3-毗啶基)-3,4 〔化學式6 0〕 甲氧苯磺醞胺 (請先閲讀背面之注意事項再填寫本頁) 裝· 訂-
經濟部中央標準局貝工消費合作社印製 依例1之方法可製得目的化合物。 熔點:1 7 1 - 1 7 2 °C (由乙醇再結晶) FAB 質譜 m/z: 386 ( [Μ+Η]+) xH-NMR (DMSO-d6) δ (ppm): 3.64 (3Η, s), 3.69 (3H, s), 6.75 (1H, dd, J=4.8, -55- 本紙張尺度逍用中國B家«準(CNS)甲4規格(210X297公;it) 206208 Λ6 B6 7.6Hz), 6.88 (1H, t, J=7.6Hz), 6.93 (1H, d, 五、發明説明(54) J=8 . 8Hz), 7.10 (1H, d, J=2.0Hz), 7.17-7·22 (3H, m), 7.32 (1H, d, J=7.6 Hz), 7.39 (2H, d, J=8 · 0Hz), 7.89 (1H, br- s) f 8.00 (1H, d, J=4.8Hz), 9.48 (1Η, ,br-s) C 13 Η ! 13 Ν Ξ 〇 4 s之元素 分析: c H N 計算 值 5 9 . 2 1 4.97 10.90 實測 值 59 . 2 2 4.91 10.63 2 3 4-羥 基_ Ν - [2- 〔(4-甲氣苯基 )胺基〕- 3-吡 啶基]苯 磺醯胺: 〔化學式6 1〕
(請先閲讀背而之注意事項再塡寫本頁) 裝. 線- 經濟部中央標準局貝工消費合作社印製 依例1 4之方法可製得目的化合物。 溶點:2 1 4 - 2 1 6 °C (由乙醇/水再結晶) F A B 質譜 m/z: 3 7 2 ( [Μ+Η] Ί ^-NMR (DMSO-d6) δ (ppm): 3.71 (3Η, s), 6.63 (1H, dd, J=7.6, 4.8Hz), 6.80 (2H, d, J=8.8Hz), 6.82 (2H, d, J=8.8Hz), 7.16 (1H, dd, J=7.6, 1.6Hz), 7.35 (2H, d, J=8.8Hz), 7.51 (2H, d, J=8.8Hz), 7.75 (1H, s), 7.90 (1H, dd, J=4.8, 1.6Hz), 9.41 (1H, s), 10.42 (1H, s) -5 6 - 本紙張尺度遑用中a B家樣竿(CNS)肀4規格(210X297公《:) 206208 Λ 6 Β 6 五、發明説明(55) c 18 Η '17 Ν ; 3 0 4 S之元 素分析: C Η Ν 計算 值 58.21 4.61 11.31 實測 值 58.21 4.74 11.01 例 2 4 N - ( 2 -苯胺基-3 -吡啶基)-4 -氯苯磺藥胺 〔化學式6 2〕CI- —s〇2nh-
<〇Μη 乂 J (請先閲讀背而之注意事項再填寫本頁) 經濟部中央標準局员工消費合作社印製 依例1之方法可製得目的化合物。 熔點:1 8 6 - 1 8 8 °C (由乙醇再結晶) FAB 質譜 m/z: 360 ( [Μ+ΗΓ) 'H-NMRiDMSO-de) δ (ppm): 6.77 (1H, dd, J=7.6, 4.8Hz), 6.90 (1H, dt, J=7.6, 〇.8Hz), 7.22 (2H, t, J=7.6Hz), 7.30 (1H, dd, J=7.6, 1.2Hz), 7.38 (2H, dd, J=7.6, 0. 8Hz), 7.51 (2H, d, J=8.4Hz), 7.64 (2H, d, J=8.4Hz), 7.89 (1H, s), 8.02 (1H, dd, J=4.8, 1.2Hz), 9.76 (1H, br-s) 17 C1N 3 0 2 S之元素分析 57- 本紙張尺度遑用中《Β家樣毕(CNS)f4規格(210父297公!《:) 裝· 訂- 線· 2〇62Ci£ Λ 6 13 6 五、發明説明(56) C Η Ν 計算值 56.74 3.92 11.68 實測值 56.79 4.03 11.67 例 2 5 Ν -( 2 -苯胺基-3 -吡啶基)-3 -氮苯磺_胺: 〔化學式6 3〕
熔點:1 4 3 - 1 4 4 °C (由乙醇再結晶) FAB 質譜 m/z: 360 ([Μ+ΗΓ} ^-NMR (DMSO-d6) δ (ppm): 6.77 (1Η, dd, J=7.6, 4.8Hz), 6.91 (1Η, dt, J=7.6, 1.2Hz), 7.21 (2H, t, J=7.6Hz), 7.32 (1H, dd, J=7.6, 1.6Hz), 7.41 (2H, dd, J=7.6, 1.2Hz), 7.46 (1H, t, J=8.0Hz), 7.54-7.61 (2H, m) , 7.68 (1H, br-s), 7.92 (1H, br-s), 8.04 (1H, dd, J=4.8, (請先閲讀背而之注意事項再填寫本頁) 裝- 訂* 線- 經濟部中央標準局员工消費合作社印製 1 •6Hz), 9.80 (1Η, br—s> c 17 Η 14 c 1 Ν 3 〇 2 S之元 素分析: C Η Ν 計算 值 5 6.74 3.92 11.68 實測 值 5 6.73 4.09 11.68 -58- 本紙張尺度逍用中B Η家樣毕(CNS)甲4規格(210X297公*) 206208 Λ 6 13 6 五、發明説明(57)例 2 6Ν-(2 -苯胺基-3-吡啶基)-3 -甲苯磺醯胺: 〔化學式6 4〕
經濟部中央標準局貝工消t合作社印製 依例1之方法可製得目的化合物。 熔點:161-162 °C (由乙醇再結晶)FAB 質譜 m/z: 340 ( [Μ+ΗΓ) ^-NMR (DMSO-d6) δ (ppm): 2.22 (3Η, s), 6.74 (1H, dd, J=7.6, 4.8Hz), 6.90 (1H, dt, J=7.2, 1.2Hz), 7.21 (2H, t, J=7.2Hz), 7.27-7.35 (3H, m), 7.42 (2H, dd, J=7.2, 1,2Hz), 7.45 (1H, td, J=7.2, 2.0Hz), 7.52 (1H, br-s), 7.92 (1H, s), 8.00 (1H, dd, J=4.8, 1.2Hz), 9.68 (1H, br-s) C!sH17N3 02 S之元素分析: C Η N 計算值 63.7(] 5.05 12.38 實測值 63.81 5.16 12.43 例 2 7 N-(2 -苯胺基-3-吡啶基)-4 -乙氧苯磺醯胺: -5 9 - (請先閲讀背而之注意事項再填寫本頁) 裝· 訂_ -線· 本紙張尺度逍用中B Η家楳準(CHS)甲4規格(210父297公龙) 206208 Λ 6 13 6 五、發明説明(58) 〔化學式6 5〕
依例1之方法可製得目的化合物。 溶點:1 6卜1 6 2 °C (由乙醇再結晶) FAB 質譜 ra/z: 370 ( [M+H]+) ^-NMR (DMSO-d6) δ (ppm): 1.26 (3H, t, J=7.0Hz), 3.94 (2H, g, J=7.〇Hz), 6.74 (1H, dd, J=7.6, 4.8Hz), 6.89 (1H, tt, J=7.2, 0.8Hz), 6.92 (2H, d, J=8.8Hz), 7.21 (2H, t, J=7.2Hz), 7.27 (1H, dd , J=7.6, 1.6Hz), 7.42 (2H, dd, J=7.2, 0.8Hz), 7.57 (2H, d, J=8.8Hz), 7.88 (1H, s), 7.99 (1H, dd, J=4.8, 1.6’Hz), 9.53 (1H, br-s) c 19 H 19 N 3 0 3 S之元素分析: C Η N 計算值 61.77 5.78 11.37 實測值 61.72 5.31 11.43 (請先閲讀背面之注意事項再填寫本頁) 裝- 訂 線. 經濟部中央標準局员工消費合作社印製 例 基 3 6 胺 6 醯式 乙學 4-化 胺 醯 磺 苯 Λ7- 基 啶 ¾ I 3 I 基 胺 苯 本紙張尺度逍用中困8家搮準(CNS)甲4規格(210父297公釐) 206208 Λ 6 13 6 五、發明説明(59) CH,C0NH-/~V-S03NH^nΛ=/〇-νη^) 依例1之方法可製得目的化合物。 溶點:234-236 °C (由甲醇再結晶) FAB 質譜 m/ z : 3 8 3 ( [Μ+ΗΓ) ^-NMR (DMSO-d6) δ (ppm): 2.04 (3H, s), 6.72 (1H, dd, J=7.6, 4.8Hz), 6.90 (1H, tt, J=8.0, 1.2Hz), 7.19-7.24 (3H, m), 7.45 (2H, dd, J=8.0, 1.2Hz), 7.60 (2H, d, J=9.2Hz), 7.65 (2H, d, J=9.2Hz), 7.91 (1H, s) , 7.98 (1H, dd, J=4.8, 1.6Hz), 9.60 (1H, br-s), 10.23 (1H, br-s) (請先閲讀背面之注意事項再塡寫本頁) 裝- 訂-
線· 本紙張尺度埠用中國國家橾準(CNS)T4規格(2K1X297公:Jt)
9.0G20B Λ 6 Β 6 五、發明説明(60) 依例1之方法可製得目的化合物。 熔點··】6 4 - 1 6 6 °C (由乙醇再結晶) FAB 質譜 m/ z : 4 1 8 ( [Μ+ΗΠ ^-NMR (DMSO-d6) δ (ppm): 6.78 (1H, dd, J=7.6, 4.8Hz), 6.84 (2H, dd, J=7.6, 1.2Hz), 6.91-6.96 (3H, m), 7.19-7.27 (3H, m), 7.36-7.40 (3H, m), 7.44 (2H, dd, J=7.6, 1.2Hz), 7.62 (2H, d, J=9.2Hz), 7.85 (1H, s), 8.02 (1H, dd, J=4.8, 1.6Hz), 9.62 (1H, br-s) c 23 Η 19 N 3 0 3 S之元素分析: c e n 計算值 66.17 4.59 10.06 實測值 66.15 4.68 10.04 Μ 3 0 N-(2 -苯胺基-3-吡啶基)-4 -氟苯磺醯胺: 〔化學式6 8〕
(請先閲讀背面之注意事項再填寫本頁) 裝< •II_ 線. 經濟部中央標準局员工消费合作社印製 依例1之方法可製得目的化合物 溶點:155-157 °C (由甲醇再結晶) FAB 質譜 m/ z : 351 ([Μ+ΗΠ -62 本紙張尺遑用中a國家樣準(CNS)甲4規格(210X297公釐) 206208 Λ 6 Β6 五、發明説明(61) ^-NMR (DMSO-d6) 5 (ppm): 6.80 (1H, dd, J=7.6, 4.8Hz), 6.90 (1H, t> J=7.6Hz), 7.20 (2H, t, J=7.6Hz), 7.31 (2H, d, J=7.6Hz), 7.36 (1H, dd, J=7.6, 1.6Hz), 7.76 (2H, d, J=7.6Hz), 7.86-7.89 (3H, m), 8.05 (1H, br), 9.90 (1H, br-s) c 18 H 14 N 4 〇 2 s之元素分析: C Η 計算值 61.70 4 .0 3 15.99 實測值 61.73 4 .14 15.75 例 3 1 N - ( 2 -苯胺 基-3 -咐啶基 )-2,4-: 二甲氧 化學式6 9〕 CH30
(請先閲讀背面之注意事項再填寫本頁) 裝· 訂_ 線· 經濟部中央標準局员工消費合作社印製 依例1之方法可製得目的化合物 熔點:1 7 6 - 1 7 8 °C (由乙醇再結晶) FAB 質譜 m/z: 386 ( [Μ+ΗΓ) -63- 私紙張尺度埠用中國國家樣準(CNS)甲4規格(210X297公*) 206208 Λ 6 Β6 五、發明説明(62) ^-NMR (DMSO-d6) δ (ppm): 3.76 (3Η, s), 3.81 (3H, s), 6.53 (1H, dd, J=8.8, 2.4Hz), 6.59 (1H, d, J=2.4Hz), 6.69 (1H, dd, J=7.6, 4.8Hz), 6.92 (1H, t, J=7.6Hz), 7.25 (2H, t, J=7.6Hz), 7.33 (1H, dd, J=7.6, 1.6Hz), 7.50 (2H, d, J=7.6Hz), 7.55 (1H, d, J=8.8Hz), 7.92 (1H, dd, J=4.8, 1.6Hz), 8.07 (1H, s) CigHisNs 〇4 S之兀素分析: C 計算值 59.21 4.97 10.90 實測值 59.19 5.04 10.91 例 3 2 N-(2 -苯胺基-3-吡啶基)-2 -氛苯磺醯胺 〔化學式7 0〕 Η
(請先閱讀背面之注意事項再填寫本頁) 裝· 訂_ 線· 經濟部中央標準局员工消費合作社印製 依例1之方法可製得目的化合物。 熔點:1 4 0 - 1 4 1 °C (由甲苯再結晶) FAB 質譜 m/z: 360 Γ[Μ+Η]+) ^-NMR (DMSO-d6) 6 (ppm): 6.72 (1Η, dd, J=7.6, 4.8Hz), 6.93 (1Η, t, -6 4 - 本紙張尺庠每用中a國家樣準(CNS)甲4規格(210x297公釐) 206208 Λ 6 13 6 五、發明説明(63) J=7.6Hz), 7.25 (2H, t, J=7.6Hz), 7.31 (1H, dd, J=7.6, 1.6Hz), 7.42-7.46 (1H, m), 7.49 (2H, d, J=7.6Hz), 7.56-7.59 (2H, m), 7.87 (1H, d, J=7.6Hz), 7.95-8.01 (2H, m), 10.14 (1H, br-s) Cl? H 14 C 1 N 3 〇 2 s之元素分析: C Η Ν 計算值 5 6.74 3.92 11.68 實測值 56.86 4.06 11.62 例 3 3 4 -乙醯基-N- (2 -苯胺基-3-吡啶基)苯磺醯胺: 〔化學式7 1〕
(請先閲办!?背面之注意事項再填寫本頁) 裝· 訂 經濟部中央標準局貝工消t合作社印製 依例1之方法可製得目的化合物。 熔點:171-173 °C (由乙醇再結晶) FAB 質譜 m/ z : 3 6 8 ( [Μ+ΗΠ lH-NMR (DMSO-d6) δ (ppm): 2.46 (3H, s), 6.78 (1H, dd, J=7.6, 4.8Hz), 6.85 (1H, t, J=7.6Hz), 7.15 (2H, t, J=7.6Hz), 7.31 (2H, dd, J=7.6, 1.2Hz), 7.35 (1H, dd, J=7.6, 1.6HZ), 7.74 (2H, d, J=8.4Hz), 7.85 (1H, s) , 7.94 (2H, d, J=8.4Hz), 8.03 (1H, dd, J=4.8, 1.6Hz), 9.83 (1H, br-s) -6 5 - 本紙張尺度逍用中B國家樣毕(CNS)f 4規格(210x297公釐) 線· 20G208 Λ 6 13 6 五、發明説明庐4) C 19 Η 17' N 3 〇3 S之元素分析: C Η Ν 計算值 62.11 4.66 11.44 實測值 62.31 4.78 11.19 例 3 4 Ν-〔 2 -〔(2-羥苯基)胺基〕-3 -吡啶基)-4-甲氧苯磺 _胺: 〔化學式72〕
CH,Q
HO (請先閲讀背而之注意事項再填寫本頁) 裝· 經濟部屮央標準局員工消费合作社印製 將製備例6所得化合物4.0g(19.9niniol)與4.11g(19.9 mmol)對-甲氣苯磺醯氣反應,並將産物依1之方法處理 可得5 . Q g目的化合物。 熔點:1 8 1 - 1 8 2 °C (由甲苯再結晶) FAB 質譜 m/z: 372 ([Μ+ΗΓ) 'H-NMR (DMSO-d6) δ (ppm): 3.72 (3Η, s), 6.31 (1H, dd, J=8.0, 2.0Hz), 6.72 (1H, dd, J=7.6, 4.8Hz), 6.79 (1H, d, J=8.0Hz), 6.96 (2H, d, J=8.8Hz), 6.98 (1H, t, J=8.0Hz), 6 6- 本紙張尺度逍用中《國家樣毕(CNS)甲4規格(210X297公:Jt)
20620B Λ 6 13 6 五、發明説明(65) 7.02 (1Η, t, J=2.0Hz), 7.25 (1H, dd, J=7.6, 1.6Hz), 7.59 (2H, d, J=8.8Hz), 7.77 (1H, s), 7.99 (1H, dd, J=4.8, 1.6Hz), 9.18 (1H, br-s) Cis H17 N : 3 〇 4 S之元 素分析 C H N 計算值 58.21 4.61 11.31 實測值 58.26 4.67 10.99 例 3 5 N-〔 2-〔(4 -乙氣苯基)胺基〕-3 -吡啶基)-4-甲氣苯 磺醯胺: 〔化學式6 3〕
(請先閲讀背而之注意事項再塡寫本頁) 裝< 訂- 經濟部中央標準局貝工消f合作社印製 依例1之方法可製得目的化合物。 熔點:1 4 4 - 1 4 6 °C (由乙醇再結晶) FAB 質譜 m/z: 400 ( [Μ+ΗΠ ^-NMR (DMSO-d6) δ (ppm): 1.31 (3Η, t, J=2.8Hz), 3.73 (3H, s) , 3.97 (2H, q, J=2.8Hz), 6.65 (1H, dd, J=4.8, 7.6Hz), 6.80 (2H, d, J=8.8Hz), 6.98 (2H, d, J=8.8Hz), 7.21 (1H, dd, J=1.6, 7.6Hz), 7.28 (2H, d, J=8.8Hz), 7.60 (2H, d, J=8.8Hz), 7.72 (1H, br-s), 7.92 (1H, dd, J=l.6, 4.8Hz), 9.47 (1H, br-s) -6 7 - 線· 私紙張尺度填用中《國家«準(CNS)甲4規格(210X297公¢)
2Q620B Λ 6 Β6 五、發明説明(66) H2iN3 04 S之元素分析 C Η 計 算 值 6 0. 13 5 1.30 10.52 實 測 值 6 0 . 02 5 .27 10.21 例 3 6 N - C 2 - [ (4-羥 基-3 -甲 苯基 )胺基〕- 氧 苯 磺 ϋ 胺 : [ 化 學 式 7 4 ]
(請先閲讀背而之注意事項再填寫本頁) 經濟部中央標準局貝工消費合作杜印製 依例1之方法可製得目的化合物。 懷點:89- 91 °C (由甲苯再結晶) FAB 質譜 m/ ζ : 3 8 6 ([Μ+ΗΓ) ^-NMR (DMSO-d6) δ (ppm): 2.07 (3H, s), 3.75 (3H, s), 6.60 (1H, dd, J=4.8, 7.6Hz), 6.63 (1H, d, J=8.4Hz), 6.93 (1H, d, J=2.8Hz), 6.98-7.03 (3H, m) , 7.18 (1H, dd, J=1.6, 7.6Hz), 7.50 (1H, br-s), 7.60 (2H, d, J=8.8Hz), -68 本紙張尺度逍用中國國家楳毕(CNS) T 4規格(210X297公*) 206208 Λ 6 13 6 五、發明説明(67) 7.88 (1Η, dd, J=1.6, 4.8Hz), 8.87 (1H, s), 9.44 (1H, br-s) C 19 H IS Ν 3 0 4 S之元素分析: C Η Ν 計算值 5 9.21 4.97 10.90 實測值 5 8.97 5.06 10.53 例 3 7 4-〔(3-(4 -甲氣苯磺醯胺基)-2 -吡啶基)〕胺基〕苯 甲酸乙酷: 〔化學式7 5〕 so2nh- CH3CHa〇〇C-/~VNH^N· (請先閲讀背而之注意事項再填寫本頁) 裝_ 訂- 經濟部中央標準局貝工消贽合作社印製 依例1之方法可製得目的化合物β 熔點:1 7 2 - 1 7 3 °C (由乙醇再結晶) FAB 質譜 ra/z: 428 ( [Μ+Η]+) ^-NMR (DMSO-d6) δ (ppm): 1.31 (3H, t, J=3.2Hz), 3.63 (3H,s), 4·27 (2H, q, J=3.2Hz), 6.88 (2H, d, J=8.8Hz), 6.88 (1H, dd, J=4.8, 7.6Hz), 7.38 (1H, dd, J=1.6, 7.6Hz), 7.51 (2H, d, J=8.8Hz), 7.54 (2H, d, J=8.8Hz), 7.80 (2H, d, J=8.8Hz), 8.10 (1H, dd, J=l.6, 4.8Hz), 8.34 (1H, br-s), 9.58 (1H, br-s) 6 9 本紙》•尺度逍用中國《家標毕(CHS)肀4規格(210X297公;Jt) 線. 206208 Λ 6 Β6 五、發明説明(68) C 21 Η 21 Ν 3 計算值 實測值 例 3 8 4-甲氣基 苯磺醯胺: 〔化學式7 6 s S之元 素分析: C Η Ν 5 9.00 4.95 9.83 58.98 4.91 9.63 -C 2-[ (4 -甲硫苯基 )胺基)-3 -吡啶基
(請先閲讀背而之注意事項再填寫本頁) 裝· 經濟部中央標準局貝工消費合作社印製 熔點:1 4 8 - 1 4 9 °C (由乙醇再結晶) FAB 質譜 ιπ/ζ: 402 < [M+H]+)^-NMR (DMSO-d6) 5 (ppm): 2.43 (3H, s), 3.70 (3H, s), 6.73 (1H, dd, J=4.8, 7.6Hz), 6.94 (2H, d, J=8.8Hz), 7.17 (2H, d, J=8.8Hz), 7.26 (1H, dd, J=1.6, 7.6Hz), 7.39 (2H, d, J=8.8Hz), 7.57 (2H, d, J=8.8Hz), 7.93 (1H, br-s), 7.98 (1H, dd, J=1.6, 4.8Hz), 9.51 (1H, br-s)C19H19N3 〇3 S2 之 7C 素分析: -70- 本紙張尺度遑用中B H家標準(CNS)甲4規格(210X297公*) 線· 206208 A 6 B6 五、發明説明 (69) C Η Ν 計算值 56.84 4.77 10.47 實測值 56.90 4.77 10.24 例 3 9 硫酸4-〔(3-(4 -甲氣苯磺醯胺基)-2 -吡啶基)〕.胺基〕 苯酯鉀 〔化學式Ή〕
(請先閲讀背而之注意事項再塡寫本頁) 經濟部中央標準局貝工消费合作社印製 將例6化合物2 . 0 g ( 5 . 3 8 m in ο 1溶於2 0 m in 1吡啶。於-I 5至 -10°C下滴加入800mg(6.87niniol)氣磺酸(95% )。逐漸回 溫至室溫並攪拌3天。加入1N磺酸鉀溶液以調整pH為8 至9。減壓蒸除溶劑。加入水及乙酸乙酯,並分離所形 成之水層,濃縮,由矽膠柱層析純化,並以甲醇/二氣 甲烷沈澱可得1.58g目的化合物。 熔點:1 6 5 - 1 6 6 °C FAB 質譜 m/z: 528 <[M+K]+) ^-NMR (DMSO-d6) δ (ppm): ’ 3.73 (3H, s), 6.68 (1H, dd, J=4.8, 8.0Hz), 6.98 (2H, d, J=8.8Hz), 7.02 (2H, d, J=8.4Hz), 7.25-7.27 (3H, m>, 7.61 (2H, d, J=8.8Hz), 7.83 (1H, s), 7.94 (1H, dd, J=l.2, 4.8Hz), 9·55 (1H, s) -7 1 - 裝- 本紙张尺度逍用中國國家標毕(CNS)甲4規格(210X297公¢) 2〇_8 Λ 6 B 6 五、發明説明(70) C 18 Η 16 Ns 0 7 S 2 K • 3/2H 2 〇之元素分 C Η Ν 計算 值 4 1.85 3.71 8-13 實測 值 4 1.88 3.41 8.08 例 4 0 4 -甲氣基-N -〔 2 - [( 4 -苯氣苯基)胺基〕-3 -吡啶基〕 苯磺醯胺: 〔化學式7 8〕
(請先閲讀背而之注意事項再塡寫本頁) 裝< 訂 經濟部中央標準局貝工消费合作社印製 依例1之方法可製得目的化合物。 熔點:1 7 4 - 1 7 6 °C (由乙醇再結晶) FAB 質譜 m/z: 448 ( [Μ+ΗΓ) ^-NMR (DMSO-dg) δ (ppm): 3.75 (3Η, s), 6.72 (1H, dd, J=4.8, 7.6Hz), 6.92 (2H, d, J=8.8Hz), 6.91-6.97 (2H, m), 6.96 (2H, d, J=8.8Hz), 7.05-7.10 <1H, m), 7.27 (1H, dd, J=l.6, 7.6Hz), 7.32-7.40 (2H, m), 7·43 (2H, d, J=8.8Hz), 7.59 (2H, d, J=8.8Hz), 7.92 (1H, br-s), 7.98 (1H, dd, J=l.6, 4.8Hz), 9.44 (1H, br-s) -7 2 - 線 本紙張尺戽埠用中《 S家標準(CNS)f 4規格(210X297公*) 206208 Λ 6 13 6 ί、發明説明 (71) C 24 Η 21 Ν 3 〇 4 s之元 素分析: C Η 計算值 6 4.41 4.73 9.39 實測值 64.71 4.96 9.30 經濟部中央標準局貝工消費合作社印製 例 4 1 4-〔(3-(4 -甲氣苯磺醯胺基)-2 -吡啶基)〕胺基〕苯 甲酸: 〔化學式7 9〕ειι3〇-/Λ—so2nii· hooc-^Vnh· 將例3 7之化合物依一般方法進行鹼性水解作用可得目 的化合物。 熔點:2 4 8 - 2 5 0 °C (由乙醇再結晶) FAB 質譜 m/z: 400 ([Μ+ΗΓ) lH-NMR (DMSO—de) δ (ppm): 3.64 (3H, s), 6.87 (1H, dd, J=4.8, 7.6Hz), 6.89 (2H, d, J=8.8Hz), 7.37 (1H, dd, J=1.6, 7.6Hz), 7.49 (2H, d, J=8.8Hz), 7.54 (2H, d, J=8.8Hz), 7.78 (2H, d, J=8.8HZ), 8.09 (1H, dd, J=1.6, 4.8Hz), 8.29 (1H, br-s), 9.58 (1H, br-s), 12.44 (1H, br) Ci9H17N3 os s之元素分析:
(請先閲讀背而之注意事項再塡寫本頁) 裝- 線· -7 3- 本紙張尺度逍用中國國家《準(CHS)甲4規格(210x297公釐) ^0620¾ Λ 6 13 6 五、發明説明(72) C Η Ν 計算值 5 7.13 4.29 10.52 實測值 5 7.10 4.42 10.35 2 Ν-〔 2-〔(4 -氮苯基)胺基]-3 -吡啶基〕-4 -甲氧苯磺 醯胺: 〔化學式8 0〕
(請先閲讀背而之注意事項再填寫本頁) 經濟部中央標準局貝工消費合作社印製 依例1之方法可製得目的化合物。 熔點:2 Q 5 - 2 0 7 °C (分解)(由乙醇再結晶) FAB 質譜 m/ z : 3 9 0 ([Μ+ΗΓ) 1H—NMR (DMSO—d6) δ (ppm): 3.70 (3H, s), 6.78 (1H, dd, J=7.6, 4.8Hz), 6.93 (2H, d, J=8.8Hz), 7.24 (2H, d, J*8.8Hz), 7.30 (1H, dd, J=7.6, 2.0Hz), 7.45 (2H, d, J=8.8Hz), 7.56 (2H, d, J=8.8Hz), 8.02 (1H, dd, J=4.8, 2.0Hz), 8.05 (1H, s), 9.51 (1H, br-s) C is H 16 C 1 N 3 0 3 S之元素分析: C Η N 計算值 55.46 4.14 10.78 實測值 55.44 4.32 10.71 -7 4 - 丁 % 本紙ft尺>1逍用中B困家樣準(CNS)甲4規格(210X297公釐) 206208 Λ 6 13 6 五、發明説明(73) 例4 3 Ν-〔 2-〔(2 -羥苯基)胺基)-3 -吡啶基〕-4 -甲氣苯磺 醯胺: 〔化學式8 1〕
CiUO
依例1之方法可製得目的化合物。 熔點:1 5 4 - 1 5 5 °C (由甲苯再結晶) FAB 質譜 m/ z : 3 7 2 ([M+H]*) 1H-NMR (DMSO-d6) 5 (ppm): 3.81 (3H, s), 6.63 (1H, dd, J=8.0, 5.2Hz), 6.72-6.79 (2H, m), 6.82-6.86 (2H, m) , 7.07 (2H, d, J=8.8Hz), 7.66 (2H, d, J=8.8Hz), 8.05 (1H, dd, J=5.2, 1.6Hz), 8.15 <1H, s), 8.29 (1H, dd, J=7.6, 2.0Hz), 9.70 (1H, s), 9.94 (1H, s) 18 Π i? 4 S之元素分析 (請先閲讀背面之注意事項再塡寫本頁) 裝· 訂- -線- 經濟部中央標準局貝工消t合作社印製 計算值 58.22 4.61 11.32 實測值 5 8.39 4.60 11.20 例 4 4 -75- 本紙張尺度遑用中國國家標準(CNS)甲4規格(210X297公龙) 206208 Λ 6 13 6 五、發明説明(74) Ν-(2 -苯胺基-3-吡啶基)-2, 4, 6 -三甲苯磺醯胺: 〔化學式8 2〕
依例1之方法可製得目的化合物。 熔點:;4 0 - 1 4 2 °C (由乙醇再結晶) FAb 質譜 m/z: 368 ( [Μ+ΗΓ) ^-NMR (DMSO-d6) δ (ppm): 2.16 (3Η, s), 2.41 (6Η, s), 6.70 (1Η, dd, J=7.6, 4.8Hz), 6.89-6.94 (3H, m), 7.08 (1H, dd, J=7.6, 1.6Hz), 7.24 (2H, t, J=7.6Hz), 7.43 (2H, d, J=7.6Hz), 7.89 (1H, s), 8.01 (1H, dd, J=4.8, 1.6Hz), 9.58 (1H, s) (請先閲讀背而之注意事項再填寫本頁) 裝· 訂 線. 經濟部中央標準局貝工消t合作社印製 C 2 ο Η 21 Ν ξ Ξ 〇 2 S之元 素分析: C Η Ν 計 算值 6 5.37 5.76 11.43 實 測值 6 5.45 5.67 11.34 例 4 5 N- (2 -苯胺基-3-吡啶基)-4 -氣-2, 5 -二甲苯磺醛胺: 〔化學式8 3〕 -7 6 - 冬紙張尺度逍用中國B家標毕(CNS)甲4規格(210x297公釐) 206208 Λ 6 Β6 五、發明説明(75) /CH,CHaP〇~Ni 丨工) 依例1之方法可製得目的化合物。 熔點:1 5 3 - 1 5 4 °C (由乙醇再結晶) FAB 質譜 m/z: 388 ( [Μ+ΗΓ) ^-NMR (DMSO-d6) δ (ppm): (請先閲讀背而之注意事項再填寫本頁) 經濟部中央標準局貝工消费合作社印製 2. 20 (3H, s), 2.41 (3H, s), 6.75 (1H, dd, J— 7.6, 4. 8Hz), 6 .91 (1H, t, J=7.6Hz), 7 •23 (2H, t, J=7. 6Hz), 7.26 (1H ,dd, J=7.6, 1 •6Hz), 7. 33 (1H, S) • 7.38 (2H, d, J=7.6Hz) , 7.63 (1H, s), 7.93 (1H, S) / 8.02 (1H, dd, J-4.8, 1. 6Hz), 9.76 (1H, c !9 Η .18 C 1 N 3 0 2 S之元素分析: C Η N 計 算 值 58 .83 4 .68 10.83 實 測 值 58 • 97 4 •64 10.85 4 6 4 - 甲 氣 基 -N- 1 ;2- [(2- 甲氣基-5 -吡商 ?基)胺基 ]-3- 啶 基 苯 磺醯 胺: 〔化學式8 4〕 -77- 本紙张尺度蟓用中B B家楳毕(CNS) T4規格(210X297公ft) 裝- 訂 線· 206208 Λ 6 13 6 五、發明説明(76) CHa〇O^〇aNHY^ CHaO-ZJ^-NH^N^ 依例1之方法可製得目的化合物。 熔點:1 5 9 - 1 6 0°C (由乙醇再結晶) FAB 質譜 m/z: 387 ( [Μ+ΗΓ) 1H-NMR (DMSO—d6) δ (ppm): 3.73 (3H, s), 3.81 (3H, s), 6.68—6.73 (2H, m), 6.98 (2H, d, J=8.8Hz), 7.25 (1H, dd, J=7.6, 1.2Hz), 7.60 (2H, d, J=8.8Hz), 7.72 (1H, dd, J=8.8, 2.8Hz), 7.90 (1H, s), 7.93 (1H, dd, J=4.8, 1.2Hz), 8.13 (1H, d, J=2.8Hz), 9.44 (1H, br-s)
IS 計算值 實測值 例 4 7 N-(4-苯胺基 〔化學式8 5〕 4 S之元素分析: C Η 55.95 4.69 55.95 4.72 14.50 14.46 甲氣基-5-嘧啶基)-4 -甲氧苯磺醯胺 (請先閲讀背而之注意事項再填寫本頁) 裝- 訂 經濟部中央標準局貝工消费合作社印製 CH〇0
S〇aNN O-NIi -78 本紙張尺度逍用中國國家橾準(CNS)甲4規格(210X297公釐) qch3
206208 Λ 6 13 6 五、發明説明(77) 依例1之方法可製得目的化合物。 熔點:1 5 9 - 1 6 (TC (由乙醇再結晶) FAB 質譜 m/z: 387 ([M+H]。 ^-NMR (DMSO-d6) 5 (ppm): 3.38 (3H, s), 3.80 (3H, s), 7.01-7.07 (3H, m),7.30 (2H, t, J=8.0Hz), 7.57 (2H, dd, J=8.0, 0.8Hz), 7.63 (2H, d, J=8.8Hz), 8.20 (1H, s), 8.33 (1H, s), 9.29 (1H, s) C is Η is Ν ^ 〇 4 S之元 素分析: C Η Ν 計算值 5 5.95 4.70 14.50 實測值 5 5.90 4.71 14.49 例 4 8 N-(4 -苯胺基-6 -氯-5-嘧啶基)-4 -甲氣苯磺醯胺: 〔化學式8 6〕C1 (請先閲讀背而之注意事項再填寫本頁) 裝· 訂- -線· 經濟部中央標準局貝工消费合作社印製
依例1之方法可製得目的化合物。 熔點:1 7 4 - 1 7 5 °C (由乙醇再結晶) FAB 質譜 m/z: 391( [Μ+ΗΓ) -7 9 - 泰紙張尺度逍用中B B家搮準(CNS) T4規格(210x297公址) 206208 Λ 6 13 6 五、發明説明(78) I ^-NMR (DMSO-d6) δ (ppm): 3.75 (3Η, s), 7.03 (2H, d, J=8.8Hz), 7.09 (1H( J=7.6Hz), 7.32 (2H, t, J=7.6Hz), 7.46 (2H, d, J=7.6Hz), 7.65 (2H, d, J=8.8Hz), 8.29 (1H, s), 8.63 (1H, s), 9.74 (1H, br-s) 17 n s c 1之元素分析·. C Η Ν 計算值 5 2.24 3.87 14.23 實測值 5 2.29 3.85 14.27 例 4 9 N- (2 -苯胺基-6-二甲胺基-3-吡啶基)-4 -甲氣笨磺醯 按: 〔化學式8 7〕 CHaO- —SO a Nil NH一N〜N(CH3)
Or
(請先閲讀背而之注意事項再塡寫本頁) 經濟部中央標準局員工消費合作社印製 依例1之方法可製得目的化合物。 熔點:152-153 °C (由乙酸乙酯/正己烷再結晶) FAB 質譜 ffl/z: 399 ([M+H]+) 'H-NMR (CDC13) δ (ppm): 3.04 (6Η, s), 3.83 (3H, s), 5.71 (1H, d, J=8.8Hz), 5.75 (1H, s), 6.59 (1H, d, J=8.8Hz) 8 0 - 本紙張尺度遑用中a B家標準(CHS)甲4規格(210X297公;«:) 206208 Λ 6 Β 6 五、發明説明(79)6.91-6.96 (3Η, m), 7.24-7.28 (3Η, m), 7.53 (2Η, d, J=7.6Hz), 1.12 (2H, d, J=9.2Hz) C20H22N4 〇3 S之元素分析: C Η N 計算值 60.28 5.56 14.06 實測值 60.21 5.47 13.92 例 5 0 N-(2 -苯胺基-6-氯-3-吡啶基)-4 -甲氧苯磺醯胺: 〔化學式8 8〕
(請先閲背面之注意事項再塡寫本頁) 裝· 訂- 經濟部中央標準局貝工消t合作社印製 依例1之方法可製得目的化合物。 熔點:2 0 6 - 2 0 8 °C (由乙醇再結晶) FAB 質譜 m/z: 390 ([Μ+ΗΓ) lH-NMR (DMSO-d6) 5 (ppm): 3.71 (3H, s), 6.79 (1H, d, J=8.〇Hz), 6.93-6.99 (3H, m), 7.26 (3H, t, J=8.〇Hz)/ 7.38 (2H, d, J=8.0Hz), 7.61 (2H, d, J=9.2Hz), 8.15 (1H, s), 9·56 (1H, s) c 18 H 16 c 1 N 3 0 3 S之元素分析: - 8 1 - 本紙張尺A:遑用中國國家樣準(CNS)甲4規格(210X297公愛)
9.Q620B Λ 6 13 6 五、發明説明 (8〇) C Η Ν 計算值 55.46 4.14 10.78 實測值 55.49 4.04 10.62 例 5 1 Μ-(4-苯胺基-3-吡啶基)-4 -甲氣苯磺醯胺: 〔化學式8 3〕
(請先閲讀背而之注意事項再塡寫本頁) 經濟部中央標準局员工消費合作社印製 依例1之方法可製得目的化合物。 熔點:2 0 1 - 2 0 2 °C (由乙醇再結晶)FAB 質譜 m/ z : 3 5 6 ([M+H]。 'H-NMR (DMSO-d6) δ (ppm): ’ 3.75 (3H, s), 6.92 (1H, d, J=6.4Hz), 6.95 (2H, d, J=8.8Ez)/ 7.13-7.20 (3H, m), 7.39 (2H, t, ’ ’ J=8.0Hz)/ 7.67 (2H, d, J=8.8Hz), 7.78 (1H, s), 7.82 (1H, d, J=5.6Hz) C is Η 17 N 3 0 3 S之元素分析: C Η N 計算值 60.83 4.82 11.82 實測值 60.78 4.77 11.84 Μ 5 2 N-〔 2-〔(4 -二甲胺甲醯氣苯基)胺基]-3 -毗啶基〕 -8 2 - 本紙張尺度逍用中B B家標毕(CNS)甲4規格(210X297公釐) 206208 A 6 13 6 五、發明説明(81) -4 -甲氣苯磺醯胺: 〔化學式9 0〕
經濟部中央標準局员工消費合作社印製 依例1之方法可製得目的化合物。 熔點:2 0 2 - 2 0 3 °C (由乙醇再結晶) FAB 質譜 m/ z : 4 4 3 ([M+H]+) ^-NMR (DMSO-d6) δ (ppm):2.90 (3Η, s), 3.03 (3Η, s), 3.72 (3Η, s), 6.72 (1H, dd, J=7.6, 4.8Hz), 6.96 (2H, d, J=8.8Hz), 6.97 <2H, d, J=8.8Hz), 7.26 (1H, dd, J=7.6, 1.6Hz), 7.41 (2H, d, J=8.8Hz), 7.60 (2H, d, J=8.8Hz), 7.94 (1H, s), 7.97 (1H, dd, J=4.8, 1.6Hz), 9.52 (1H, br-s) C2lH22N4 Os S之元素分析: C Η N 計算值 57.00 5.01 12.66 實測值 57.35 4.98 12.55 例 5 3 N-(4 -苯胺基-5-嘧啶基)-4 -甲氣苯磺醛胺: 〔化學式9 1〕 -8 3 - (請先閲讀背面之注意事項再填寫本頁) 裝· .1T_ 線· 本紙張尺/t逍用中明明家搮準(CNS)甲4規格(210X297公*) 2〇62〇8 Λ 6 13 6 五、發明説明(82)
經濟部中央標準局®:工消t合作社印製 將例4 8化合物依常法,於存在P d - C之下進行催化還原 作用可製得目的化合物。 熔點:1 8 9 - 1 9 0 °C (由乙醇再結晶) FAB 質譜 m/z: 357 ( [M+H]+) ^-NMR (DMSO-d6) δ (ppm): 3.73 (3H, s), 7.01 (2H, d, J=8.8Hz), 7.05 (1H, t, J=8.0Hz), 7. 30 (2H, t, J=8.0Hz), 7.50 (2H, d, J=8.0Hz), 7.64 (2H, d, J=8.8Hz), 7.87 (1H, s), 8.40 (1H, s), 8.57 (1H, br-s) C 17 H IS N 4 〇 3 s之元素分析: C Η N 計算值 57.29 4.53 15.72 實測值 5 7 · 2 5 4.6 8 1 5.3 6 例 5 4 N-(2 -苯胺基-6-甲氣基-3-吡啶基)-4 -甲氣苯磺醯胺: 〔化學式9 2〕 CH3〇_〇Ti0aNHY^) <〇)~ΝΗ·^Ν九 0C丨丨, 依例1之方法可製得目的化合物。 ~ 8 4 ~ (請先閲讀背面之注意事項再填寫本頁) 裝· 訂 線< 本紙張尺;1蟓用中國Η家標毕(CHS)肀4規格(210x297公*) 2〇62〇δ Λ 6 13 6 五、發明説明(83) 熔點:187-188 °C (由乙醇再結晶)FAB 質譜 m/ z : 3 8 6 ([M+H]+)'H-NMR (DMSO-d6) 6 (ppm): 3.70 (3Η, s), 3.77 (3Η, s), 6.11 (1Η, d, J=8.0Hz), 6.89 (1H, t, J=7.6Hz), 6.95 (2 H, d, J=9.2Hz), 7.07 (1H, d, J=8.0Hz), 7.22 (2H, t, J=7.6Hz), 7.43 (2H, d, J=7.6Hz), 7.52 (2H, d, J=9.2Hz), 7.83 (1H, br-s), 9.23 (1H, br-s) C 19 H 1S N1 3 0 4 S之元素分析: C Η N 計算值 59.21 4.97 10.90 實測值 59.32 4.97 10.96 例 5 5 > N-(4, 6 -二苯胺基-5-嘧啶基)-4 -甲氣苯磺醯胺:〔化學式93〕
(請先閲讀背而之注意事項再填寫本頁) 裝- 訂- 經濟部中央標準局员工消费合作社印製 依例1之方法可製得目的化合物。 熔點:149-151 °C (由二氣甲烷/正己醇再结晶) FAB 質譜 m/z: 448 ( [M+H]+) -85- 本紙張凡度逍用中《國家標準(CNS)甲4規格(210X297公*) 206208 Λ 6 Ο 6 五、發明説明釤4 ) ^-NMR (DMSO-d6) δ (ppm): 3,53 (3H, s)/ 6.82 (2H, dt. J=8.8Hz) , 6 .96 (2H, J=7 . 6Hz), 7.23 <4H, t, J=7.6Hz) , 7.40 (4H, d, J-7. 6Hz), 7·62 <2H, d, J=8,8Hz), 8.05 (2H, s), 8.11 (1H, s), 8.90 (1H, s) C 23 Η 21 Ν 5 〇 3 s之元素分析 : C H N 計 算值 6 1.73 4 .7 3 15.65 實 測值 6 1.91 4 .7 2 15.74 例 5 6 4 -甲氣基- N-〔 2-(甲苯基)胺基-3-吡啶基〕苯磺醯胺: 〔化學式9 4〕
ch3 (請先閲讀背面之注意事項再填寫本頁) 裝· 線. 經濟部中.央標準局貝工消费合作社印製 依例1之方法可製得目的化合物。 熔點:8 0 - 8 1 °C (由二異丙醚再結晶) FAB 質譜 ια/ z : 3 7 0 ( [Μ+ΗΠ ^-NMR (DMSO-d6) δ (ppm): 3.01 (3H, s), 3.82 (3H, s), 6.46-6.51 (2H, m), 6.78-6.84 (1H, m), 7.04 (2H, d, J=8.8Hz), 7.11-7.17 (2H, m), 7.17 <1H, dd, J=4.8, 8.0Hz), -8 6 - 本紙》疋/t遑用中國國家標準(CHS)甲4規格(210X297公釐) 206208 Λ 6 Β6 五、發明説明(85) 7.65 <1H, dd, J=1.6, 8.0Hz), 7.68 (2H, d, J=8.8Hz), 8.14 (1H, dd, J=1.6, 4.8Hz), 9.30 (1H, br-s) c is H 19 N 3 0 3 S之元素分析: C Η N 計算值 61.77 5.18 11.38 實測值 61.85 5.28 11.36 例 5 7 4-甲氣基- N-〔 2-〔(2-嘧啶基)胺基〕苯基〕苯磺醯胺: 〔化學式9 5〕
(請先閲讀背面之注意事項再填寫本頁) 裝< 訂' 經濟部中央標準局貞工消#合作杜印製 依例1之方法可製得目的化合物。 熔點:193-195 °C (由乙醇再結晶)FAB 質譜 π/ζ: 357 ( [M+H]。 lH-NMR (DMSO-d6) 5 (ppm): 3.70 (3H, s), 6.79-6.83 (3H, m), 6.96 (1H, dt, J=l.6, 8.4Hz>, 7.01 (1H, dd, J=l.6, 8.4Hz), 7.19 (1H, dt, J=1.6, 8.4Hz), 7.47 (2H, d, J=8.8Hz),7.87 (1H, dd, J=1.6, 8.4Hz), 8.38 (2H, dd, J=1.6, 4.8Hz), 8.54 (1H, br-s), 9.53 (1H, br-s) -8 7 - 線· 本紙张尺本遑用中· a家橾準(CNS)甲4規格(210x297公¢) 206208 五、發明説明 (S6) C 17 Η 16 Ν 4 〇 3 S之元素 分析: C Η Ν 計算值 5 7.29 4.53 15.72 實測值 5 7.18 4.57 15.80 例 5 8 N-(2-苯胺苯基)-4-甲氣苯磺醯胺: 〔化學式9 6〕
口13卩 依例1之方法可製得目的化合物。 熔點:1 4 0 - 1 4 2 °C (由乙醇再結晶) FAB 質譜 m/z: 354(M+ ) 1H-NMR (DMS〇-d6) δ (ppm): 3.69 (3H, s), 6.66-6.72 (2H, m), 6.81 (2H, d, J=8.8Hz), 6.76-6.87 (2H, m), 7.04-7.17 (5H, m), (請先閲讀背而之注意事項再填寫本頁) 裝· 訂' 線- 經濟部中央標準局员工消費合作社印製 7.24 (1H, br-s), 7.52 (2H, d, J=8.8Hz), 9.30 (1H, br-s) C 19 Η IS N 2 0 3 S之元素 分析: C Η N 計算 值 64.39 5.12 7 . 90 實測 值 6 4.49 5.17 7 . 7 7 5 9 -8 8 一 本紙張尺度遑用中國國家標毕(CHS)T4規格(210X297公*) 206208 Λ 6 13 6 五、發明説明$7 ) N-〔 2-〔(4 -苄氣苯基)胺基〕-3 -吡啶基〕-4 -甲氣苯 磺醯胺: 〔化學式9 7〕 CH,〇-/\-S〇aNH-coqhQ)- NH^I 依例1之方法可製得目的化合物。 熔點:2 0 8 - 2 1 0 °C (由甲醇再結晶) FAB 質譜 m/z: 476 ( [M+H] *) ^-NMR (DMSO-d6) δ (ppm): 3.73 (3Η, s), 6.75 (1Η, d, J=4.8, 7.6Hz), 6·98 (2H, d, J=8.8Hz), 7.13 (2H, d, J=8.8Hz), 7.28 (1H, dd, J=1.6, 7.6Hz), 7.51 (2H, d, J=8.8Hz), 7.61 (2H, d, J=8.8Hz), 7.58-7.65 (2H, m), 7.72-7.78 (1H, m), 8.00 <1H, dd, J=1.6, 4.8Hz), 8.04 (1H, br-s), 8.11-8.16 (2H,m), 9.54 (1H, br-s) C25H21N3 05 S之元素分析:
(請先閱讀背而之注意事項再塡寫本頁) 裝- 訂_ 經濟部中央標準局貞工消费合作社印製 計算值 實測值 例 6 0 C Η Ν 6 3.15 4.45 8.84 62.95 4.57 8.76 4-(第三 丁氣羰胺乙 醯氣2 -8 9 - 本紙張尺度遑用中B國家«毕(CNS)T4規格(210X297公釐) 206208 Λ 6 13 6 五、發明説明(88) -3-批啶基]-4 -甲氣苯磺醯胺: 〔化學式9 8〕Ci,3〇~0^〇2NH>^(C1U) 3COCONIICH2COO-/y- NH^N^ 依例1之方法可製得目的化合物。 'H-NMR (CDC13) δ (ppm): 1.47 (9H, s), 3.82 (3H, s>, 4.18 (2H, d, J=5.6Hz), 5.17 (1H, br-s), 6.58 (2H, dd, J=7.6, 4.8Hz), 6.89 (1H, dd, J=7.6, 1.6Hz), 6.90 (2H, d, J=8.8Hz), 7.00 <2H, d, J=8.8Hz), 7.35 (1H, br-s), 7.47 (2H, d, J=8.8Hz), 7.68 (2H, d, J=8.8Hz), 8.10 (1H, dd, J=4.8, 1.6Hz) * 例 6 1 N-〔2-〔 〔 4-(胺乙醯氣基)苯基〕胺基〕-3 -吡啶基〕 -4-甲氣苯磺醯胺二鹽酸鹽: 〔化學式9 9〕 (諳先閲讀背而之注意事項再塡寫本頁) 裝. 經濟部中央標準局员工消費合作社印製
將272mg(0.515nimol)例60之化合物加至10nl四氫呋喃 。加入2 οι 1濃鹽酸並於室溫下攢拌3小時。減壓蒸除溶 劑並由乙醇再結晶可得159rag目的化合物。 -9 0 - 本紙張反/t逍用中國8家楳毕(CNS)T4規格(210X297公*) 206208 Λ 6 13 6 五、發明説明(89) 熔點:1 9 6 - 1 9 9 °C (分解) FAB 質譜 m/z: 429 ([Μ+ΗΓ) ^-NMR (DMSO-d6) δ (ppm): 3.71 (3Η, s>, 4.08-4.11 (2Η, m), 6.78 (1Η, dd, J=4.8, 7.6Hz), 6.94 (2H, d, J=8.8Hz), 7.04 (2H, d, J=8.8Hz), 7.32 (1H, dd, J=1.6, 7.6Hz), 7.48-7.51 (2H, m), 7.61 (2H, d, J=8.8Hz)/ 7.97 <1H, dd, J=i.6, 4.8Hz), 8.48 (3H, br-s), 9.84 (1H, br-s) C 20 Η 20 Ν 4 0 5 S · 2HC 1 · 1/2Η 2 〇之元素分析 C Η Ν 計算值 4 7.07 4.54 10.98 實測值 47.38 4.45 10.78 m 6 2 4-甲氧基-N-〔 2-〔(4 -甲氧苯基)胺基〕-3-毗啶基〕 -N -甲笨磺醯胺: 〔化學式1 0 0〕 (請先閲讀背面之注意事項再塡寫本頁) 經濟部中央標準局员工消费合作社印製 將入 加 ε ffl 9
ο η 0 3 ο 0 5 例 Η & 〇攪 胺下 醯溫 甲室 基於 甲液 二溶 1得 所 溶將 物)0 合 % 化60 5 本紙張尺度逍用中B Η家標毕(CNS)甲4規格(210X297公*) 206208 A 6 13 6 五、發明説明(90) 拌30分並加入?5// 1(1.5mmol)甲基碘。 攪拌過一夜後,減壓蒸除溶劑。將殘渣溶於乙酸乙酯並 將溶液以水洗。於M g S 0 4下乾燥後,濃縮並由矽膠柱層 析純化可得290rag目的化合物。 FAB 質譜 m/ z : 4 0 0 ( [Μ+ΗΓ) ^-NMR (CDC13) δ (ppm): 3.15 (3H, s), 3.80 (3H, s) , 3. 88 (3H, s) , 6.50 (1H, dd, J=4.8, 7.6Hz), 6.67 (1H, dd, J=1.6, 7.6Hz), 6.89 (2H, d, J=8.8Hz), 6.98 (2H, d, J=8.8Hz), 7.29 (1H, br-s), 7.47 (2H, d, J=8.8Hz), 7.65 (2H, d, J=8.8Hz), 8.09 (1H, dd, J=1.6, 4.8Hz) C 20 H 21 N 計算值 實測值 例 6 3 4 S之元素分析: C Η Ν 60.14 5.30 10.52 60.08 5.39 10.29 -〔2-〔(4-(2 -胺苄氧基)苯基〕ϊ安基〕-3 -吡啶基〕 (請先閲讀背面之注意事項再塡寫本頁) -裝- 訂- 經濟部中央標準局貝工消費合作社印製 4 -甲氣苯磺醯胺 〔化學式1 01 ] CIU0
NIU -92- 本紙張尺度遑用中國Η家樣毕(CNS)甲4規格(210X297公*) Λ 6 13 6 soe2〇a- 五、發明説明釤1 ) 將 5G0mg(1.35ntinol)例 6化合物,260mg(1.59minol)Si 红酸酐及17〇mg(1.39mmol)4-二甲胺吡啶溶於5ml二甲基 甲醛胺,並於8 0°C下攪拌5小時。減壓蒸除溶劑並加入 乙酸乙酯。將所形成之沈澱由乙醇再結晶可得500ing目 的化合物。 熔點2 2 1 - 2 2 5 °C (分解) FAB 質譜 m/ z : 49 1 ( [M+H]+) ^-NMR (DMSO-d6) 5 (ppm):3.74 (3Η, S), 6.60 (1Η, td, J=1.6, 8.4Ηζ), 6.73(2H, br-s), 6.74 (1H, dd, J=4.8, 8.0Hz), 6.83 (1H, dd, J=〇.8, 8.4Hz), 6.98 (2H, d, J=8.8Hz), 7.08(2H, d, J=9.2Hz), 7.27 (1H, dd, J=2.0, 8.0Hz), (請先閱讀背而之注意事項再填寫本頁) 裝· .可_ j=l.6, 8.4Hz), 7.99 (1H, dd, J=2.〇, 4.8HZ), 8.02 經濟部中央標準局貝工消費合作社印製 7.33 (1H, td, J=l.6, 7.2Hz), 7.49 (1H, d, J-9.2Hz), 7.61 (2H, d, J=8.8Hz), 7.92 (1H, dd, (1Η, s) ,9.60 (1Η, r br- S) C2S Η 22 Ν 4 〇 5 S之 元素 分 析 * C Η N 計 算 值 6 1.21 4 . 5 2 11 • 42 實 測 值 6 0.98 4 . 5 2 11 .24 6 4 二 氫 磷酸4- C [3 -(4 - 甲 氣 苯 磺醯 胺基 胺基〕苯酯 -93- 本紙張尺度埠用中國《家橾準(CNS)甲4規格(210x297公釐) 206208 Λ 6 Β6 五、發明説明(92) 〔化學式1 0 2〕 CHaO-^)—SOaNH (ηο)2〇ρο~/"\·νη 將7.44g(20mniol)例6之化合物懸浮於ΙΟΟιηΙ氣氯化磷 並加熱回流直到溶液為均質。減壓蒸除氣氯化磷並加入 二異丙醚以形成固體,將其過濾分離並懸浮於lQOml四 氫呋喃。於冰冷卻摄拌下加入5 ϋ m 1直到溶液為均質。減 壓蒸除溶劑後,加入lOQml甲醇及lOQnl水,並減壓濃縮 直到形成不溶物。移出不溶物,減壓濃縮,並過濾分離 所得沈澱可得4 . 2 7 g目的化合物。 熔點:2 1 5 - 2 1 6 °C FAB 質譜 m/z: 452 ([M+H]+) 1H-NMR (DMSO-d6) δ (ppm): 3.73 (3H, s), 6.70 (1H, dd, J=7.6, 4.8Hz), 6.98 (2H, d, J=8.8Hz), 7.02 (2H, d, J=8.8Hz), 7.24 (1H, dd, J=7.6, 1.6Hz), 7.35 (2H, d, J=8.8Hz), 7.60 (2H, d, J=8.8Hz>, 7.88 (1H, s), 7.95 (1H, dd, J=4.8, 1.6Hz), 9.50 (1H, br—s) (請先閲讀背面之注意事項再填寫本頁) 裝· 訂- 線< 經濟部中央標準局貝工消f合作社印製 18 H PS之元素分析 C Η Ν 計算值 47.90 4.02 9.31 實測值 4 7.72 4.00 9.39 -9 4 - 本紙張尺度迷用中國國家樣毕(CNS)甲4規格(210x297公;St) 206208 Λ 6 Β 6 五、發明説明(93) 例65 氫磷酸3-〔〔 3-(4 -甲氣苯磺醯胺基)-2 -吡啶基 胺基〕苯酯 〔化學式1 〇 3
Cl!30
(HO)aOPO
將1.0Qg(27nmol)例34之化合物與10ml氣氣化磷反應 ,並將産物依例6 4之方法處理可得1 2 0 m g目的化合物。 熔點:1 6 6 - 1 6 8 °C FAB 質譜 m/z: 452 ( [M+H]+) iH-NMR jDMSO-d6) δ (ppm): 3.70 (3H, s), 6.73 (1H, d, J=7.6Hz>, 6.77 (1H, dd, J=7.6, 4.8Hz), 6.95 (2H, d, J=8.8Hz), 7.15 (1H, t, J=7.6Hz), 7.21 (1H, d, J=7.6Hz), 7.30 (1H, dd, J=7.6, 1.6Hz), 7.37 (1H, s), 7.5S (2H, d, J=8.8Hz), 8.01 (1H, dd, J=4.8, 1.6Hz), 8.10 (1H, s), 9.61 (1H, br-s) (請先閲讀背而之注意事項再塡寫本頁) 經濟部中央標準局貝工消費合作社印製 :i8HisN3 07 PS· H2 0之元素分析: C Η N 計算值 46.06 4.29 8.95 實測值 46.16 4.13 8.83 -9 5 - 本紙》尺度逍用中國國家楳毕(CHS)甲4規格(210X297公*) 206208 Λ 6 13 6 五、發明説明(94) 例66 4 -甲氣基-Ν-〔 2-〔〔 4-(4 -甲氧苯磺醯胺基)苯胺 胺基〕-3-吡啶基〕胺基〕苯磺醯胺: 〔化學式1 0 4〕 ciuo
將例4所得化合物與4 -甲氣苯磺醯氱,於1:2之當量 比例下反應,可得目的化合物。 熔點:1 2 2 - 1 2 3 °C (由乙醇再結晶) FAB 質譜 m/z: 542 ( [M+H] +) ^-NMR (DMSO-d6) δ (ppm): 3.71 (3Η, s), 3.88 (3H, s), 6.76 (1H, dd, J=7.6, 4.8Hz), 6.84 (2H, d, J=8.8Hz), 6.94 (2H, d, J=8.8Hz), 7.17 (2H, d, J=8.8Hz), 7.25 (1H, dd, J=7.6, 1.2Hz), 7.42 (2H, d, J=8.8Hz), 7.56 (2H, d, J=8.8Hz), 7.76 (2H, d, J=8.8Hz), 7.98 (1H, dd, J=4.8, 1.2Hz), 8.06 (1H, s), 9.51 (1H, br-s) C2sH23N307S2之元素分析: (請先閱讀背面之注意事項再填寫本頁) 裝- 訂- 線- 經濟部中央標準局貝工消#合作杜印製 C Η Ν 計算值 5 5.40 4.28 7.76 實測值 5 5.57 4.26 7.61 例 6 7 9 6 私紙張尺度遑用中困H家樣準(CNS)甲4規格(210X297公;¢) 206208 Λ 6 13 6 經濟部中央標準局貞工消费合作社印製 五、發明説明(95) Ν-〔 2-〔<4-羥苯基)胺基〕苯基〕-4-甲氣苯磺醯胺: 〔化學式1 0 5〕CH3〇-^〇Ks〇aNH^ 依例1之方法可製得目的化合物。 熔點:1 6 3 - 1 6 4 -C (由乙醇再結晶) F A B 質譜 m / z : 3 7 0 (M + ) lH-NMR (DMSO-d6) δ (ppm): 3.76 (3H, s), 6.58-6.67 (5H, m), 6.77 (1H, br-s),6.80 (1H, dd, J=l.6, 8.0Hz), 6.90-7.00 (4H, m), 7.56 (2H, d, J=8.8Hz), 9.05 (1H, s), 9.23 (1H, br-s) C 19 H 1S N 2 0 4 S之元素分析: C Η N 計算值 61.61 4.90 7.56 實測值 61.86 4.9 0 7.3 9 m 6 8 4-甲氣基-N-〔2-〔 〔4-(4-特戊醯氣苯基)胺基〕-3-吼啶基〕苯磺醯胺: 〔化學式1 0 6〕 -97- (請先閲讀背而之注意事項再填寫本頁) 本紙張尺度逍用中國Η家標毕(CNS)甲4規格(210X297公*) 206208 Λ 6 13 6 五、發明説明沒6) CM·/,^ (CH3)3CC00 依例1之方法可製得目的化合物。 熔點:188-189 °C (由甲苯再結晶) F AB 質譜 m/ z : 4 5 6 ( [Μ+ΗΓ)^-NMR (DMSO-d6) δ (ppm): 1.30 <9H, s>, 3.72 (3H, s), 6.73 (1H, dd, J=7.6, 4.8Hz), 6·94 (2H, d, J=8.8Hz), 6.97 (2H, d, J=8.8Hz), 7.25 (1H, dd, J=7.6, 1.6Hz), 7.45 (2H, d, J=8.8Hz)/ 7.60 (2H, d, J=8.8Hz)/ 7.97-8.00 (2H, m), 9.52 (1H, br-s) c 23 H 25 N 3 0 s S之元素分析: C Η N 60.64 5.53 9.22 60.57 5.43 9.95 計算值 實測值 例69 4 -甲氧基- N-〔 2-〔(4 -吡啶基〕胺基〕苯基〕苯磺醯 胺 (請先閲讀背而之注意事項再填寫本頁) 裝· 訂- 線· 經濟部中央標準局負工消费合作社印製 〔化學式1 0 7
-9 8 - 本紙張尺度蟓用中國國家樣毕(CHS)I14規格(210X297公釐) 206208 Λ 6 13 6 五、發明説明?7 ) 依例1之方法可製得目的化合物。 熔點:185-187 -C (由乙酵再結晶) FAB 質辑 b/ z : 3 5 6 ( [Μ+ΗΓ) lH-NMR (DMSO-d6) δ (ppm):3.67 <3H, s}, 6.45 (2H, d, J=6.0Hz>, 6.73 <2H, d, J-8.8HZ), 7.07 (1H, dt, J=7.6, 1·2Hz), 7.16 (1H, dt, J=7.6, 1.2Hz}, 7.22 (1H, dd, J=7.6, 1.2Hz), 7.28 (1H, dd, J=7.6, 1.2Hz), 7.45 (2H, d, J=8.8Hz), 7.90 (1H, br-s), 8.05 (2H, d, J=6.0H2) CisH17N3 03 S之元素分析: C Η N 計算值 60.83 4.82 11.82 實測值 61.08 4.86 11.87 例 7 0 N-〔 2-(4 -甲氣苯磺酵胺基)苯基〕-2 -甲基菸鹸醯胺: 〔化學式1 0 8' Χί CIU0
(請先閲讀背而之注意事項再塡寫本頁) 裝· 訂- 線· 經濟部中央標準局员工消費合作社印製 將0.97g(7eeol)2-甲基w齡酸懸浮於4.5ml二氣甲烷。 加入 1.33g(16.8»B〇l)吡啶及 1.05g(8.4mmol)亞硫酷氱。 將反應液於室溫下携拌30分,再加入含1.77g(6.36mmo]) 製備例1 2所製得化合物之二氯甲烷7 n U Μ拌過一夜後 ,加入硪酸氫納溶液並將産物以二氣甲烷萃取β濃縮後 加入乙醇,濾集所形成之結晶並由乙醇再結晶可得目的 化合物》 熔點:1 4 8 - 1 4 3 °C FAB 質譜 η/ z : 3 9 8 ( [Μ+Η]Ί -yy- 本紙張尺度迫用中國國家橾準(CNS)f4規格(210乂297公釐) 206208 66 ΛΒ 五、發明説明(98) ^-NMR (DMSO-d6) δ (ppm): 2.56 (3H, s), 3.80 (3H, s), 7.02 (2H, d, J=8.8Hz), 7.08 (1H, dd, J=2.0, 8.4Hz), 7.11 (ih, dt, J=1.6, 4.4Hz), 7.18-7.27 (1H, m), 7.37 (1H, dd, J=4.8, 7.6Hz), 7.57 (2H, d, J=8.8Hz), 7.71-7.84 (2H, m), 8.58 (1H, dd, J=1.6, 4.8Hz), 9.37 (1H, br-s), 9.60 <1H, br-s) C 2〇 H 1S N 3 0 4 S之元素分析: C H 計算值 60.44 4.82 實測值 60.37 4.90 例71 N-〔 2-(4-甲i苯磺醯胺基)苯 鹼醯胺: 〔化學式1 0 9〕 10.57 10.41 基〕-4-甲基菸 (請先閲讀背而之注意事項再塡寫本頁) 裝< 訂 線· CHa〇 經濟部中央標华局貝工消#合作社印製
X) 依例70之方法可製得目的化合物。 熔點:1 9 9 - 2 0 0 °C (由甲醇再結晶) FAB 質譜 m/z: 398 ([M+H]。 -1 0 0 - 各紙ft尺度逍用中國B家樣準(CNS)甲4規格(210X297公釐) 206208 Λ 6 Β 6 經濟部屮央標準局员工消#合作社印製 五、發明説明(99) ^-NMR (DMSO-d6) δ (ppm): 2.58 (39, s), 3.81 (3H, s), 7.00-7.07 (3H, m), 7.09-7. 18 (1H, m), 7.19-7.27 (1H, m), 7.62 (2H, d, J=8.4Hz), 7.74-7.80 (1H, m), 7.82 (1H, d, J=5.6Hz), 8.80 (1H, d, J=5.6Hz), 8.87 (1H, s), 9.62 (1H, br-s), 10.16 (1H, br-s) 例 7 2 N -〔 2 - ( 4 -甲氧苯磺醯胺基)苯基〕-3 -甲基異菸鹼醯 胺:〔化學式110〕 -CH3〇~^〇-s〇3nhCONH ^CII3依例7 Q之方法可製得目的化合物。熔點·· 1 9 4 - 1 9 5 °C (由乙醇再結晶) FAB 質譜 m/ z : 3 9 8 ( [M+Hn NMR (DMSO—d6) δ (ppm): 2.36 (3H, s), 3.81 (3H, s), 7.03 (2H, d, J=8.8Hz), 7.07 (1H, dd, J=1.6, 8·0Ηζ), 7.12 (1H, -1 0 1 -
(請先閲讀背面之注意事項再填寫本頁) 裝· 線· 本紙張尺度逍用中SH家標準(CNS)甲4規格(210X297公;《:) Λ 6 D 6 206208
五、發明説明(L〇Q dt, J=1.6, 8.0Hz), 7.20—7.27 (1H, m), 7.36 (1H, d, J=4.8Hz), 7.58 (2H, d, J=8.8Hz), 7.76-7.83 (1H, m), 8.55-8.61 (2H, m), 9.39 (1H, br-s), 9.65 (1H, br-s) 一 C20H19N3 〇4 S之兀素分析:
C Η N (請先閲讀背而之注意事項再填寫本頁) -裝-
HO
HO ch3〇
OH 線- 經濟部中央榀準而β工消赀合作社印製 將製備例1 1所製得化合物6 3 7 m g ( Q . 9 0 8 m η 0 1 )溶於1 N N a 0 H 7 m 1及2 0 in 1乙醇中,並回流3小時。冷卻後,加入 4 E I 1 N H C 1 ,並将溶液潑締。加入乙酸乙酯並分離所形 成之乙酸乙酯腸,乾燥,濃縮,並由矽膠柱層析可得270 ra g目的化合物。 -1 0 2 - 計 算 值 60.44 4 .8 2 10 .5 7 實 測 值 60.29 4 .83 10 .4 9 例 7 3 4 - C 〔 (3 -( 4-甲氣苯磺 酵胺基 )苯 基 ]-2 -毗啶基〕胺 基 ] 苯 基 β -D -Ptt喃葡糖 C 化 學 式 11 1〕 本fcUfc尺度逍用中國B家標毕(CNS)甲4規格(210x297公龙) 2〇62〇8 Λ 6 13 6 五、發明説明(οι) ^-NMR (DMS0-d6+D20) δ (ppm> : 3.15-3.33 (4H, m), 3.49 (1H, dd, J=5.6, 11.6Hz), 3.70-3.73 (4H, s+dd), 4.75 (1H, d, J=7.6Hz), 6.68 (1H, dd, J=4.8, 8.0Hz), 6.93 (2H, d, J=9.2Hz), 6.97 (2H, d, J=9.2Hz), 7.23 (1H, dd, J=2.0, 7.6Hz), 7.29 (2H, d, J=9.2Hz), 7.60 (2H, d, J=9.2Hz), 7.95 (1H, dd, J=2.0, 4.8Hz) 例 7 4 4_〔 〔(3-(4 -甲氧苯磺醯 基)-2 -吡啶基〕胺基〕苯 基吡喃葡糖醛酸 〔化學式1 1 2〕
(請先閲讀背面之注意事項再填寫本頁) 裝· 訂_ 線. 經濟部屮央梂準局貝工消赀合作社印製 0H 依製備例1 1及例7 3之方法可製得目的化合物。 iH-NMR (DMS0-D6+D20) 5 (ppm): 3.27 (1H, t, J-8.8HZ), 3.33 (1H, t, J=8.8Hz), 3.42 (1H, t, J=8.8Hz), 3.71 (3H, s), 3.86 (1H, d, J-9.6Hz), 4.92 (1H, d, J-=7.6Hz), 6.70 (1H, dd, J=5.2, 7.6Hz), 6.90 (2H, d, J=8.8Hz), 6.96 (2H, -1 0 3 - 本紙張尺度逍用中國困家標毕(CKS)甲4規格(210父297公货) 206208 Λ 6 Β6 五、發明説明(10? d, J=8.8Hz), 7.25 (1Η, dd, J=l.6, 7·6Ηζ), 7.29 (2H, d, J=8.8Hz), 7.59 (2H, d, J=8.8Hz), 7.95 (1H, dd, J=1.6, 5.2Hz) 例 7 5 4 -甲氣基-N-〔2-〔(3, 4 ,5 -三甲氣苯基)胺基〕-3 -(¾ 啶基〕苯磺醯胺: 〔化學式1 1 3〕
(請先閲讀背面之注意事項再填窝本頁) 装< 經濟部屮央橾準局Μ工消赀合作社印製 依例1之方法可製得目的化合物。 FAB 質譜 ra/z: 445(M+ ) XH-NMR (DMSO-d6) 5 (ppm): 3.61 (3H, s), 3.71 (3H, s), 3.74 (6H, s), 6.72 (1H, dd, J=4.8, 7.6Hz), 6.79, 6.80 (2H, s+s), 6.98 (2H, d, J=8.8Hz), 7.24 (1H, dd, J=1.6, 7.6Hz), 7.59 (2H, d, J=8.8Hz), 7.81 (1H, br-s), 8.00 (1H, dd, J=l.6, 4.8Hz), 9.47 (1H, br-s) C21 «23 N 3 06 S之元素分析: C Η Ν 計算值 5 6.62 5.20 9.43 實測值 5 6.42 5.22 9.14 -10 4- 本紙張尺度逍用中®a家標毕(CNS)〒4規格(210x297公没) 訂_ 線. 206208 Λ 6 13 6 五、發明説明(ιοί 例76 4 -甲氧基- Ν-〔 2-〔(2 -吡啶基〕胺基〕苯磺醯胺 〔化學式1 1 4〕
CHaO—— S 0 a NII
依例1之方法可製得目的化合物。 熔點:113-116 °C (由環己烷再結晶) FAB 質譜 m/ z : 3 5 6 ( [Μ+ΗΓ) ^-NMR (DMSO-d6) δ (ppm): 3.70 (3H, s), 6.53-6.59 (1H, m), 6.70-6.75 (1H, m), 6.71 (2H, d, J=8.8Hz), 6.95 (1H, dt, J=1.2, 8.0Hz), 7.11 (1H, dd, J=1.2, 8.0Hz), 7.14 (1H, dt, J=1.6, 8.0Hz), 7.41-7.52 (3H, m), 7.61-7.66 (1H, m), 8.05 (1H, dd, J=1.2, 4.8Hz), 8.06 (1H, br-s), 9.59 (1H, br-s) 17 Η 18
析 分 素元 之 S (請先閲讀背面之注意事項再填寫本頁) -裝- 訂- 線· 經濟部屮央櫺準局κχ工消贽合作社印製 值 值 算測 計s' 7 7 例 式 (2學 N-化 ο 6 3 8 2 8 8 基 苯 氟 - 4- 基 胺 苯 胺 is 0 苯 瓴 甲 本紙56:尺度逍用中國國家榣準(CNS)甲4規格(210x297公放) 206208 Λ 6 Β6 五、發明説明(10争 CIU0
"V-S02NH\^X 依例1之方法可製得目的化合物。 熔點:173-174 °C (由乙醇再結晶) FAB 質譜 m/z: 372(M+ ) ^l-NMR (DMSO-d6) δ (ppm): 3.69 (3H, s), 6.57 (1H, dt, J=2.8, 8.8Hz), 6.73-6.91 (6H, m), 7.00 (1H, dd, J=6.4, 8.8Hz), 7.19 (2H, t, J=7.6Hz), 7.37 (1H, br-s), 7.50 (2H, d, J=8.8Hz), 9.33 (1H, br-s) C ^ H i7 F N 2 〇3 S之元素分析: C Η N 計算值 61.28 4.60 7.52 實測值 61.39 4.62 7.25 例78 N-〔2-〔(4 -氛苯基)胺基)苯基〕-4 -甲氣苯磺藍胺·· 〔化學式1 1 6〕 (請先閱讀背面之注意事項再填寫本頁) 裝· 線- 經濟部屮央標準局βΗ消费合作社印製 CH 3〇 —y-S0aNH'^;^\nh 依例1之方法可製得目的化合物。 10 6 表紙張尺度逍用中®困家標华(CNS〉甲4規格(210x297公婕) 206208 Λ 6 Β 6 五、發明説明(lQ》 熔點:127-128 °C (由乙醇再結晶) FAB 質譜 m/ z : 3 8 8 (M+ ) ^-NMR (DMSO-d6) δ (ppm): 3.69 (3H, s), 6.61 (2H, d, J=8.8Hz), 6.77 (2H, d, J=9.2Hz), 6.88-6.94 (1H, m), 7.07—7.14 (4H, m), 7.18 (1H, dd, J=l.2, 8.0Hz), 7.36 (1H, br-s), 7.47 (2H, d, J=9.2Hz), 9.28 (1H, br-s) C 19 H 17 C 1 N 2 03 S之元素分析: C Η Ν 計算值 5 8.68 4.41 7.20 實測值 58.85 4.39 7.04 例7 9 N-〔2-〔(3-羥苯基)胺基)苯基〕甲氣苯磺醯胺: 〔化學式1 1 7〕
H0 (請先閱讀背面之注意事項再填寫本頁) 裝- 訂 線' 經濟部屮央標準局β工消费合作社印製 依例1之方法可製得目的化合物。 熔點:1 6 5 - 1 6 (TC (由乙酵再結晶) FAB 質譜 ra/z: 370(M+ ) -1 0 7 - 本紙張尺度逍用中國國家標準(CNS)甲4規格(210x297公龙) 20_8 Λ 6 13 6
五、發明説明咎〇弓 ^-NMR (DMSO-d6) δ (ppm): 3.71 (3H, s), 6.12-6.17 (2H, m), 6.19-6.24 (1H, m) , 6.79—6.86 (3H, in), 6.91 (1H, t, J=8.4Hz), 7.07 (1H, dt, J=1.2, 8.0Hz), 7.08 <1H, dd, J=l.2, 8.0Hz), 7.13 (1H, dd, J=1.2, 8.0Hz), 7.14 (1H, br-s), 7.52 (2H, d, J=8.8Hz), 9.16 (1H, s), 9.28 (1H, br-s) C !9 H 18 N 2 04 S之元素分析: C Η N 計算值 61.61 4 .9 0 7.56 實測值 61.62 4 .91 7.42 8 0 4-苄氧基- N -〔 2_(4'甲 氣苯 磺醯胺基)苯基〕苄醯胺 (請先閱讀背面之注意事項再塡寫本頁) 裝. 經濟部屮央梂準局EX工消贽合作社印製 〔化學式1 1 8〕 CHaQ—— SOaNH。丨丨3〇~^0^ conh 依例7 0之方法可製得目的化合物。 熔點:1 4 8 - 1 4 9 °C (由乙醇再結晶) FAB 質譜 in/ z : 489 < [M+H]+) ^-NMR (DMSO-d6) δ (ppm): 3.74 (3H, s), 5.23 (2H, s), 6.89 (2H, d, J=8.8Hz), 7.07 (1H, dd, J=2.0, 8.0Hz), 7.10 (1H, -1 0 8 -
線_ 本紙5fc尺度逍用中國a家標準(CNS)甲4規格(210x297公¢) 206208 Λ 6 Β 6 五、發明説明 dt, J=1.2, 8,0Hz) ,7.17 (2H, d, J=8.8Hz), 7.23 (1H, dt, J=2.0, 8 •0Hz), 7.33—7.39 (1H, m), 7.42 (2H, t, J=7 •6Hz), 7.47-7 .52 (4H, m), 7.74 (1H, dd, J=1.2, 8.0Hz) ,7.81 (2H, 山 J=8.8Hz), 9.44 (1H, br-s ), 9.47 (1H, br. -s ) C 27 Η 24 Ν 2 〇 5 S 之兀 素分析 ; C H N 計 算值 6 6. 38 4.95 5.7 3 實 測值 6 6. 3 4 4.92 5.7 3 例8 1 4-羥基-Ν-〔 2-(4-甲氣苯磺醯胺基)苯基〕苄ϋ胺: 〔化學式1 1 9〕
(請先閲讀背面之注意事項再塡寫本頁) 裝- *tT_ 經濟部屮央櫺準局β工消贽合作社印製 將例8 0所裂得化合物,依普通方法進行催化還原可製 得目的化合物。 熔點·· 2 0 5 - 2 0 7 °C (由乙酸乙酯再结晶) FAB 質譜 π/ζ: 399 ( [Μ+ΗΠ ^-NMRiDMSO-dJ δ (ppm): 3.76 (3H, s), 6.89 (2H, d, J=8.8Hz), 6.91 (2H, d, J=*8.8Hz) , 7.04 (1H, dd, J=1.6, 8.0Hz), 7.09 (1H, -1 0 9 - 本紙5fc尺度逍用中國ffl家樣準(CNS)甲4規格(210x297公¢) 206208 Λ 6 13 6 五、發明説明(10戶 dt, J=1.6, 8.0Hz)7 7.20-7.25 (1H, m), 7.50 (2H, d, J =8.8Hz), 7 .68-7.76 (3H, m) ,9 •38 (1H, s), 9.47 (1H, s), 10.20 (1H, s) c 20 H IS N 2 〇 5 S 之 元素分析: C Η N 計 算值 6 0.29 4.55 7 . 0 3 實 測值 6 0.38 4.58 6 . 7 5 例82 4-氟- Ν-〔 2- (4-甲氣苯磺醯胺基)苯基〕苄醛胺: 〔化學式1 2 0〕
(請先閱讀背面之注意事項再填寫本頁) 裝· 訂 經濟部中央標準局CX工消贽合作社印製 依例7 0之方法可製得目的化合物。 熔點:1 6 9 - 1 7 0 °C (由乙醇再结晶) FAB 質諸 in/ z : 40 1 ([M+H]+) ^-NMR (DMSO-d6) δ (ppm): 3.75 (3Η, s), 6.90 (2H, d), 7.07-7.16 (2H, m), 7.19-7.26 (1H, m), 7.39 (2H, t, J=8.8Hz), 7.50 (2H, d, J=8.8Hz), 7.66-7.73 (1H, m), 7.91 (2H, dd, J=5.6, 8.8Hz), 9.38 (1H, br-s), 9.54 (1H, br- s) C 20 H 17 F N 2 〇4 S之元衆分析: -1 1 0 - 線· 本紙尺度逍用中困國家標準(CNS)甲4規格(210x297公龙) 2〇6_ Λ 6 13 6 五、發明説明ί〇9) C Η Ν 計算值 5 9.99 4.28 7.00 實測值 6 0.00 4.31 6.70 8 3 3羥基-N - 〔2 - ( 4 -甲 氣苯横醒 胺基)苯基〕苄醛胺 〔化學式1 2 1〕 ch3〇
X) (請先閲讀背面之注意事項再塡寫本頁) 經濟部+央楳準局β工消费合作社印製 依例81之方法可製得目的化合物。 熔點:1 9 1 - 1 9 2 °C (由乙醇再結晶) FAB 質譜 η/ z : 3 9 9 ( [Μ+ΗΠ ^-NMR (DMSO-d6) δ (ppm): 3."77 (3H, s), 6.92 (2H, d, J= 8.8Hz), 6.99 — 7.06 (2H, m), 7.09 (1H, dt, J=1.6, 8.0Hz), 7.20-7.2' (3H, m), 7.34 (1H, t, J=8.0Hz), 7.51 (2H, d, J=8.8Hz), 7.75-7.81 (1H, m) , 9.46 (1H, s), 9.5; (1H, s), 9.81 (1H, s) c 20 H 18 N 2 〇5 S之元素分析: 計箨值 6 0.29 4.55 7.03 實測值 6 1.41 4.55 6.71 111- 本紙張尺度逍用中國國家標準(CNS)甲4規格(210X297公龙) 裝. 訂- 線. 206208 Λ 6 Β 6 五、發明説明莎1Q 例84 N-〔 2-(4 -甲氣苯磺醯胺基)苯基〕-2 -基盼羧醯胺: 〔化學式1 2 2 ] Cll3〇-<^>—s〇3nhO^CONH S 依例7 Q之方法可製得目的化合物。 熔點:1 3 6 - 1 3 7 °C (由乙醇再结晶) FAB 質譜 m/ z : 3 8 9 ([M十H]+) 1H-NMR (DMS0-ds) δ (ppm): 3.75 (3Η, s), 6.85 (2Η, d, J=8.8Hz), 7.05-7.13 (2H, m), 7.17-7.26 (2H, m), 7.49 (2H, d, J=8.8Hz), 7.60-7.70 (1H, m), 7.77 (1H, dd, J=l.6, 4.0Hz), 7.87 (1H, dd, J=l.6, 5.2Hz), 9.50 (2H, br-s)
(請先閱讀背面之注意事項再填寫本頁) 裝- 訂' 線- 經濟部+央櫺準局β工消赀合作社印製 C 18 Η 16 Ν 2 0 4 S 2 之元素分析: C Η Ν 計窝值 5 5.65 4.15 7.21 實测值 55.80 4.27 7.24 例8 5 N-〔 2-(4 -甲氣苯a醯胺基)苯基〕-2 -呋喃羧醯胺: 本紙張尺度逍用中國國家榣準(CNS)甲4規格(210x297公货) 206208 Λ 6 13 6 五、發明説明:(11) 〔化學式1 2 3〕CH3t]-^>—S02NHV~J— CONH 0 依例7 0之方法可製得目的化合物。 熔點:1 5 8 - 1 5 9 °C (由乙醇再結晶) FAB 質譜 m/ z : 3 7 3 ( [M+H]+)
(請先閱讀背面之注意事項再塡寫本頁) 經濟部中央橾準局KX工消贽合作社印製 1H—NMR (DMSO—d6) δ (ppm): 3.76 (3H, s), 6.73 (1H, dd, J=1.6f 3.6Hz), 6.91 (2Η, d,J= 8 · 8 H z), 6.98 (1H, dd, J=1 .6, 8.0Hz), 7.08 (1H, dt, J=1, 6, 8. OHz), 7.21 (1H, dd, J=0. 3.6Hz), 7. 24 (1H, dt/ J=1·6, 8.0Hz) ,7 .53 (2H, J=8.8Hz), 7.84 (1H, dd, J=1.6, 8.0Hz), 7.99 (1H dd, J=0.8, 1.6Hz), 9.42 (1H, br-s), 9. 62 (1H, br-s) C is Η 16 N 2 0 ς S 之元素 分析 : c Η N 計 算 值 5 8 . 0 5 4 .3 3 7.52 赏 测 值 5 8. 0 8 4 .3 9 7.44 8 6 Ν - C 2-(4 -甲m 苯磺醯胺基)苯基〕-2 -吡 啶 錢醯胺: 化 學 式12 4〕 -113- 本紙張尺度逍用中國困家標準(CNS)甲4規格(210x297公龙) 裝- 訂_ 線_ 206208 Λ 6 Β 6 五、發明説明(11尹 CH3〇-</ "V-SOaNH^Y^v
依例7 0之方法可製得目的化合物。 熔點:1 7 4 - 1 7 5 °C (由乙醇再結晶) F AB 質譜 m/z: 384 ( [M+H]+) 1H-NMR (DMSO-d6) δ (ppm): 3.75 (3H, s), 6.82 (1H, dd, J=l.6, 8.0Hz), 6.92 (2H, d, J=8.8Hz), 7.03 (1H, dt, J=1.6, 8.OHz), 7.30 (1H, dt, J=1.6, 8.0Hz), 7.57 (2H, d, J=8.8Hz), 7.70 (1H, td, J=1.6, 4.8, 7.6Hz), 8.08 (1H, dt, J=l.6, 7.6Hz), 8.12-8.17 (1H, m), 8.24 (1H, dd, J=1.6, 7.6Hz), 8.77 (1H, dd, J=1.6, 4.8Hz), 9.73 (1H, br-s), 10.67 (1H, br-s) (請先閱讀背面之注意事項再填寫本頁) 裝· 訂 線- 經濟部屮央梂準局β工消f合作社印製 13 H 17 N 3 4 S之元素分析: C Η Ν 計算 值 5 9.52 4.47 10.96 實測 值 5 9.73 4.54 10.92 8 7 N- C 2 - ( 4 -甲氣苯磺 醛胺基)苯 基〕祕鹼趦胺 〔化學式1 2 5
Cll3〇
A) 本紙張尺度逍用中a囷家標準(CNS)平4規格(210父297公犮) 206208 Λ 6 13 6 五、發明説明头1弓 依例7 Q之方法可製得目的化合物。 熔點:179-180°C (由乙醇再結晶) FAB 質譜 m/ z : 3 8 4 ( [M+H]+) 1H-NMR (DMSO—d6) δ (ppm): 3.74 (3H, s), 6.89 (2H, d, J=8.8Hz), 7.12-7.19 (2H, m), 7.19-7.27 (1H, m), 7.51 (2H, d, J=8 . 8Hz), 7.59 (1H, dd, J=4.8, 8.0Hz) ,7.63-7, (1H, m), 8.17 (1H, dd, J=1.2, 8.0Hz), 8.79 (1H dd, J=1.2, 4. 8Hz), 8.99 (1H, d, J=1.2Hz), 9.49 (1H, br-s), 9 .68 (1H, br-s) c ΐί 3 Η 17 N 3 0 4 S 之 元素分析 ; C Η N 計 算 值 5 9.52 4.47 10.96 實 m 值 5 9.61 4.57 10.84 88 Ν - C 2- (4-甲氣苯a 横醯胺基)苯基〕異菸鹼 醯胺: 〔化學式1 2 6〕0Η30-〇- 503ΝΗγΧ f(V-C0NH-^/ (請先閲讀背面之注意事項再填寫本頁) 裝 線· 經濟部屮央梂準局员工消贽合作社印製 依例7 Q之方法可製得目的化合物β 熔點:1 6 2 - 1 6 3 °C (由乙酵再結晶) FAB 質譜 m/ z : 3 8 4 ( [Μ+ΗΓ) -1 1 5 - 本紙張尺度逍用中國國家標準(CNS)甲4規格(210X297公婕) 206208 Λ 6 13 6 五、發明説明αι4 'H-NMR (DMSO-dg) δ (ppm): 3.75 (3H, s), 6.90 (2H, d, J=8.8Hz), 7.11-7.27 (3H, m), 7.53 (2H, d, J=8.8Hz), 7.64—7·71 (1H, m), 7.75 (2H, d, J=4.8Hz), 8.81 (2H, d, J=4.8Hz), 9.52 (1H, br-s), 9.73 (1H, br-s) C 19 H 17 N 3 0 4 S之元素分析: C Η N 計算值 59.52 4.47 10.96 實測值 59.59 4.52 10.96 Μ 8 9 4-氟-N-〔2-(4-甲氣苯磺醯胺基)-6-甲苯基〕苄醯胺: 〔化學式1 2 7〕
(請先閱讀背面之注意事項再塡寫本頁) 經濟部屮央榣準局A工消赀合作社印製 ch3 依例70之方法可製得目的化合物。 熔點:2 0 4 - 2 0 6 °C (由乙酵再結晶) F A B 質譜 ra/z: 415 ( [M+H] *) ^-NMR (DMSO-d6) δ (ppm): 2.10 (3Η, s), 3.80 (3Η, s), 6.97 (2Η, d, J=8.8Hz), 7.00-7.12 (3H, m), 7.37 (2H, t, J=8.8Hz), 7.65 (2H, d, J=8.8Hz), 8.03 (2H, dd, J=5.6, 8.8Hz), 9.46 (1H, br-s), 9.48 (1H, br-s) -1 1 6 - 本紙張尺度逍用中國國家標準(CNS)甲4規格(210x297公龙) 206208 Λ 6 Β 6 五、發明説明 C 21 Η 19 FN 2 0 4 S之元 素分析: C Η Ν 計算 值 6 0.86 4.62 6.76 實測 值 6 0.74 4.56 6.65 例90N-〔2-(4-甲氣苯磺醯胺基)苯基)-6-甲苯基〕菸鹼醯 胺:〔化學式1 2 8〕
(請先閱讀背面之注意事項再填寫本頁) 經濟部屮央榡準局A工消t合作社印製 CH3依例7 0之方法可製得目的化合物》熔點:2 0 7 - 2 0 3 °C (由乙醇再結晶) FAB 質譜 m/z: 398 ( [M+H]+) 1H-NMR (DMSO—d6) δ (ppm):2.11 (3H, s), 3.79 (3H, s), 6.98 (2H, d, J=8.8Hz), 7.02 (1H, ddr J=1.6, 7.6Hz), 7.05-7.14 (2H, m), 7.58 (1H, dd, J=4.8, 8.0Hz), 7.66 (2H, d, J=8.8Hz), 8.29 (1H, dt, J=1.6, 8.0Hz), 8.77 (1H, dd, J=1.6, 4.8Hz), 9.13 (1H, d, J=1.6Hz), 9.53 (1H, br), 9.64 (1H, br-s) C 20 H 19 N 3 〇4 S之兀素分析: -1 1 7 - 裝· 線. 本紙張尺度逍用中國國家標準(CNS)甲4規格(210x297公釐) 206208 Λ 6 Β 6 五、發明説明(Ll$ C Η Ν 計算值 6 0.44 4.82 10.57 實測值 6 0.55 4.90 10.53 9 1 經濟部屮央tt半而β工消费合作社印31 N-〔 2-(4 -甲氧苯磺醯胺基)-6 -甲苯基〕異菸鹼醯胺: 〔化學式1 2 9〕 οη,ο-/Λ—s〇2nh _〇~conhCli, 依例7 0之方法可製得目的化合物。 熔點:2 1 3 - 2 1 7 °C (由乙醇再結晶) FAB 質譜 m/z: 398 ( [Μ+Η]+) ^-NMR(DMSO-d6) δ (ppm): 2.10 (3H, s), 3.80 (3H, s), 6.99 (2H, d, J=8.8Hz), 7.02 (1H, dd, J=1.6, 7.6Hz), 7.04-7.14 (2H, m), 7.67 (2H, d, J=8.8Hz), 7.87 (2H, dd, J=1.6, 8.4Hz), 8.80 (2H, dd, J=1.6, 8.4Hz), 9.56 (1H, br-s), 9.73 (1H, br-s) c 20 H 19 N 3 0 4 s之元素分析:
C II Ν 計算值 6 0.44 4.82 10.57 實測值 6 0.60 4.85 10.53 -1 1 8 - 本紙張尺度边用中國國家標毕(CNS)<fM規格(210x297公龙) (請先閱讀背面之注意事項再塡寫本頁) 裝· 訂- 線. 206208 Λ 6 13 6 五、發明説明U7) m 9 2 N-〔 2-(4 -甲氣苯磺IS胺基)-6 -甲苯基〕-2 -吡啶羧醯 胺: 〔化學式1 3 0〕
依例7 Q之方法可製得目的化合物。 熔點:1 8 0 - 1 8 2 °C (由乙醇再結晶) FAB 質譜 m/z:398 < [M+H]+) ^-NMR (DMSO-d6) δ (ppm): 2.12 (3H, s), 3.78 (3H, s), 6.90 (2H, d, J=8.8Hz), 6.93 (1H, t, J=4.8Hz), 7.11 (2H, d, J=4.8Hz), 7.54 (2H, d, J=8.8Hz), 7.65-7.72 (1H, m), 8.03—8.08 (2H, m), 8.75 (1H, dd, J=1.2, 5.2Hz), 9.53 (1H, br-s), 10.11 (1H, br-s) C20H19N3 〇4 S之兀素分析: C Η N (請先閱讀背面之注意事項再填寫本頁) -裝- 訂 線· 經濟部+央梂準局β工消#合作社印製 計 算 值 6 0. 4 4 4.82 10 , ‘57 黄 測 值 6 0. 4 3 4.92 10 , .45 例93 Ν - C 2 - (4-甲氣 苯磺 醛胺基)苯 基〕 -2 -硝节醯胺 -119- 本紙張尺度逍用中國國家«準(CNS)甲4規格(210x297公龙) 0S308 Λ,Λ 6 _ 13 6 五、發明説明 〔化學式1 3 1〕CHaO-Z^V-SOaNH ~<^-CONH ^NOa 經濟部屮央梂準局β工消t合作社印製
依例 7 〇之方法 可製得 目的化 合物。 熔點 :1 6 ί 8 - 1 7 0 °C (由 乙醇再 結晶) F AB 質譜 m/ z :4 2 8 ([M+H]+) 1H-NMR (DMSO—d6) 6 (ppm): 3.80 (3H, s), 7 .05 (2H, d, J=8.8Hz), 7.07-7.16 (2Η, m), 7.19-7 .26 (1H, m), 7.62 (2H, d, J=8. 8Hz), 7.66 (1H, d, J=8.0Hz), 7.73 (1H, d/ J=8 . 0Hz), 7.79 (1H, t, J=8.0Hz), 7.92 (1H, t, J=8 · 0Hz), 8.16 (1H, d, J=8.0Hz)f 9.23 (1H, br-s), 9.93 (1H, br-s ) C 20 Η 17 N : 3 〇 6 S 之元 素分析 ; c H N 計算 值 5 6 .20 4 . 0 1 9.83 贲測 值 5 6 .21 4 . 0 5 9.77 4 9例 - 式 氮學 2-化 氣 2 3 (請先閱讀背面之注意事項再填寫本頁) 裝· 訂- 線_ 胺苄 U基 ί本 \ly基胺00苯铤 甲 本紙尺度边用中困國家標準(CNS)甲4規格(210x297公龙) 206208 Λ 6 Β 6 五、發明説明¢1马CH,0
依例7 Q之方法可製得目的化合物。 熔點:1 6 0 - 1 6 2 Ό (由乙醇再結晶) FAB 質譜 m/z: 435 ( [Μ+ΗΓ) XH-NMR (DMSO-d6) δ (ppm): 3.81 (3H, s), 6 97-7.18 (4H, ra), 7.19-7.28 (1H, m), 7.34-7.44 (1H, m) , 7.51-7.64 (4H, m), 6.74-7.82 (1H, m), 9.33 (1H, br-s), 9.69 (1H, s; C20H1SCIN2 〇4 S之元素分析: 計 算 值 5 5. 2 4 3.71 6( .44 實 測 值 5 5. 4 2 3.90 6. ,20 9 5 N - C 2 - (4-甲氣 苯磺 醯胺基)苯基〕 -2 -甲苄醯胺 化 學 式 13 3] (請先閲讀背面之注意事項再填寫本頁) 裝. 線- 經濟部屮央橾準局β工消t合作社印製 C1U0
依例7 G之方法可製得目的化合物 -12 1 本紙張尺度边用中國國家標準(CNS)甲4規格(210X297公龙) 206208 Λ 6 Β 6 五、發明説明(12p 熔點:1 2 9 - 1 3 0 °C (由乙醇再結晶) FAB 質譜 m/z: 397 ( [Μ+ΗΓ) 1H-NMR (DMSO—d6) δ (ppm): 2.38 (3H, s), 3.81 (3H, s), 7.03 (2H, d, J=8.8Hz), 7.07 (1H, dd, J=2.0, 8.0Hz), 7.10 (1H, dt, J=l.2, 8.0Hz), 7.19-7.27 (1H, m), 7.27-7.39 (3H, m), 7.42 (1H, dt, J=2.0, 7.2Hz), 7.56 (2H, d, J=8.8Hz), 7.80-7.87 (1H, m), 9.40 (1H, br-s) 9.46 (1H, br-s) C 21 Η 2D Ν 2 0 4 S之 元素分析: C Η Ν 計算值 6 3.62 5.09 7.07 實測值 6 3.64 5.09 7.03 m 9 6 2-氯- N-〔 2-(4-甲氣苯磺醛胺基)苯基〕菸齡醯胺: 〔化學式1 3 4〕 CH,0 (請先閲讀背面之注意事項再填寫本頁) 裝. 線· 經濟部屮央櫺準局KX工消赀合作社印製
X) 依例7 0之方法可製得目的化合物。 熔點:1 3 3 - 1 3 5 °C (由乙酵再結晶) F A B 質譜 m/z: 4 18( [M+H] *) 本紙張尺度逍用中國B家標毕(CNS)甲4規格(210x297公釐) 206208 Λ 6 13 6 五、發明説明(L2》 iH-NMR (DMSO-d6) 6 (ppm): 3.81 (3H, s), 7.04 (2H, d, J=8.8Hz), 7.07-7.15 (2H, m), 7.18-7.22 (1H, m), 7.60 (2H, d, J=8.8Hz), 7.61 (1H, dd, J=4.8, 7.6Hz), 7.78 (1H, d, J=7.6Hz), 7.98 (1H, dd, J=2.0, 7.6Hz), 8.56 (1H, dd, J=2.0, 4.8Hz), 9.29 (1H, br-s), 9.87 (1H, s) C 19 H 16 c 1 N 3 〇4 S之元素分析: C Η Ν 計算值 5 4.61 3.86 10.06 贲測值 5 4.71 3.87 9.90 例97 4 -氟- N-〔 2- (4 -甲氣苯磺醯胺基)苯基〕苯硫醯胺: 〔化學式1 3 5〕
將549mg(1.371mmol)於例82所製得之化合物,333mg (0.823ramol)之Lawesson試劑及10ml甲苯於100°C下加熱 。jS縮後,將殘渣以矽膠柱猫析纯化可得5 Q 6 m g目的化 合物。 (請先閱讀背面之注意事項再塡寫本頁) 裝· 訂_ 線· 經濟部屮央梂準局β工消贽合作社印製 熔點:1 5 5 - 1 5 6 "C (由正丁酵再結晶) FAB 質譜 ra/z: 417 ( [Μ+ΗΓ) 本紙張尺度逍用中a國家楳準(CNS)甲4規格(210x297公釐) 206208 A 6 13 6 五、發明説明《22 ^-NMR (DMSO-d6) δ (ppm): 3.80 (3Η, s), 7.02 (2H, d, J=8.8Hz), 7.10-7.25, (3H, m), 7.33 (2H, t, J=8.8Hz), 7.47-7.58 (1H, m) , 7.63 (2H, d, J=8.8Hz), 7.98 (2H, dd, J=5.6, 8.8Hz), 9.45 (1H, br), 11.13 (1H, br) C 20 H 17 F N 2 〇 3 S 2 之兀素分析: C Η Ν 計算 值 57 . 6 8 4.11 6.73 實測 值 5 7 . 6 3 4.12 6.58 9 8 Ν-[ 5 -氟 -2-(4 -甲 氯苯磺醯胺基 )苯基〕苄醛胺 (請先閱讀背面之注意事項再填寫本頁) 裝· 經濟部屮央梂準局β工消費合作社印製 〔化學式1 3 6〕CIMH^S讀 依例7 Q之方法可製得目的化合物。 熔點:1 5 3 - 1 5 4 °C (由乙醇再结晶) FAB 質譜 m/ Z : 4 0 1 ( [M+H] +) ^-NMR (DMS0-d6) δ (ppm): 3.75 (3H, s), 6.88 (2H, d, J=8.8Hz), 6.94 (1H, dt, J=3.2, 8.8Hz), 7.00 (1H, dd, J=6.0, 8.8Hz), 7.47 (2H, d, J=8.8Hz), 7.55 (2H, t, J=7.6Hz), 7.59-7.66 (1H, m), 7.74—7.83 (3H, m), 9.45 (1H, br-s), 9.55 (1H, br-s) -1 2 4 - 訂_ 線. 本紙張尺度边用中國H家標準(CMS)甲4規格(210x297公垃) 206208 Λ 6 Β 6
五、發明説明(Ι·2^ C 20 Η 17 F N 2 〇4 S之元素分析: C Η N 計算值 5 9.55 4.28 7.00 賁測值 5 9.97 4.32 6.79 例99 4-氟- N-〔 2-(4-硝苯磺醯胺基)苯基〕苄醯胺: 〔化學式1 3 7〕
(請先閱讀背面之注意事項再塡寫本頁) 經濟部屮央?I準局A工消贽合作社印製 將製備例1 3所製得化合物,依例7 G之方法處理可得目 的化合物。 熔點:265-266 °C (由乙酸乙酯再結晶) FAB 質譜 in/ z : 4 1 6 ( [Μ+ΗΠ 'H-NMR (DMSO-d6) δ (ppm): 7.21 (1H, dt, J=1.6, 8.0Hz), 7.25 (1H, dd, J=2.0, 8.0Hz), 7.30 (1H, dt, J=2.0, 8.0Hz), 7.35 (2H, t, J=8.8Hz), 7.55-7.60 (1H, m), 7.76 (2H, d, J=8.8Hz), 7.83 (2H, dd, J=5.6, 8.8Hz), 8.22 (2H, d, J=8.8Hz), 9.42 (1H, s), 9.89 (1H, s) C 13 H 14 F N 3 0 5 S之元眾分析: C II N 計算值 54.94 3.40 10.12 賁測值 54.90 3.36 9.93 -125- 裝· 本紙張尺度边用中國國家標準(CNS)甲4規格(210x297公龙) 206208 Λ 6 Β 6 五、發明説明(12年 例1 0 0 2-氯-6-甲基-Ν-〔2_(4-甲氣苯磺醛胺基)苯基〕異菸 鹼醯胺: 〔化學式1 3 8〕
(請先閲讀背面之注意事項再填寫本頁) 經濟部屮央榀準而β工消贽合作社印製 依例7 〇之方法可製得目的化合物。 熔點:1 5 0 - 1 5 1 °C (由乙醇再結晶) FAB 質譜 in/ z : 4 3 2 ( [Μ+ΗΓ) 1H-NMR (DMSO—d6) δ (pom): 2.58 (3H, s), 3.76 (3H, s), 6.90 (2H, d, J=8.8Hz), 7.15-7.26 (3H, m), 7.52 (2H, d, J=8.8Hz), 7.54-7.63 (3H, m), 9.44 (1H, br-s), 9.73 (1H, br-s) c 20 H 18 C 1 N 3 0 4 s之元素分析: C K N 計筇值 55.62 4.20 9.73 筲測值 55.80 4.26 9.75 例1 〇 1 N -〔 2 - ( 4 -甲氣苯磺醯胺蕋)苯基〕乙醛肢: -126- 本紙張尺度逍用中圉國家標準(CNS)甲4規格(210X297公釐) 206208 A 6 η 6 經濟部屮央標準局β工消赀合作社印製 五、發明説明$2弓 〔化學式1 3 9〕CH3〇-^~^— S〇aNH'^<iiir>v 依例7 〇之方法可製得目的化合物。 熔點:1 6 0 - 1 6 1 °C (由乙醇再結晶) FAB 質譜 m/z: 3 2 1( [H+H] +) 1H—NMR (DMSO—d6) 6 (ppm): 1.96 (3H, s), 3.80 (3H, s), 6.99-7.17 (5H, m), 7.48 (1H, d, J=8.0Hz), 7.53 (2H, d, J=8.8Hz),9.23 (2H, br-s) c 15 H 16 N 2 0 4 S之元素分析: C Η N 計算值 56.24 5.03 8.75 實測值 56.26 5.03 8.72 例1 Ο 2 Ν-〔 2-(4-甲氣苯磺醯胺基)苯基〕甲醯胺: 〔化學式1 4 0〕CII3〇-^-SOaNH^v 依例7 0之方法可製得目的化合物。 -127- (請先閲讀背面之注意事項再填寫本頁) 裝· 線- 本紙張尺度逍用中國國家標準(CNS)甲4規格(210x297公龙) :06208 Λ 6 13 6 五、發明説明(12$ 熔點:1 4 3 - 1 4 4 °C (由乙醇再結晶) F A B 質 譜m/ ζ :3 0 7 ([M+H]+) C 14 Η .14 N 2 〇 4 S之元 素分析: C Η Ν 計算 值 5 4 .8 9 4.61 9.14 實測 值 5 5 05 4.65 9.09
例1 0 3 N-〔2-〔(乙氣羰基)胺基]苯基〕-4-甲氣苯磺醯胺 〔化學式1 4 1〕CH3CHa〇CONH--^J (請先閲讀背面之注意事項再填寫本頁) 裝. 經濟部屮央榡準沿A工消費合作社印製 依例7 D之方法可製得 目的 化合 物。 熔點: 1 1 8 - 1 1 9 °C (由 乙醇 再結 晶) F A Β質 譜 m / z : 3 5 1 ([M+H]+) iH-NMR (DMSO-d6) δ (ppm): .1 .22 (3H, t, J»7.2Hz), 3 :79 (3Η, s), 4 .03 J-7,2Hz), 6.98-7.03 (4H, m), 7.17 (1Η, t, J=8.0Hz), 7.52 (2H, d, J=8.8Hz), 7.57 (1H, J-8.OHz), 8.43 (1H, S), 9.35 (1H, s) C 16 H 18 N 2 〇 5 S之元 r 素分 Η 析: Μ 計算值 L 5 4.84 11 5 . i 8 [Λ 7 .9 9 實測值 5 4.78 δ . 1 9 7 .86 -128- 本紙張尺度逍用中國國家標準(CNS)甲4規格(210x297公龙) 訂 線- 206208 Λ 6 Β 6 五、發明説明〇_2匁 例1 0 4 Ν-〔2〔(乙胺羰基)胺基〕苯基〕-4 -甲氧苯磺醯胺: 〔化學式1 4 2〕 CHaO—^"^-S0aNH\^J:svCHaCiUNHCONH-^%^ 將製備例12所製得化合物,依常法處理以異氣酸乙酯 ,可得目的化合物。 熔點:1 5 2 - 1 5 4 °C (由乙醇再結晶) FAB 質譜 m/ z : 3 5 0 ([M+H]+> ^-NMR (DMSO-d6) δ (ppm): 1.08 (3Η, t, J=7.2Hz), 3.10 (2H, dq, J=5.6, 7.2Hz), 3.82 (3H, s), 6.61 (1H, dd, J=1.6, 8.0Hz), 6.77 (1H, dt, J=1.2, 8.0Hz), 6,89 (1H, t, J=5.6Hz), 7.04 (2H, d, J=8.8Hz), 7.05-7.12 (1H, m), 7.57 (2H, d, J=8.8Hz), 7.78 (1H, dd, J=1.2, 8,4Hz), 7.94 (1H, s), 9.41 (1H, s) (請先閲讀背面之注意事項再填寫本頁) 裝· .可_ 線-
經濟部屮央樣準局β工消赀合作社印M C 16 Η 19 Ν 3 0 4 S之元素 分析: C H Ν 計箄值 5 5 .00 5 .4 8 12.03 贲測佰 5 5 .0 8 5 .4 7 11.88 例1 0 5 N -〔 3 - ( 4 -甲氣苯磺IS胺越)-2 -吡啶基〕-2 -甲苄藍胺: -129- 本紙張尺度边用中國困家標準(CNS)甲4規格(210x297公釐) 206208 Λ 6 13 6 五、發明説明《28 〔化學式1 4 3〕
CliaO
依例7 〇之方法可製得目的化合物。 熔點:160-162 °C (由乙醇再結晶) FAB 質譜 in/ z : 3 9 8 ( [M+H]+) ^-NMR (DMSO-d6) δ (ppm): (請先閱讀背面之注意事項再填寫本頁) 經濟部屮央楳準局只工消贽合作社印製 2.37 (3H, s) ,3.81 (3H, s), 7.05 (2H, d, J=8.8Hz), 7. 22-7. 33 (4H, m), 7.36-7.43 (1H, m) 7.59 (2H, d, J—8 · 8Hz), Ί .71 (1H, dd, J=1.6, 8.0Hz), 8.25 (1H, dd, J=1.6, 4.8Hz), 9.24 (1H, br-s) ,10.47 (1H, br-s) C2〇 H 19 N 3 0 4 s之元素 ;分析: C H N 計算 值 6 0.44 4.82 10 .5 7 贲測 值 6 0.53 4.84 10 .67 10 6 N-[ 2-(4- 胺苯磺 醯胺 基)苯基 ]- 4-氟 苄醯 胺: 化學式1 4 4〕 -130- 本紙張尺度边用中國國家標毕(CNS)甲4規格(210x297公釐) 裝· 訂' 線. 206208 Λ 6 13 6 五、發明説明〇L2合
經濟部屮央標準工消费合作社印姐 將例9 9所製得化合物以Z n / H C 1進行還原可製得目的 化合物。 熔點:2 0 3 - 2 G 5 °C (由乙醇再結晶) FAB 質譜 m/ z : 3 8 6 ( [M+H]+) ifi-NMR (DMSO-d6) δ (ppm): 5.98 (2Η, br-s), 6.45 (2H, d, J=8.8Hz), 7.05 (1H, dd, J=1.6, 8.0Hz), 7.09 (1H, dt, J=l.6, 8.0Hz), 7.20 (1H, dt, J=1.6, 8.0Hz), 7.23 (2H, d, J=8.8Hz), 7.39 (2H, t, J=8.8Hz), 7.74-7.80 (1H, m) , 7.93 (2H, dd, J=5.6, 8.8Hz), 9.20 (1H, br-s), 9.63 (1H, br-s) C 19 H 16 F N 3 03 S之元素分析: C Η N 計算值 59.21 4.18 10.90 贲測值 59.36 4.21 10.80 例1 0 7 N-〔 2-(4-氛苯磺醯胺基)苯蕋〕苄醯胺: 〔化學式1 4 5〕 -131- 本紙張尺度边用中國囷家標準(CNS)甲4規格(210X297公龙) (請先閲讀背面之注意事項再塡寫本頁) 206208 Λ 6 13 6
五、發明説明(L3Q
s〇2nhCONH 將例7 Q之方法可製得目的化合物。 熔點:1 9 1 - 1 9 2 °C (由乙醇再結晶) FAB 質譜 ηι/ z : 38 7 ( [M+H]+) XH-NMR (DMS〇-d6) δ (ppm): 7.13-7.20 (2Η, m) , 7.24-7.30 (1H, m), 7.42 (2H, d, J=8.8Hz), 7.54 (2H, d, J=8.8Hz), 7.55 (2H, t; J=8.8Hz), 7.60-7.66 (1H, m) , 7.68-7.72 (1H, m), 7.78-7.83 (2H, m), 9.52 (1H, s), 9.71 (1H, s) CisHisCINz 〇3 s之兀素分析:
計 算 值 5 8 . 9 9 3.91 7 . 2 4 實 測 值 5 9 . 2 5 4.02 7 . 2 9 10 8 N - C 2 - (3 , 4-二 甲氣苯 磺醛胺基 )苯 基〕苄醯胺 化 學 式 14 6] (請先閲讀背面之注意事項再填寫本頁) 裝· 訂 線· 經濟部屮央標準局β工消贽合作社印製
依例7 0之方法可製得目的化合物 132 — 本紙張尺度逍用中國a家標準(CNS)甲4規格(210x297公犮) 206208 Λ 6 13 6 五、發明説明〇_33) 熔點:1 8 3 - 1 8 4 °C (由乙醇再結晶) FAB 質譜 ra/z: 413 ( [Μ+ΗΓ) iH-NMR (DMSO_d6) δ (ppm): 3.53 (3Η, s) , 3.75 (3H, s), 6.90 (1H, d, J=8.4Hz), 6.95 (1H, d, J=2.0Hz), 7.13 (1H, dd, J=2.0, 8.4Hz), 7.13-7.18 (2H, m), 7.23-7.29 (1H, m), 7.54 (2H, t, J=7.6Hz), 7.59-7.65 (1H, m), 7.71-7.76 (1H, m), 7.76-7.82 (2H, m), 9.43 (1H, br-s), 9.53 (1H, br-s) C21 H20 N 2 0 5 S之元素分析: C Η Ν 計算值 6 1.15 4.89 6.79 實測值 6 1.16 4.90 6.82 (請先閱讀背面之注意事項再填寫本頁) 裝· 訂 經濟部屮央榫準局β工消t合作社印製 例1 0 9 Ν-〔 2-(4-甲氣苯磺醯胺基)苯基〕苄醯胺: 〔化學式1 4 7〕CH3〇hQ>—SQaNH ^)-ε〇ΝΗ 依例7 Q之方法可製得目的化合物。 熔點:1 6 7 - 1 6 8 °C (由乙酵再結晶) FAB 質譜 π/ z : 3 8 3 (
-133- 本紙張尺度逍用中固國家標準(CHS)甲4規格(210x297公放) 206208 Λ 6 Β6 五、發明説明(133 ^-NMR (DMSO-d6 )δ (ppm): 3.7 5 (3H, s), 6.91 (2H, d, J=8.8Hz), 7.08 (1H, dd, J-1.6 ,8.0Hz), 7 .12 (1H, dt, J=1.6, 8·0Ηζ), 7.24 (1H, dt, J=1.6/ 8.0Hz), 7·51 (2H, d, • J=8. 8Hz), 7.52-7.59 (2H, m), 7.60-7.66 (1H, m), 7.76 (1H, dd, J=1.6/ 8.0Hz), 7.81—7.86 (2H, m), 9.50 (1H, br-s), 9.55 (1H, br-s) C 20 H is N 2 0 4 S 之元素分 析: C Η N 計算值 6 2. 8 1 4.7 4 7 _ 3 3 實測值 6 3 . 0 6 4 . 7 7 7 .32 例1 10 4 -乙氧基-N-〔 2-((4 -羥苯基)胺基)-3 -吡啶基〕苯礙 酷胺。
cH 3 chU。-(2)-S 〇 2 W Ηh〇-©-nh^nIJ (請先閲讀背面之注意事項再填寫本頁) 裝· 訂 線· 經濟部屮央#準局只工消t合作社印製 熔點 : 1 9 4 - 1 9 5 °C (由 乙醇再結 晶) FAB 質 辑 m / z : 3 8 6 ([Μ+Η]Ί C is H 13 N 3 0 3 S之元 素分析: C Η Ν 計算 值 5 9.21 4.97 10.90 實測 值 5 9.12 4.93 10.66 _ 13 4 — 本紙張尺度逍用中國國家標準(CNS)甲4規格(210X297公货) 20謂8 Λ 613 6 五、發明説明(133)1 H-NHR(DMSO-d 6 ) ί (P P m ): 1.27(3H,t,J=7.2Hz), 3.98(2H,q,J=7.2Hz), 6.59(lH,dd,J = 4.8,7.6Hz) ,6.61(2H,d,J = 8.8Hz), 6.95(2H,d,J = 9.2Hz) ,7.12(2H,d,J = 8.8Hz), 7.17(lH,dd, J=1.6, 7.6Hz), 7.55(1H, br-s)# 7.56(2HId,J=9.2Hz),7.87(lH,dd,J=1.6,4.8Hz)> 8.97(lH,s) ,9.41(lH,br-s) (請先閲讀背面之注意事項再塡寫本頁) 裝· 線- 經濟部+央棵準局貝工消t合作社印製 -135- 本紙張尺度边用中困Η家«準(CNS)甲4規格(210X297公龙) 修iE ί心 本年月日 補充 206208 分裂指數 將小白鼠白血病細胞?-388 75乂104腩放在2 4穴撇穴板 ,加m-AMSA或例6化合物,在371CC02保溫箱培餐12小時 後,以0 . 0 7 5 Μ K C 1予以低滲壓處理,以甲酵:乙酸=3 : 1溶液固定,塗在玻Κ上,用0.〗%結晶紫液染色,用顯 撇鏡檢査,測定全細胞數中正在有絲分裂細胞數之百分率 實驗 1 m-AMSA 濃度 分裂指數 (u g / m 1) (Mitotic Index) 0 2.2¾ 0.17 1.2% 0.86 0 % 4.30 0 增殖抑制 ICS()=0.022 w g/nl 實驗2 (例6 ) 潘度 分裂指數 (u g/m 1) (Μ ί tot i c Index ) a 2.8± 1.2¾ 0.11 7.9± 0‘7 0.33 33.1士 2-0 1 66.7士 9.4 3 65.2士 1.8 9 63.6士 4.6 增殖抑制 1C SO=0.23 w g/ml
Claims (1)
- 20G208B7 C7 D7 —& 0 1 0 6 4 3 5¾「磺醯陔衍生物」專利案 (8 1年7月修正) 1. 一種如下式(I)磺醯胺衍生物或其藥理容許鹽:式中: R1為氮原子,齒素,Ct - 4烷基,Cl - 4烷氣基 ,羥基,硝基,苯氣基,氰基,乙醯基或可被保護之 胺基,R2及R3為相同或不同,各表為氫,鹵素, C! - 4烷基或C! - 4烷氣基,R4及R7為相同或 不同,各表為氩或Ct - *烷基,R5及Rs可為相同 或不同,各表為氫,囪素,Ci - *烷氯基或可被苯 基及Cl -,烷基取代之胺基, A為=N-或= CH -之基, 『先間讀背面之注意事項再填寫本頁 k. -訂. 經漪部屮央標準扃Η工消费合作社印製 C 為 為 C 或 子 原 氫 為 ο 1 R 中 其 基 之 I 'C 或 基 烷 9 硫 或 氣 為 以 代 取 可 其 中 , 其基 , 胺 基 , 之基 11烷 子 原 氫 為 f* 1 R 且 C 基 烷 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) 206208 B7 C7 D7 六、申請專利範園Ci - 4烷氣基,2-曛盼基,2-呋喃基或 所示之基,(D為=N-或= CH -之基,且R12及R13可為 相同或不同,且各為氫,鹵原子,硝基,可被保護之 羥基或- 4烷基);或芳族S員環基,其可取代以 1-3個相同或不同之取代基G,且此環可念有1或2値氮 原子(G為鹵原子,Ct - *烷基.— *烷氣基, 可被保護之羥基,可被酯化或醯胺化之羧基,C} - Λ 烷硫基或苯氣基, 但下列組合除外: (l)R1為氫原子,Ci - *烷基,硝基或可被保護之 胺基,R2及R3各為氫原子,A及B各為= CH-,及E為 可取代以1-3個相同或互不相同之取代基G之苯基之組 合,及 (2 ) R 1 , R 2及R 3為相同或互不相同,且各為氳原子 ,C, - 4烷基,硝基或卤原子,且/\&B各為= CH- 0 之組合,及E為-C-R11之基,其中R11為C 院基 {¾先聞讀背面之注意事項再填寫本頁 •訂. 捃濟部屮央標準局貝工消f合作社印^ .線. ,可取代以C丄 4烷基之胺基或所示 之基,其中R12及R13之定義如上的組合。 2.如申謓專利範圍第1項之磺醯胺衍生物或其藥理容許 鹽,式中R1表為C 烷氣基 2 一 本纸張尺度適用中B國家標準(CNS)甲4規格(210X297公嫠) 經浒部屮央標準局员工消费合作社印製 B7 Λ Cl2〇fi2G8___D7_ 六、申請專利範圊 3. 如申請專利範圍第1項之磺醛胺衍生物或其藥理容許 鹽,式中A表=CH之基,且B為=H-之基。 4. 如申請專利範圍第1項至第3項中任一項之磺醛胺衍 生物或其藥理容許鹽,式中E表為苯基,毗啶基或嘧 啶基,其可取代以1-3個相同或不同之取代基G(G為如 申請專利範圍第1項所定義)。 5. 如申請專利範圍第1項至第3項中任一項之磺醛胺衍 生物或其藥理容許鹽,式中E表為己取代以羥基之苯 基,且此羥基可被保護。 6. 如申請專利範圍第1項至第3項中任一項之磺醯胺衍 生物或其藥理容許鹽,式中A及B客表為= CH-之基, 且E表為下式之基: (論先閱讀背vg之注意事項再嗔寫本頁 .襄.式中D,R 及R 之定義如上。 7. 如申請專利範圍第1項或第2項之磺醯胺衍生物或其 藥理容許鹽,式中A表為= CH-之基。严3 ? B基為 之基,且E表為-C-R11之基,其中R 如 申請專利範圍第1項所示。 8. —種製備依申請專利範圍第1項所示之磺醯胺衍生物 或其藥理容許鹽之方法,其偽由下列(a)至(d)之任一 -3 ~ 本纸張尺度適用中HS家標準(CNS)甲4規格(210X297公釐) .ίτ. 2D6208 B7 C7 D7 六、申請專利範圍 製法而製得: (a)將下式(II)所示磺酸或其反應衍生物:SOaH (II) 式中為氫,鹵素,C, - 4烷基,Ci - 4烷氣基 ,己保護之羥基,硝基,苯氣基,氰基,乙醯基或己 保護之胺基,且,R2及R 3之定義為依申請專利範圍 第1項所示,與下式U I I )之化合物反應: R4(III) (-先閱讀背面之注意事項再填宵本頁 *訂· 迎泖部屮央櫺準局貝工消f合作社卬製 式中R* ,R7 ,Α,Β及E如申請專利範圍第1項所示, 及Rl可為相同或不同.各表為氫.齒素,Ct - 4 烷氣基或已保護或己取代之胺基, 且當所得化合物含保護基,則該保護基可視需要除去, (b )將式(I V )之化合物 -4 - 本纸張尺度適用中國國家櫺準(CNS)甲4規格(210x297公釐) A7 B7^0620¾---------21 六、申請專利範®經濟部屮央標準局貝工消贽合作社印製 式中 R 1 a ,R 2 ,R 3 , R 4 , R 5 & ,R e a , R 7 ,A 及 B 之定 義如上E a表為芳族6員環基(其琿中可含有1或2個氡原 子),且其已取代以1 - 3値相同或互不相同之取代基G a ,Ga為鹵原子,Ci - a烷基,- 4烷氣基,羥 基,可酯化或ϋ胺化之羧基,C i - *烷硫基或苯氣 基,但環中至少1個Ga為羥基, 與式(V )所示化合物反應: •χ-γ m 式中X為可與羥基中氧原子結合之基,且 y為可移去 之基,或者與羥基有反瞜性之無機或有機酸酐反應, 且當所得化合物含有保護基時,若需要,可將該保護 基除去, (C )將式(V I)的化合物:-5 - 本纸張尺度適用中國國家樣準(CNS)甲4規格(210x297公釐) (-先間讀背面之注意事項再填寫本頁 -訂· 9,06208 A/ B7 C7 D7 六、申請專利範IB 式中 R1 s ,R2 ,R3 ,RS a ,R6 a ,R7 ,A,B及 E之定義 如上.與烷化劑反應,且當所得化合物含保護基時, 若需要,可將該保護基除去, (d )將式(V I I )的化合物: R56 式中 R1 s ,R2 ,R3 ,ir ,RS s ,Re s 及 B 之定義如 (VII) (-先閱讀背面之注意事項再填窝本頁) 經濟部屮夹櫺準局貝工消费合作社卬製 上,與下式(V I I I )之化合物反應 R 1 1 - Z (VIII) 式中r11之定義如上,a z為羧基或其反應衍生物,或 當R 11為C i 4烷胺基時,則與異氰酸C i 4烷酯 反應。 9. 一種可為抗增生劑之藥學組成物,包含依申請專利範 圍第1項之磺醯胺衍生物或其藥理容許鹽作為活性組 成分。 10如申請專利範圍第1項之磺醯胺衍生物或其藥理容許 鹽,其中化合物為選自下列磺醯胺衍生物: 1) N -(2-苯胺基-3-毗啶基)-對-甲苯磺醯胺. 2) N-(2 -苯胺基-3 -毗啶基)-4 -乙苯磺醛胺, 3) N-(2 -苯胺基-3-毗啶基)-4 -甲氣苯磺醯胺, 6 本纸張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) B7 C7 D7 20G208 六、申請專利範® 4 )4 -甲氣基-H-〔2-〔(4 -甲氣苯基)胺基〕-3 -吡啶基〕 苯磺醯胺, 5) N-〔2-〔(4 -羥苯基)胺基]-3 -毗啶基〕-4 -甲氣苯 磺醛胺, 6) 4 -甲氣基-N-〔2-〔(4 -毗啶基 > 胺基〕-3 -毗啶基] 苯磺醯胺, 7) 二氫磷酸-4 -〔〔 3 - (4 -甲氣苯磺醯胺基>-2 -毗啶基〕 胺苯酷, 8) N-(2 -苯桉苯基)-4 -甲氣苯磺醯胺, 9) N-〔 2-(4 -甲氣苯磺醯胺基)苯基〕-2 -甲基菸鹼輥 胺,及 10) N-〔2-U -甲氣苯磺_胺基)苯基〕-3 -甲基異菸飴 醯胺。 (J4先閱讀背面之注意事項再说蒋本頁) 經漪部屮央櫺準局貝工消费合作社印製 -7- 本紙張尺度適用中困國家標準(CNS)甲4規格(210X297公釐)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21871090 | 1990-08-20 | ||
JP3850991 | 1991-03-05 | ||
JP12104191 | 1991-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW206208B true TW206208B (zh) | 1993-05-21 |
Family
ID=27289857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW080106438A TW206208B (zh) | 1990-08-20 | 1991-08-14 |
Country Status (15)
Country | Link |
---|---|
US (6) | US5250549A (zh) |
EP (1) | EP0472053B1 (zh) |
KR (1) | KR950001686B1 (zh) |
CN (2) | CN1036650C (zh) |
AT (1) | ATE167473T1 (zh) |
AU (1) | AU636239B2 (zh) |
CA (1) | CA2049496C (zh) |
DE (1) | DE69129611T2 (zh) |
FI (1) | FI913815A (zh) |
HU (1) | HUT59663A (zh) |
IE (1) | IE912936A1 (zh) |
NO (1) | NO178695C (zh) |
NZ (1) | NZ239425A (zh) |
RU (1) | RU2059615C1 (zh) |
TW (1) | TW206208B (zh) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3929582A1 (de) * | 1989-09-06 | 1991-03-07 | Hoechst Ag | Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament |
GB9311281D0 (en) * | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | Novel composition of matter |
US5698711A (en) | 1991-01-28 | 1997-12-16 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
US5679696A (en) * | 1992-07-28 | 1997-10-21 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group |
IT1256354B (it) * | 1992-08-31 | 1995-12-01 | Francesca Pelizzoni | Derivati della combretastatina ad attivita' anti-tumorale e procedimento per la loro preparazione |
EP0679641B1 (en) * | 1993-07-26 | 2002-10-02 | Eisai Co., Ltd. | Sulfonamide and sulfonic ester derivatives each having tricyclic hetero ring |
KR100293867B1 (ko) * | 1994-04-06 | 2001-09-17 | 니뽄 신야쿠 가부시키가이샤 | 아미노스틸바졸유도체및의약 |
CA2150609C (en) * | 1994-06-01 | 1998-12-08 | Mikiro Yanaka | Pyrimidine derivatives and pharmaceutical composition |
AU695255B2 (en) * | 1994-12-20 | 1998-08-13 | F. Hoffmann-La Roche Ag | Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists |
CN1063443C (zh) * | 1995-03-28 | 2001-03-21 | 日本脏器制药株式会社 | 新的苯并噻唑衍生物 |
EA001367B1 (ru) * | 1996-02-22 | 2001-02-26 | Туларик, Инк. | Пентафторбензолсульфонамиды и их аналоги |
US6653331B2 (en) * | 1996-07-03 | 2003-11-25 | Pharmacia & Upjohn Company | Targeted drug delivery using sulfonamide derivatives |
EP0939627B1 (en) | 1996-07-19 | 2003-09-10 | Tularik, Inc. | Pentafluorobenzenesulfonamides and analogs |
US6083986A (en) * | 1996-07-26 | 2000-07-04 | Icagen, Inc. | Potassium channel inhibitors |
KR20010012868A (ko) | 1997-05-30 | 2001-02-26 | 다께다 가즈히꼬 | 신규 설폰아미드 유도체 |
CA2297943A1 (en) * | 1997-07-25 | 1999-02-04 | Nippon Kayaku Kabushiki Kaisha | Novel compound having effect of promoting neuron differentiation |
US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
CA2315070A1 (en) * | 1997-12-17 | 1999-07-01 | Schering Aktiengesellschaft | Ortho-anthranilamide derivatives as anti-coagulants |
DE19802437A1 (de) * | 1998-01-23 | 1999-07-29 | Bayer Ag | Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe |
US6333337B1 (en) | 1998-01-27 | 2001-12-25 | Icagen, Inc. | Potassium channel inhibitors |
US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
JP4253126B2 (ja) | 1998-01-29 | 2009-04-08 | アムジェン インコーポレイテッド | Ppar−ガンマ調節剤 |
CA2335559A1 (en) | 1998-06-25 | 1999-12-29 | Tularik Inc. | Arylsulfonanilide phosphates |
US6153585A (en) | 1998-07-20 | 2000-11-28 | Tularik Inc. | Arylsulfonanilide derivatives |
EA003924B1 (ru) * | 1998-09-23 | 2003-10-30 | Туларик, Инк. | Арилсульфонанилидмочевины |
EP1285911A3 (en) * | 1998-09-23 | 2003-03-26 | Tularik Inc. | Arylsulfonanilide ureas |
US6194458B1 (en) | 1998-10-30 | 2001-02-27 | Merck & Co., Inc. | Benzamide potassium channel inhibitors |
US6632836B1 (en) | 1998-10-30 | 2003-10-14 | Merck & Co., Inc. | Carbocyclic potassium channel inhibitors |
US6303637B1 (en) | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
US6521658B1 (en) * | 1999-05-28 | 2003-02-18 | Abbott Laboratories | Cell proliferation inhibitors |
US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
PT1206256E (pt) | 1999-07-29 | 2005-09-30 | Amgen Inc | Terapia de combinacao utilizando pentafluorobenzenosulfonamida e compostos de platina |
WO2001034148A1 (fr) * | 1999-11-11 | 2001-05-17 | Kyorin Pharmaceutical Co., Ltd. | Preparations solides pour administration orale |
US6458794B2 (en) | 1999-12-21 | 2002-10-01 | Icagen, Inc. | Potassium channel inhibitors |
US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
US6566380B2 (en) | 2000-07-25 | 2003-05-20 | Icagen, Inc. | Potassium channel inhibitors |
US6620849B2 (en) | 2000-07-26 | 2003-09-16 | Icafen, Inc. | Potassium channel inhibitors |
AU2002234165A1 (en) | 2000-11-03 | 2002-05-27 | Tularik, Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
US20050250854A1 (en) * | 2000-11-03 | 2005-11-10 | Amgen Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
US6849634B2 (en) | 2000-12-21 | 2005-02-01 | Icagen | Potassium channel inhibitors |
FR2827280B1 (fr) * | 2001-07-13 | 2003-10-31 | Servier Lab | Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AUPR738301A0 (en) * | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
WO2004048544A2 (en) * | 2002-11-26 | 2004-06-10 | Bayer Healthcare | Ca ix-specific inhibitors |
US7833734B2 (en) * | 2002-11-26 | 2010-11-16 | Institute Of Virology Of The Slovak Academy Of Sciences | CA IX-specific inhibitors |
US20050075395A1 (en) * | 2003-05-28 | 2005-04-07 | Gary Gordon | Continuous dosing regimen |
JP2007500240A (ja) * | 2003-05-29 | 2007-01-11 | アボット・ラボラトリーズ | Abt−751による持続投与レジメン |
US20040242649A1 (en) * | 2003-05-29 | 2004-12-02 | Hagey Anne E. | Extended dosing regimen |
US7393873B2 (en) * | 2003-07-02 | 2008-07-01 | Merck & Co., Inc. | Arylsulfonamide derivatives |
US7504401B2 (en) * | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
KR20060101772A (ko) * | 2003-12-19 | 2006-09-26 | 화이자 인코포레이티드 | 당뇨병 및 비만을 치료하기 위한,11-베타-하이드록시스테로이드 데하이드로게나제 유형1(11-베타-hsd-1)의 저해제로서의벤젠설폰일아미노-피리딘-2-일 유도체 및 관련 화합물 |
WO2005086904A2 (en) * | 2004-03-08 | 2005-09-22 | Amgen Inc. | Therapeutic modulation of ppar (gamma) activity |
MXPA06013830A (es) * | 2004-05-28 | 2007-03-01 | Abbott Lab | Tratamiento del cancer en pacientes pediatricos. |
KR100839511B1 (ko) * | 2004-07-02 | 2008-06-19 | 주식회사 코오롱 | 은-함유 설파제를 디아조화체로 하는 산성 항균 염료와그의 제조 방법 및 그를 이용한 항균 섬유 |
KR100839512B1 (ko) * | 2004-07-02 | 2008-06-19 | 주식회사 코오롱 | 설파제를 디아조화체로 하는 산성 항균 염료 및 그를이용한 항균 섬유 |
JP2008517930A (ja) * | 2004-10-21 | 2008-05-29 | トランス テック ファーマ,インコーポレイテッド | GalR1のアゴニストとしてのビススルホンアミド化合物、組成物、及び使用法 |
US7449584B2 (en) | 2005-01-13 | 2008-11-11 | Abbott Laboratories Inc. | N-(2((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide Crystalline Form 1 |
US20060293367A1 (en) * | 2005-01-13 | 2006-12-28 | Zhang Geoff G | Amorphous N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide |
US20060293368A1 (en) * | 2005-01-13 | 2006-12-28 | Zhang Geoff G | Amorphous N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride |
US20070004781A1 (en) * | 2005-01-13 | 2007-01-04 | Schmitt Eric A | Crystalline N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride |
US20070021470A1 (en) * | 2005-01-13 | 2007-01-25 | Jorge Gandarilla | Crystalline N-(2-((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide methanolates |
CA2594654A1 (en) * | 2005-01-13 | 2006-07-20 | Abbott Laboratories | N-((2z)-2-((4-hydroxyphenyl)imino)-1,2-dihydro-3-pyridinyl)-4-methoxybenzenesulfonamide crystalline form 2 |
US20070021471A1 (en) * | 2005-01-13 | 2007-01-25 | Jorge Gandarilla | Crystalline N-(2-((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide ethanolates |
EP2474532A1 (en) * | 2005-01-14 | 2012-07-11 | ChemoCentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
US7622583B2 (en) * | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
KR100821898B1 (ko) * | 2005-02-23 | 2008-04-16 | 주식회사 코오롱 | 은 함유 항균 산성 염료와 그의 제조 방법 및 그를 이용한항균 섬유 |
KR100821900B1 (ko) * | 2005-09-15 | 2008-04-16 | 주식회사 코오롱 | 항균 산성 염료와 그의 제조 방법 및 그를 이용한 항균섬유 |
FI20055498A0 (fi) * | 2005-09-16 | 2005-09-16 | Biotie Therapies Corp | Sulfonamidijohdannaisia |
GB0524786D0 (en) * | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
US20080280891A1 (en) * | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
DK2175859T3 (da) | 2007-07-12 | 2012-06-18 | Chemocentryx Inc | Kondenserede heteroarylpyridyl- og phenylbenzen-sulfonamider som ccr2-modulatorer til behandling af inflammation |
HUE035029T2 (en) | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Kinase inhibitor phosphorus derivatives |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US8673908B2 (en) | 2008-11-10 | 2014-03-18 | Kyowa Hakko Kirin Co., Ltd. | Kynurenine production inhibitor |
EP2576514A1 (en) | 2010-06-04 | 2013-04-10 | Exonhit Sa | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
WO2012142698A1 (en) * | 2011-04-20 | 2012-10-26 | Universite Laval | Alkylurea derivatives active against cancer cells |
JP5999177B2 (ja) | 2011-05-04 | 2016-09-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
WO2013055793A1 (en) | 2011-10-12 | 2013-04-18 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
JP6564380B2 (ja) | 2013-09-20 | 2019-08-21 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 前立腺癌を治療するための化合物 |
WO2016007993A1 (en) * | 2014-07-16 | 2016-01-21 | University Of South Australia | Benzene sulfonamide-based inhibitors of sphingosine kinase |
CA2957785C (en) | 2014-08-11 | 2023-01-03 | Angion Biomedica Corporation | Cytochrome p450 inhibitors and uses thereof |
CN107531631B (zh) | 2014-12-31 | 2021-09-03 | 安吉昂生物医药公司 | 用于治疗疾病的方法和药剂 |
US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
CA3242005A1 (en) | 2016-11-23 | 2018-05-31 | Chemocentryx, Inc. | Method of treating focal segmental glomerulosclerosis |
AU2018347361A1 (en) | 2017-10-11 | 2020-04-30 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists |
WO2019139979A2 (en) * | 2018-01-09 | 2019-07-18 | The Scripps Research Institute | Arylfluorosulfate compounds and methods |
US11286236B2 (en) | 2018-06-05 | 2022-03-29 | Vector Vitale Ip Llc | Compound, agent and composition for the suppression of cancer growth |
CN109331868B (zh) * | 2018-09-29 | 2021-03-26 | 广东工业大学 | 一种苯甘氨酸类双官能团催化剂及其制备方法和应用 |
WO2021071499A1 (en) * | 2019-10-11 | 2021-04-15 | Vector Vitale Ip Llc | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
WO2021150109A1 (en) | 2020-01-22 | 2021-07-29 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Abt-751 and ionizing radiation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2307650A (en) * | 1938-11-29 | 1943-01-05 | Nepera Chemical Company Inc | Sulphanilamido-amino-pyridines and processes for producing the same |
US2202933A (en) * | 1939-08-30 | 1940-06-04 | Nepera Chemical Co Inc | Sulphanilamido-aminopyridines and process for producing the same |
DE1670761A1 (de) * | 1966-10-27 | 1970-12-23 | Forsch Borstel Inst Fuer Exper | Verfahren zur Herstellung von in 3- oder 5-Stellung durch elektronegative Substituenten substituierten 2-Sulfanil-amido-pyridinen |
DE3686688T2 (de) * | 1985-06-24 | 1993-03-18 | Merck & Co Inc | Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten. |
JPH0610174B2 (ja) * | 1986-09-29 | 1994-02-09 | 株式会社大塚製薬工場 | アミノフエノ−ル誘導体 |
-
1991
- 1991-08-07 AT AT91113256T patent/ATE167473T1/de not_active IP Right Cessation
- 1991-08-07 EP EP91113256A patent/EP0472053B1/en not_active Expired - Lifetime
- 1991-08-07 DE DE69129611T patent/DE69129611T2/de not_active Expired - Lifetime
- 1991-08-08 US US07/742,618 patent/US5250549A/en not_active Expired - Lifetime
- 1991-08-12 HU HU912676A patent/HUT59663A/hu unknown
- 1991-08-12 FI FI913815A patent/FI913815A/fi not_active Application Discontinuation
- 1991-08-14 TW TW080106438A patent/TW206208B/zh active
- 1991-08-16 AU AU82493/91A patent/AU636239B2/en not_active Ceased
- 1991-08-16 KR KR1019910014156A patent/KR950001686B1/ko not_active IP Right Cessation
- 1991-08-16 NO NO913207A patent/NO178695C/no unknown
- 1991-08-16 NZ NZ239425A patent/NZ239425A/xx unknown
- 1991-08-19 CN CN91105827A patent/CN1036650C/zh not_active Expired - Fee Related
- 1991-08-19 IE IE293691A patent/IE912936A1/en not_active Application Discontinuation
- 1991-08-19 CA CA002049496A patent/CA2049496C/en not_active Expired - Fee Related
- 1991-08-20 RU SU915001370A patent/RU2059615C1/ru active
-
1992
- 1992-07-31 US US07/923,345 patent/US5292758A/en not_active Expired - Lifetime
-
1993
- 1993-06-30 US US08/085,962 patent/US5332751A/en not_active Expired - Fee Related
-
1994
- 1994-04-22 US US08/231,272 patent/US5434172A/en not_active Expired - Fee Related
-
1995
- 1995-03-17 CN CN95103522A patent/CN1136036A/zh active Pending
- 1995-05-26 US US08/450,138 patent/US5610320A/en not_active Expired - Fee Related
- 1995-05-26 US US08/453,058 patent/US5610304A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FI913815A0 (fi) | 1991-08-12 |
US5292758A (en) | 1994-03-08 |
AU636239B2 (en) | 1993-04-22 |
FI913815A (fi) | 1992-02-21 |
EP0472053B1 (en) | 1998-06-17 |
US5250549A (en) | 1993-10-05 |
US5434172A (en) | 1995-07-18 |
US5332751A (en) | 1994-07-26 |
RU2059615C1 (ru) | 1996-05-10 |
CA2049496C (en) | 1997-02-04 |
ATE167473T1 (de) | 1998-07-15 |
CN1136036A (zh) | 1996-11-20 |
CN1059519A (zh) | 1992-03-18 |
NO913207D0 (no) | 1991-08-16 |
NZ239425A (en) | 1993-10-26 |
KR920004341A (ko) | 1992-03-27 |
DE69129611T2 (de) | 1998-12-17 |
CN1036650C (zh) | 1997-12-10 |
NO913207L (no) | 1992-02-21 |
HUT59663A (en) | 1992-06-29 |
EP0472053A3 (en) | 1994-08-10 |
US5610320A (en) | 1997-03-11 |
CA2049496A1 (en) | 1992-02-21 |
NO178695B (no) | 1996-02-05 |
US5610304A (en) | 1997-03-11 |
HU912676D0 (en) | 1992-01-28 |
DE69129611D1 (de) | 1998-07-23 |
KR950001686B1 (ko) | 1995-02-28 |
IE912936A1 (en) | 1992-02-26 |
NO178695C (no) | 1996-05-15 |
AU8249391A (en) | 1992-02-27 |
EP0472053A2 (en) | 1992-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW206208B (zh) | ||
TW548274B (en) | Dihydropyrimidines having hepatitis B therapeutic efficacy | |
TW442481B (en) | Imidazole compounds having an action of inhibiting cytokine, a process for the preparation thereof, and a pharmaceutical composition comprising them | |
TWI234558B (en) | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | |
TW523511B (en) | Pharmaceutical composition comprising substituted imidazole compounds and process for preparing compounds | |
CA2209018C (en) | Sulfonamides and their use | |
CZ302359B6 (cs) | Triazolové slouceniny a jejich použití | |
WO2006024837A1 (en) | Isoindolin-1-one derivatives | |
BRPI0720635A2 (pt) | Compostos orgânicos e seus usos | |
CA2729108A1 (en) | Organic compounds | |
US6727239B1 (en) | Derivatives of 2-aminopyridines, their use as medicaments and pharmaceutical compositions containing them | |
Xi et al. | Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking | |
TW200418799A (en) | Phenyl or heteroaryl amino alkane derivatives | |
CA2552953A1 (en) | Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors | |
TW426658B (en) | Guanidine derivatives, the preparation process and the pharmaceutical compositions thereof | |
CA2527586A1 (en) | Pyridine n-oxides as antiviral agents | |
JP2005521689A (ja) | Atm阻害剤として有用なピラノン | |
JPH0741461A (ja) | スルホン酸エステル誘導体 | |
AU2005219689A1 (en) | Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein | |
Revelant et al. | Exploring S1 plasticity and probing S1′ subsite of mammalian aminopeptidase N/CD13 with highly potent and selective aminobenzosuberone inhibitors | |
TW580498B (en) | A novel amide compound and a pharmaceutical composition containing the same | |
JPH11269140A (ja) | 分化誘導剤 | |
JP2790926B2 (ja) | スルホンアミド誘導体 | |
EP2794009B1 (en) | Bisarylsulfonamides useful in the treatment of inflammation and cancer | |
WO2006106914A1 (ja) | ピリミジニルアルキルチオ基を有する新規環式化合物 |